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Biological therapies are currently at the forefront of pharmaceutical innovation and drug discovery. 
Seminal developments in molecular biology and recombinant technologies in the 1990’s brought 
about a new era in biomedicine, inasmuch as they expanded the ability to manipulate the synthetic 
machinery of biological systems for the production of recombinant macromolecules with exquisite 
therapeutic potential and versatility. Most prominent among these developments were advances in 
the manufacture of humanised and human monoclonal antibodies in a streamlined fashion. 
Biotherapeutics then experienced a remarkable boom in the early 2000’s and currently remain the 
fastest-growing class of therapeutics. As the field of molecular biology continues to advance at an 
accelerated pace, manifold opportunities are presented to implement new tools and technologies 
in the design of novel biotherapeutics and the refinement of existing biological therapies. The 
empirical research contained in this thesis reports on various approaches to address crucial aspects 
of the development of novel biotherapeutics, and demonstrates the application of modern mass 
spectrometry methods to gain insight into the complex structural features of macromolecules.  
Three main aims were defined and addressed in this work. The first aim consisted in employing a 
tailored mass spectrometry method to acquire the site-specific glycan profile of an influenza 
surface glycoprotein that plays a crucial role in infectivity and antigenicity. The structural data 
obtained sheds light into antigenic properties of the virus that can aid in the design of recombinant 
vaccines. The second aim sought to evaluate a protein engineering strategy to improve the 
biophysical properties of monoclonal antibodies through the targeted insertion of glycosylation 
sites in strategic positions on the protein. The data reported demonstrates the capabilities of the 
technique to increase physical stability and underlines aspects that require further refinement 
moving forward. The final aim focused on the synthesis of a nanoparticle-based drug delivery 
platform that employs antibodies as targeting agents for increased treatment specificity. We 
demonstrated the feasibility of chemically modifying the antibody using concomitant protein 
functionalisation techniques to produce antibody-drug conjugates that bind to the surface of gold 
nanoparticles to serve as targeting agents. The synthesized nanocarrier is designed to accumulate 
preferentially in tumours through the enhanced permeability and retention effect, where it can 
subsequently engage in specific interactions with tumour cells via active-targeting of the antibody. 
Thesis Abstract 
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Altogether, the body of work presented in this thesis reports on novel experimental approaches 
that will aid in the design and production of next-generation biotherapeutics.  
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 Preface 
Reports of the use of biological therapies can be traced back to the 1st millennium BC, with the 
employment of variolation in various regions of Africa and Asia. Variolation consisted in the 
inoculation of patients with smallpox pathogens through the administration of dried smallpox 
scabs into the nose of patients to prompt immunological protection – a rudimentary form of 
vaccination [1, 2]. The technique eventually spread to other parts of the world and by the 18th 
century it had reached Europe and America. By this point, it was common knowledge in Europe 
that dairymaids that had been infected with cowpox (a closely related virus) from contact with the 
cow’s udders could develop immunity against smallpox. Encouraged by this observation, English 
physician and scientist Edward Jenner hypothesized that cowpox could deliberately be inoculated 
into a patient to generate cross immunity against smallpox. Jenner tested his theory in a small 
subset of patients and published his work in a booklet in 1798; which, although initially criticised 
by the scientific community, eventually led to the spread of the technique of vaccination 
throughout Europe in the early 1800s [3, 4]. The medical community then devoted efforts into 
refining the method and developing vaccines against other infectious diseases. Louis Pasteur 
would later make the technique safer by introducing the principle of viral attenuation [5]. 
Vaccination has since become the clinical intervention with the most important contribution to 
global health, best reflected by the eradication of smallpox and dramatic reductions in the global 
incidence of polio and measles [6-8].  
Biological therapies (otherwise known as biotherapeutics, biopharmaceutics, and biologics) have 
since come a long way. Presently, biologics comprise a wide spectrum of therapeutic classes 
including vaccines, monoclonal antibodies, blood components, viruses, gene therapy, enzymes, 
and cytokines. Seminal developments in molecular biology and recombinant DNA technologies 
in the 1980’s and 1990’s enabled the manipulation of the synthetic machinery of living organisms 
to efficiently produce engineered macromolecules. The field then experienced a remarkable 
expansion since the late 1990’s with the approval of myriad recombinant products, and by 2016 
biotherapeutics comprised 25% of the global pharmaceutical market [9, 10]. Most pivotal among 
these developments was the invention of phage display technologies and complementarity-
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determining region (CDR) grafting for the production of humanised and fully-human monoclonal 
antibodies (mAbs) against predetermined molecular targets [11-13]. Therapeutic monoclonal 
antibodies now dominate the pharmaceutical market, featuring 7 of the top-10 best-selling drugs 
in 2018; and they continue to expand as the fastest growing class of therapeutics [14]. The 
astounding clinical success of mAbs has arisen from the structural and functional versatility of the 
molecule and the exquisite molecular specificity that they confer. On that account, tremendous 
research efforts are currently being devoted to implement recent technological advancements for 
the improvement of currently available therapeutic mAbs and the development of enhanced next-
generation antibody therapeutics. Prime examples of next-generation mAbs that have already 
reached the clinic include antibody fragments, fusion proteins, glycoengineered antibodies, 
antibody-drug conjugates (ADC), and bispecific antibodies (described in further detail in chapters 
3 and 6).  
Most biotherapeutics are structurally complex macromolecules, among which proteins and 
peptides are strongly predominant. In the case of proteins, the intrinsic complexity of their primary 
and higher-order structures is further complicated by post-translational modifications (PTMs) 
(e.g., glycosylation, phosphorylation, sulfation, hydroxylation, alkylation, N-acetylation, C-
terminal amidation) that have important implications in the biological activity and biophysical 
properties of the protein [15, 16]. Arguably the most tangible illustration of the latter is the case of 
mAb Fc glycosylation, wherein the absence of core fucosylation has been identified as a major 
determinant of antibody-dependent cellular cytotoxicity (ADCC), which has led to the 
development of cell lines engineered to have double knockout alleles of the enzyme responsible 
for fucose addition [17-19]. PTMs are mostly enzymatic processes sensitive to metabolic 
alterations, making it challenging to control structural heterogeneity and batch-to-batch variability. 
This poses significant hurdles in the analysis and characterisation of therapeutic proteins and can 
hinder the development of novel biotherapeutics.   
In this context, mass spectrometry (MS) has become a cornerstone in structural biology and 
currently plays a central role in the development of protein pharmaceuticals, biological therapies 
and biomarker identification. Mass spectrometry methods are particularly suited for the detailed 
study of post-translation modifications and are hence ubiquitously employed in such quality 
analyses. Broadly, different MS techniques can be applied in the analysis of an extensive range of 
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biomolecules, ranging from small metabolites to large protein complexes [20-22]. The current 
prominence of MS technologies in proteomics and protein analysis stems from numerous recent 
advancements in instrumentation and methodologies, particularly the development of 
macromolecule ionisation methods, such as electrospray ionisation (ESI), matrix-assisted laser 
desorption/ionisation (MALDI), and atmospheric pressure chemical ionisation (APCI) [23, 24]. 
Modern mass spectrometers offer exquisite m/z resolution and sensitivity, being able to detect 
molecules in the attomolar scale (10-18). The ability to couple MS instruments online to molecule 
separation methods such as liquid and gas chromatography greatly improves the analysis of 
complex samples, which can be aided by data-dependent acquisition methods (DDA) and tailored 
sample preparation workflows [25-27]. DDA methods involve the selection of predetermined 
precursor ions within allowed m/z ranges in an initial survey scan to be subjected to a subsequent 
stage of mass spectrometry. This ion “filtering” step is particularly useful in the targeted detection 
of low-abundance analytes in complex biological samples. Moreover, analysis of the 
fragmentation patterns produced through various activation modes (e.g., collision-induced 
dissociation (CID), high-energy collision dissociation (HCD), electron-transfer dissociation (ETD) 
and electron-capture dissociation (ECD)) in tandem mass spectrometry allows the elucidation of 
highly detailed structural information, as it is showcased in the experimental work in this thesis 
[28, 29]. 
Considering the opportunities that the current wealth of knowledge in molecular biology and 
biotechnology provide, the overarching aim of this thesis was to implement innovative protein 
engineering approaches aimed towards the development of improved biotherapeutics. The 
following body of work compiles a series of research manuscripts that delve into key aspects of 
the development of new generation biological therapies, with a strong component of mass 
spectrometry as a pivotal tool in the structural analysis of biomolecules.  
Aims and chapter description 
Aim 1 (Chapter 2) – Studying the glycan profile of influenza hemagglutinin to 
contribute to the design of improved vaccine platforms 
In contrast to the experience with antibody therapeutics and other biologicals, the development of 
rationally-designed recombinant vaccines for numerous infectious diseases remains elusive. In the 
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case of influenza, further elucidation of antigenic determinants and viral adaptation mechanisms 
are needed to improve rational design of recombinant platforms. Hence, we sought to make use of 
state-of-the-art mass spectrometry methods to study an important structural feature of the virus – 
the N-glycosylation profile.  
Chapter 2 – “Site-specific Glycosylation Profile of Influenza A (H1N1) Hemagglutinin 
Through Tandem Mass Spectrometry” – of this thesis describes a mass spectrometry-based 
methodology for the analysis of the site-specific glycan microheterogeneity of an influenza H1N1 
strain. Historically, the study of the evolution of the influenza virus dating back to the outbreak of 
the Spanish flu in 1918 has focused primarily on antigenic alterations in the surface glycoproteins 
(hemagglutinin and neuraminidase) caused by antigenic shift. These mechanisms indubitably play 
a critical role in viral adaptation to human immunogenic responses; however, recent reports have 
established that variations in the number and localisation of glycans on these proteins can have a 
significant contribution to antigenic masking and modulation of strain infectivity. We thus present 
a methodology that involves a simple preliminary fractionation and digestion step of the viral 
proteins obtained from whole inactivated viruses, followed by a tandem mass spectrometry setup 
that enables the analysis of digested glycopeptides. We employed this methodology on the 
hemagglutinin protein of an H1N1 strain as a proof of principle, and we were able to establish two 
important structural characteristics of the protein: (1) identification and confirmation of 
glycosylation sites, and (2) the monosaccharide composition of the glycans obtained from specific 
sites within the primary sequence. This site-specific analysis can easily be extended to the study 
of other relevant viral strains in order to obtain further insight into viral evolution and adaptation 
mechanisms. Chapter 2 was published in the Human Vaccines and Immunotherapeutics journal 
as: 
E. Cruz, J. Cain, B. Crossett, V. Kayser. Site-specific Glycosylation Profile of Influenza A 
(H1N1) Hemagglutinin Through Tandem Mass Spectrometry. Human Vaccines and 
Immunotherapeutics, 14(3) (2018), 508-517. 
The implementation of state-of-the-art structural analysis techniques like the one discussed in 
Chapter 2 will likely have pivotal contributions to the design of optimised treatment strategies 
and vaccine design. Importantly, mass spectrometry techniques can be utilized to study an 
extensive range of biomolecules, ranging from small metabolites to large protein assemblies. This 
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is further exemplified in Chapters 4, 5 and 7, where equivalent MS approaches were similarly 
employed in the development of novel antibody-based therapeutics as discussed hereafter. 
Aim 2 (Chapters 3, 4, and 5) – Targeted insertion of N-glycosylation sites to improve 
the physical stability of antibody therapeutics  
Chapter 3 – “The State-of-play and Future of Antibody Therapeutics” – is a comprehensive 
review on the current landscape of antibody therapeutics, and it serves as an introduction to 
Chapter 4 – “Enhancing the Stability of Adalimumab by Engineering Additional 
Glycosylation Motifs” – and Chapter 5 – “Glycan Profile Analysis of Engineered 
Trastuzumab with Rationally Added Glycosylation Sequons for Enhanced Physical 
Stability” – that report on an innovative approach to produce improved “biobetter” antibodies. 
The chapter gives an overview of important recent developments in antibody discovery and protein 
engineering strategies that aim to improve the therapeutic potential of the conventional IgG 
molecules that predominate in the market. Special focus is given to the limitations that derive from 
the intrinsic propensity of antibody molecules to aggregate, which represents a recurring problem 
in manufacturing and development of novel antibody therapeutics. The manuscript then discusses 
recently developed computational tools to identify aggregation-prone regions, which can then be 
targeted for replacement through mutagenesis as a means to improve the intrinsic physical stability 
of the protein. The latter engineering approach was implemented in Chapter 4 – “Enhancing the 
Stability of Adalimumab by Engineering Additional Glycosylation Motifs” – and Chapter 5 
– “Glycan Profile Analysis of Engineered Trastuzumab with Rationally Added Glycosylation 
Sequons for Enhanced Physical Stability” . This review was published in the Advanced Drug 
Delivery Reviews journal as: 
Z. Elgundi, M. Reslan, E. Cruz, V. Sifniotis, V. Kayser. The State-of-play and Future of 
Antibody Therapeutics. Advanced Drug Delivery Reviews, 122 (2017), 2-19. 
The next chapter of this thesis (Chapter 4 – “Enhancing the Stability of Adalimumab by 
Engineering Additional Glycosylation Motifs”) explores a novel engineering approach to 
enhance the intrinsic stability of antibodies against aggregation, using the blockbuster antibody 
adalimumab (Humira®) as a proof-of-concept. The strategy involved the insertion of glycosylation 
sequons on the primary structure of adalimumab to yield “hyperglycosylated” antibodies, 
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possessing glycans on engineered sites where the carbohydrate can shield identified aggregation-
prone regions. Various candidate mutants were produced and subsequently tested for their 
tendency to aggregate through accelerated stability studies. A variation of the MS method 
presented in Chapter 2 – “Site-specific Glycosylation Profile of Influenza A (H1N1) 
Hemagglutinin Through Tandem Mass Spectrometry” – was employed for structural 
characterisation of the mutants and confirmation of both the amino acid mutation and glycan 
attachment. Several of the tested mutants displayed enhanced thermodynamic stability, reflected 
by substantial increases in the melting temperature of the Fab domain where the glycan was 
introduced. Importantly, the mutations were performed on conserved regions of the antibody, 
meaning that they have potential for application on further IgG1 molecules. Chapter 2 has been 
submitted to the Biotechnology and Bioengineering journal as: 
M. Reslan, V. Sifniotis, E. Cruz, Z. Sumer-Bayraktar, S. Cordwell, V. Kayser (2019). 
Enhancing the Stability of Adalimumab by Engineering Additional Glycosylation Motifs. 
Biotechnology and Bioengineering. 
Given the established potential of the “hyperglycosylation” approach presented in Chapter 4 – 
“Enhancing the Stability of Adalimumab by Engineering Additional Glycosylation Motifs”, 
we sought to analyse the structural characteristics of the introduced glycans to better understand 
the conferred physicochemical properties. To achieve this, we performed equivalent mutations on 
another blockbuster antibody – trastuzumab (Herceptin®) – and carried out a detailed structural 
analysis of the glycan profile of the mutants. Once again, a mass spectrometry method similar to 
the ones presented in Chapter 2 – “Site-specific Glycosylation Profile of Influenza A (H1N1) 
Hemagglutinin Through Tandem Mass Spectrometry”  and Chapter 4 – “Enhancing the 
Stability of Adalimumab by Engineering Additional Glycosylation Motifs”, was employed, 
however the technique utilised herein was modified to obtain structural information of the 
carbohydrates, rather than glycopeptides. The global glycan profile of the “hyperglycosylated” 
mutants revealed that the added Fab glycosylation site greatly enhances the heterogeneity of glycan 
structures in contrast to the glycan microheterogeneity of the conserved Fc glycan. This 
observation reveals an important feature that will likely have to be addressed if this strategy is to 
be pursued in clinical development. Importantly, it was also established that most of these 
mutations on trastuzumab have only a minor impact on the binding affinity to biologically relevant 
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receptors. The latter was similarly reported for adalimumab, suggesting that the biological activity 
of antibodies that rely on effector functions is unlikely to be significantly altered through this 
strategy. Chapter 5 is prepared for submission as: 
E. Cruz, V. Sifniotis, Z. Sumer-Bayraktar, S. Cordwell, V. Kayser. (2019). Glycan Profile 
Analysis of Engineered Trastuzumab with Rationally Added Glycosylation Sequons for 
Enhanced Physical Stability. 
Aim 3 (Chapter 6 and 7) – Chemical functionalisation of an antibody molecule for 
employment as a targeting agent in the design of a nanoparticle drug delivery 
platform  
Chapter 6 – “Monoclonal Antibody Therapy of Solid Tumours: Clinical Limitations and 
Novel Strategies to Enhance Treatment Efficacy” – is a literature review that introduces the aim 
of Chapter 7 – “Synthesis and Enhanced Cellular Uptake In Vitro of Anti-HER2 
Multifunctional Gold Nanoparticles” –  that reports on an alternative approach to harness the 
specificity of antibody molecules to produce antibody-targeted nanoparticle delivery systems. The 
manuscript outlines critical challenges in the treatment of non-haematological cancers with 
monoclonal antibodies related to the architectural features of solid tumours. It emphasizes the 
importance of improving tumour penetration and distribution upon systemic delivery of an 
anticancer agent to prevent exposure to sub-therapeutic concentrations. It then briefly describes 
various novel strategies currently implemented or undergoing preclinical development to address 
such challenges. These include: (1) antibody-drug conjugates that aim to enhance intrinsic potency 
while maintaining selectivity, (2) antibody-based immune checkpoint inhibitors that can release 
the breaks of the immune anti-cancer response, and (3) nanoparticle formats that preferentially 
accumulate in solid tumours and can be granted further tumour-selectivity through the attachment 
of antibody molecules. This chapter is published in the Biologics: Targets and Therapy journal as: 
E. Cruz, V. Kayser. Monoclonal Antibody Therapy of Solid Tumours: Clinical Limitations 
and Novel Strategies to Enhance Treatment Efficacy. Biologics: Targets and Therapy. 13 
(2019), 33-51. 
Chapter 7 describes the synthesis of antibody-targeted nanoparticle formats designed for 
enhanced specificity towards HER2-positive tumours. Preferential accumulation of nanosized 
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materials has been validated in a wide range of mouse tumour models, and there is clinical 
evidence in human patients to support this effect. Enhanced localisation stems from the increased 
leakiness of tumour vasculature and concomitant impaired lymphatic drainage, leading to 
nanoparticles extravasation and accumulation, respectively. Hence, nanoparticles constitute an 
appealing vehicle for selective delivery of cytotoxic payloads to solid tumours. In this chapter, we 
employed gold nanoparticles as drug carriers due to their proven biocompatibility and ease of 
surface functionalisation. Taking advantage of the latter, the nanoparticles were granted further 
tumour specificity via surface-attachment of a trastuzumab (anti-HER2) antibody-drug conjugate. 
Trastuzumab was chemically modified to enable attachment of a potent cytotoxic agent 
(monomethyl auristatin E) via a cleavable linker for selective intracellular release. The antibody 
was then bound to the nanoparticle surface via a stable SH-gold bond through a polyethylene 
glycol linker. The nanoparticle format was tested in in vitro experiments, where it displayed 
enhanced cellular uptake and a potent cytotoxic activity in HER2-amplified cell lines. This 
manuscript demonstrates the feasibility of employing antibody-drug conjugates as a potentially 
superior active-targeting agent for payload delivery in solid tumours. Chapter 7 is published in 
the Cancers journal as: 
E. Cruz, V. Kayser. Synthesis and Enhanced Cellular Uptake In Vitro of Anti-HER2 
Multifunctional Gold Nanoparticles. Cancers, 11 (2019), 870. 
Notes on the format of the chapters 
Chapters 2-7 have been published, submitted, or prepared for publication. In the case of published 
and submitted material, the content included is identical to that of the published article, with the 
exception that some formatting changes have been made to standardise the style throughout the 
thesis. These formatting changes include a rearrangement of the order of the sections in some 
chapters, so that all research manuscripts are organised in the following order:  
1. Introduction  
2. Methods  
3. Results  
4. Discussion  
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5. Conclusions 
The format of the references has also been modified, so that all chapters follow the same style. 
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Abstract 
The study of influenza virus evolution in humans has revealed a significant role of glycosylation 
profile alterations in the viral glycoproteins – hemagglutinin (HA) and neuraminidase (NA), in the 
emergence of both seasonal and pandemic strains. Viral antigenic drift can modify the number and 
location of glycosylation sites, altering a wide range of biological activities and the antigenic 
properties of the strain. In view of the key role of glycans in determining antigenicity, elucidating 
the glycosylation profiles of influenza strains is a requirement towards the development of 
improved vaccines. Sequence-based analysis of viral RNA has provided great insight into the role 
of glycosite modifications in altering virulence and pathogenicity. Nonetheless, this sequence-
based approach can only predict potential glycosylation sites. Due to experimental challenges, 
experimental confirmation of the occupation of predicted glycosylation sites has only been carried 
out for a few strains. Herein, we utilized HCD/CID-MS/MS tandem mass spectrometry to 
characterize the site-specific profile of HA of an egg-grown H1N1 reference strain (A/New 
Caledonia/20/1999). We confirmed experimentally the occupancy of glycosylation sites identified 
by primary sequence analysis and determined the heterogeneity of glycan structures. Four 
glycosylation sequons on the stalk region (N28, N40, N303 and N497) and four on the globular 
head (N71, N104, N142 and N177) of the protein are occupied. Our results revealed a broad glycan 
microheterogeneity, i.e., a great diversity of glycan compositions present on each glycosite. The 
present methodology can be applied to characterize other viruses, particularly different influenza 
strains, to better understand the impact of glycosylation on biological activities and aid the 
improvement of influenza vaccines. 
Introduction 
Influenza viruses undergo a high rate of antigenic drift, leading to gradual antigenic modifications 
that are responsible for the persistent emergence of seasonal influenza strains. Occasional antigenic 
shift (viral reassortments) can also lead to pandemic outbreaks that pose a serious public health 
threat [1, 2]. The production of immunological memory after a primary exposure (through 
infection or vaccination) to influenza is essential to trigger an accelerated and efficacious immune 
response to subsequent infection [3, 4]. For this reason, it is crucial to elucidate the mechanisms 
that prompt such response and determine the viral antigens that elicit the generation of 
immunological memory.  
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The selection of annual strains for influenza vaccines relies on detailed characterization of the 
genetic and antigenic features of circulating viruses [5]. Due to their surface exposure, the envelope 
glycoproteins NA and HA play a prominent role in host immune cell recognition and are 
considered to be the main antigenic determinants in the virus [6, 7]. Influenza A viruses are thus 
further classified into subtypes according to the antigenic variants of their surface glycoproteins – 
18 HA (H1-H18) and 11 NA (N1-N11) subtypes [8]. HA is the most abundant protein in the viral 
envelope and is consequently also the focal point of virus surveillance [9]. 
The antigenic sites in HA are comprised mainly of polypeptide regions on the globular head; 
however, it has been demonstrated that the presence of glycans in the proximity of these sites can 
affect its biological activity, thereby altering immune cell recognition and receptor binding 
specificity [10, 11]. HA undergoes N-linked glycosylation (no O-glycosylation has been reported), 
whereby glycans are attached to asparagine residues within the consensus sequence Asn-Xaa-Ser 
(Xaa can be any amino acid except proline) [12, 13]. Hemagglutinin assembles as a homotrimer 
that displays a surface-exposed globular head formed by part of the HA1 chain, whereas the stalk 
region is comprised mostly of α-helix coils and a transmembrane domain from HA2 [9]. Both the 
stalk and the head region are often heavily glycosylated, and glycan attachment can affect a wide 
spectra of biological properties, such as immunogenicity, virulence and receptor specificity [14, 
15]. Overall, glycan attachment on the stalk region is highly conserved, and glycans on this area 
play a critical role in correct protein folding and membrane transport [16, 17]. Conversely, the 
globular head of HA exhibits a considerably higher rate of variation. Most antigenic sites are found 
on the HA head, therefore modifications on this region usually impair immune recognition [18, 
19]. 
Influenza subtype H1 has undergone extensive alteration over time in the number and position of 
glycans attached, mostly on the globular head [20]. These modifications are associated with 
adaptation mechanisms caused by antigenic drift, whereby novel virus subtypes avoid host cell 
immune recognition by masking antigenic regions through the variation in the localization or 
number of glycosites [20, 21].  
The consensus sequons required for N-glycosylation make it possible to analyse glycosylation 
occupancy profiles by searching for potential acceptor sites in the primary sequence of proteins. 
Sequence-based analysis of potential glycosylation sites on H1 has revealed that in the early stages 
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of virus evolution after the outbreak of the 1918 pandemic, the H1N1 virus subtype predominantly 
increased the number of glycosylation sites on its globular head. However, following 1950, the 
number of sites remained somewhat constant and the alteration in position became the prominent 
feature [20]. Strikingly, the H1 of the 2009 swine flu pandemic virus resembles the 1918 pandemic 
H1 not only in its antigenic epitopes, but also in that they both lack glycosylation sites near the Sa 
antigenic site [22, 23]. This absence of shielding glycans was an important factor contributing to 
the pathogenicity of the 1918 pandemic strain [14]. 
Although sequence-based glycosylation analysis has substantially contributed to the understanding 
of virus evolution, the information obtained through this method is only limited, as the sequons it 
identifies are not necessarily occupied [24]. For this reason, there remains the need to confirm site 
occupancy experimentally. Moreover, it is important to assess whether differences in glycoforms 
exist among strains, and determine if the potential variations have an impact on biological 
properties. To this end, mass spectrometry based methods, especially those based on collision-
induced dissociation (CID), higher-energy collision dissociation (HCD), electron-capture 
dissociation (ECD) and electron-transfer dissociation (ETD), are particularly suited to analyse 
protein posttranslational modifications [25, 26]. However, due to the experimental challenges that 
N-glycoproteomic analysis poses, characterization of site-specific glycosylation profiles has only 
been carried out for a few strains. 
In this study, we employed HCD/CID tandem mass spectrometry to map glycosylation sites and 
characterize the glycan microheterogeneity (i.e., the subset of glycan structures on each particular 
position within the protein) of an egg-grown A/New Caledonia/20/1999 H1N1 reference strain. 
We confirmed the occupancy of eight glycosylation sites on this reference strain – four on the stalk 
and four on the globular head. This profile was consistent to the one obtained through sequence-
based analysis using the NetNGlyc server for prediction of glycosylation potential. Moreover, a 
great diversity of glycan compositions was found on those positions close to the Sa antigenic site, 
which could have important implications on the antigenicity of the strain.  
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Materials and Methods 
N-glycosylation sequon analysis of A/New Caledonia/20/1999 HA 
The amino acid sequence for the A/New Caledonia/20/1999 HA was obtained from the National 
Institute of Allergy and Infectious Disease (NIAID) Influenza Research Database (IRD) [43]. 
through the web site at http://fludb.org. NetNGlyc 1.0 Server [24] was used for the prediction of 
potential glycosylation sites. NetNGlyc 1.0 Server utilizes several artificial neural networks that 
are able to predict the probability of an N-glycosylation motif to be occupied by analysing the 
adjacent primary sequence. The server sets a default threshold of 0.5, whereby a higher value 
indicates a predicted glycosylated residue. 
Homology modelling of A/New Caledonia/20/1999 HA 
The homology model of A/New Caledonia/20/1999 HA was created with Prime (Schrödinger) 
using H2 (PDB entry 2WR3, chain A) as a template. The molecular structures were generated 
using VMD 1.9.3. 
Hemagglutinin isolation through polyacrylamide electrophoresis and in-gel trypsin 
digestion 
Egg-grown A/New Caledonia/20/1999 virus samples were provided by Sanofi-Pasteur (PA-US). 
Viral proteins were separated by means of reducing SDS-PAGE by running whole virus samples 
(suspended in PBS) on a 10% home-made bis-acrylamide gel. The virus suspension was diluted 
with SDS-PAGE sample buffer containing 1% 2-Mercaptoethanol and 2% SDS. The samples were 
boiled at 95 °C for 10 minutes before loading onto the gel.  The gel was stained with Coomassie 
Brilliant Blue R-250 overnight, and the bands corresponding to HA0 monomers, HA1 and HA2 
were excised from the gel. The bands were subsequently destained using 40% (v/v) acetonitrile 
and dried using a vacuum concentrator prior to incubation with 5 µL 12 mg/mL trypsin (Promega) 
at 4 °C for 1 hour. 20 μL of NH4HCO3 50 mM pH 6.8 were added and incubated overnight to 
extract the proteins from the gel. 
Analysis of tryptic peptides and glycopeptides by nanoRPLC-MS/MS 
The tryptic peptide fraction was first desalted using a C18 ZipTip (Millipore) and eluted with 80% 
(v/v) acetonitrile. The desalted peptides were then dried by vacuum centrifugation and resuspended 
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in 0.1% formic acid (FA) prior to loading onto the nanoRPLC column. The glycopeptide solution 
was loaded onto an in-house packed 20 cm x 75 μm Reprosil-Pur C18AQ (3 μm, 120 A; Dr. 
Maisch GmbH) column/emitter using an easy nanoLC II HPLC (Proxeon). HPLC separation was 
carried out over 140 minutes at a flow rate of 250 nL/min using a 0-40% solvent B gradient, where 
solvent A consists in 0.1% (v/v) formic acid and solvent B is 90% (v/v) acetonitrile and 0.1% 
formic acid. Instrument parameters were set up as follows: source voltage = 2.0 kV, S-lens RF 
level = 68%, and capillary temperature = 275 °C. MS analysis was performed with an Orbitrap 
Velos Pro MS (Thermo Scientific). The initial MS scan was collected in the Orbitrap mass analyser 
(300-1,700 m/z; MS AGC = 1 x 10+6) with a resolution of 30,000 at 300 m/z. The three most 
intense precursors were then selected for fragmentation using either data-dependent higher-energy 
collisional dissociation (HCD) or collision induced (CID) fragmentation. HCD parameters were 
as follows: activation time = 0.1 ms, resolution = 7,500, maximum injection time = 500 ms, 
dynamic exclusion = enabled with repeat count 1, normalized energy = 45, exclusion duration = 
60 s, default charge state = 2, and MSn AGC 2 x 10,000. CID parameters as follows: activation 
time = 10 ms, maximum injection time = 300 ms, dynamic exclusion = enabled with repeat count 
1, normalized energy = 35, exclusion duration = 30 s, default charge state = 2, and MSn AGC = 2 
x 10+4.  
Analysis of MS/MS spectra of intact N-glycopeptides  
The MS data was processed with Proteome Discoverer 2.0 (Thermo Scientific), with HCD scans 
searched using Byonic (Protein Metrics Inc.). The search was performed against an influenza A 
virus (A/New Caledonia/20/1999) and Chicken protein sequence databases using the following 
settings: Full trypsin specificity with a maximum of two missed cleavages, an MS tolerance of 20 
ppm and a MS2 tolerance of 0.05 Da. A total of 3 common1 modifications (deamidation of 
asparagine and glutamine – +0.984016, cysteine propionamide – +71.037114 and asparagine 
glycosylation) were allowed and one total rare modification (oxidation of methionine – 
+15.994915 Da). The N-glycan database (309 mammalian no sodium) available in the Byonic 
search engine was chosen for N-linked modification. HCD spectra were manually inspected to 
confirm the matched glycopeptide fragmentation pattern and the presence of diagnostic HexNAc 
oxonium ions. CID spectra were manually inspected to validate the predicted glycan composition 
by manual annotation. 
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Results  
Prediction of N-glycosylation sites 
Prior to tandem mass spectrometry analysis, the amino acid sequence of the A/New 
Caledonia/20/1999 H1N1 strain was scanned to identify potential N-glycosylation sequons using 
the NetNGlyc 1.0 server. Figure 1 shows the predicted sites and table 1 displays the potential 
assigned for glycosylation for each sequon.  
 
Figure 1. Location of potential N-glycosylation sites within A/New Caledonia/20/1999 H1. 
Monomeric H2 (PDB entry, 2WR3) was used as a template to generate the homology model 
of A/New Caledonia/20/1999 H1. 
 
 
 
 
20 
 
Table 1. Estimated glycosylation potential of the glycosylation sequons identified using the 
NetNGlyc 1.0 server 
Residue number Position Sequence Potential assigned 
27 Stalk NNST 0.4009 
28 Stalk NSTD 0.7964 
40 Stalk NVTV 0.7477 
71 Side of head NCSV 0.7470 
104 Side of head NGTC 0.6300 
142 Top of head NHTV 0.6911 
177 Top of head NLSK 0.7380 
303 Stalk NSSL 0.6707 
498 Stalk NGTY 0.5190 
557 Cytoplasmic domain NGSL 0.6833 
 
A total of 10 sequons were identified within the amino acid sequence of the strain using the 
NetNGlyc 1.0 server. Four of these sites are located on the globular head (N71, N104, N142 and 
N177), five on the stalk (N27, N28, N71, N303 and N498) and one on the cytoplasmic tail (N557). 
With the exception of asparagine N27, all other sequons were predicted to be glycosylated (Fig. 
1). The case of N27 is exceptional as its adjacent N28 residue is also a potential acceptor site, but 
only N28 yields a positive result (≥ 0.5).  
Mass spectrometry analysis of electrophoretically-fractionated viral proteins 
The first step in sample preparation for mass spectrometry involved a preliminary fractionation of 
the viral proteins from a whole inactivated virus sample suspension through SDS-PAGE. This 
isolation step was performed in order to reduce sample complexity prior to nanoLC-MS/MS 
analysis.  
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Following gel extraction and trypsin digestion, bands 1-6 (Fig. 2) were subjected to a preliminary 
nanoLC-MS/MS analysis to identify the bands where HA was present. The whole inactivated virus 
samples used in this analysis are produced in embryonated chicken eggs, thus the Byonic search 
was conducted against the strain’s proteome database and then against a chicken proteome 
database.  This last step allowed for the detection of remnant chicken proteins from the purification 
steps of the whole virus stock suspension, which also improves the confidence of viral protein 
matches in this case.   
 
Figure 2. Reducing SDS-PAGE of whole inactivated A/New Caledonia/20/1999 H1N1 
virus. The numbering on the virus lane indicates an arbitrarily-assigned order to identify the 
prominent protein bands obtained through viral fractionation that were subjected to nanoLC-
MS/MS analysis. 
HA was predominantly detected in band 4 (~60 kDa). This band also yielded the greater HA 
protein coverage (53%) among all the bands (supplementary table 1). Subunits HA1 and HA2 were 
detected in bands 5 (~50 kDa) and 6 (~22 kDa), respectively, and were subjected to glycopeptide 
analysis. Moreover, peptides from HA were identified in bands 1 and 2, likely due to the presence 
of hemagglutinin trimers and dimers. The overall protein coverage of HA across all bands was 
71.5%. 
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Glycopeptide analysis 
Bands 4-6 (Fig. 2) were then analysed to characterize the glycosylation profile of hemagglutinin. 
Precursor glycopeptide ions subjected to HCD yield several diagnostic oxonium ions. Diagnostic 
ions at 204.08 m/z (HexNAc + H) and 366.14 m/z (Hex(1)HexNAc(1) + H)) are typically present 
in HCD spectra of glycosylated peptides. The HCD spectra were used in this study to assign 
peptide identity. The higher dissociation energy of HCD allows for the fragmentation of the 
peptide backbone, whereby the presence of b and y ions in the spectrum is matched by Byonic to 
the theoretical fragmentation patterns of the tryptic peptides to score the PSMs (peptide spectral 
matches) and assign identity. Figure 3A shows a representative HCD spectra displaying the 
diagnostic oxonium ions at 186.076, 204.087 and 366.140 along with b and y ions for the reported 
peptide. Other peptide + fragmented glycan ions (Y ions, e.g., peptide+HexNAc, 
peptide+HexNAc(2)) detected through HCD can also be instrumental to manually validate the 
peptide identity assigned by the search engine. The peptide backbone mass can be inferred from 
the trimannosyl ions detected in the HCD/CID-MS/MS spectrum pairs. The theoretical Y ions are 
then matched to the HCD/CID-MS/MS spectrum pair to validate the spectral matches. Byonic 
derives the mass of the glycan by calculating the mass difference between the precursor ion 
(peptide + glycan) and the identified tryptic peptide, which is then used to predict the composition 
of the oligosaccharide by searching this value against the mammalian glycan database within the 
engine. Byonic is thus able to predict glycoforms to the level of monosaccharide composition. 
23 
 
 
Figure 3. Representative CID and HCD spectra of H1 glycopeptides. (A) Annotated HCD 
spectrum of glycopeptide ESSWPNHTVTGVSASCSHNGK. The spectrum exhibits the 
diagnostic oxonium ion at 204.08 m/z and the presence of b and y ions derived from 
backbone fragmentation. (B) Annotated CID spectrum of glycopeptide 
ESSWPNHTVTGVSASCSHNGK with an attached glycan with a HexNAc(4)Hex(5)Fuc(1) 
composition. Sequential glycan fragmentation is predominant in the spectrum and allows for 
the validation of predicted glycan composition. The presence of a core fucose can be 
confirmed by the detection of ion Pep+2HexNAc-Fuc in both the HCD and CID spectra. 
A complementary CID fragmentation of each precursor ion also allows for the validation of the 
predicted glycan composition from the Byonic server. Figure 3B displays the CID spectrum of the 
same precursor ion as the one used for HCD in figure 3A. In this HCD/CID setup, CID causes 
predominantly the cleavage of glycosidic bonds, resulting in the sequential fragmentation of the 
glycan. The glycan information derived from low-energy CID is limited, since it does not generate 
cross-ring fragmentation to elucidate linkage information, nor does it allow to differentiate 
between glycan isomers in many cases or elucidate topology. Still, the sequential fragmentation 
enables the elucidation of glycan monosaccharide compositions, by which the prediction from the 
engine can be manually validated. Consequently, predicted glycan compositions from 
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glycopeptides with a high byonic score for the HCD spectrum were subjected to manual 
interpretation.  
Confirmation of glycosylated residues 
Eight out of the nine predicted glycosylation sites were confirmed to be occupied. Four of these 
sites are on the stalk region (N28, N40, N304 and N498) and four on the globular head (N71, 
N104, N142 and N177). Figure 4 displays the location of these sequons on a 3D structure 
homology model of the hemagglutinin monomer. Prediction for asparagine 557 was positive, 
however, no peptide was detected for the cytosolic domain nor the transmembrane domain of HA, 
suggesting that only the ectodomain of the protein can be characterized using this sample 
preparation. Inasmuch as these domains are unlikely to play an important role in immunogenic 
response – since they are not exposed to the surface to influence in host cell recognition and have 
not been related to virulence, obtaining glycosylation information for N557 was deemed 
unnecessary. Furthermore, it is not expected for glycosylation site N557 to be occupied given its 
location in the cytosolic region of the protein. 
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Figure 4. Location of confirmed glycosylation sites in relation to the most relevant antigenic 
sites on A/New Caledonia/20/1999  H1. (A) View of the globular head of H1 from the top. 
(B) View of H1 from the side to highlight the distribution of glycosites along the stalk region 
and the side of the globular head. Monomeric H2 (PDB entry, 2WR3) was used as a template 
to generate the homology model of A/New Caledonia/20/1999 H1. 
Glycan microheterogeneity profile 
Table 2 shows the glycan monomeric compositions found through HCD/CID-MS/MS on each 
glycosylation site within H1. Overall, glycan heterogeneity was quite broad, especially for sites 
N142 and N498.  
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Table 2. Microheterogeneity of A/New Caledonia/20/1999 H1. 
Position of glycan 
attachment within 
the protein 
sequence 
Predicted glycan 
composition 
Ion detected 
(m/z) 
Glycan 
mass (Da)  
Δm/z (Da) 
Site 1: Asparagine 28 
(NSTD) 
Stalk 
HexNAc(5)Hex(3) 1,389.59 (+6) 1, 501.55 -0.3369 
 
Site 2: Asparagine 40 
(NVTV) 
Stalk 
HexNAc(5)Hex(8)Fuc(1) 
 
1,474.63 (+3) 2, 457.87  0.0079 
 
HexNAc(5)Hex(6) 988.68 (+4) 1, 987.71 0.00022 
 
Site 3: Asparagine 71 
(NCSV) 
Side of the head 
HexNAc(3)Hex(5)NeuGc(1) 1,564.69 (+3) 1, 726.59 -0.36158 
 
Site 4: Asparagine 
104 (NGTC) 
Side of the head 
HexNAc(7)Hex(3)Fuc(1) 
 
1,389.85 (+4) 2, 053.77 0.27418 
HexNAc(2)Hex(3) 1,081.43 (+4) 892.31 -
0.001997 
Site 5: Asparagine 
142 (NHTV) 
Top of the head 
HexNAc(6)Hex(6)Fuc(1) 1,149.22 (+4) 2, 336.85 0.00096 
HexNAc(6)Hex(5) 1,054.67 (+4) 2, 028.74 0.24239 
HexNAc(6)Hex(4)NeuAc(1) 1,104.64 (+4) 2, 157.78 0.25827 
HexNAc(6)Hex(4)Fuc(1) 1, 068.44 (4) 2, 012.74 0.24967 
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HexNAc(6)Hex(4) 953.60 (+5) 1, 866.68 0.00167 
HexNAc(6)Hex(3)Fuc(1)Neu
Ac(1) 
1,466.57 (+3) 2, 141.78 -0.35536 
HexNAc(6)Hex(3)Fuc(2) 1,046.42 (+4) 1, 996.75 -0.00844 
HexNAc(6)Hex(3) 991.16 (+4) 1, 704.63 0.00043 
HexNAc(5)Hex(6)Fuc(2) 1,134.72 (+4) 2, 279.82 0.00087 
HexNAc(5)Hex(6)Fuc(1) 1,098.45 (+4) 2, 133.77 0.00237 
HexNAc(5)Hex(6) 1,061.70 (+4) 1, 987.71 -0.24352 
HexNAc(5)Hex(5)Fuc(3) 1,130.96 (+4) 2, 263.83 0.00054 
HexNAc(5)Hex(5)Fuc(2) 1,094.45 (+4) 2, 117.77 0.00123 
HexNAc(5)Hex(5)Fuc(1) 1,057.94 (+4) 1, 971.71 0.0035 
HexNAc(5)Hex(5) 1,021.42 (+4) 1, 825.66 -0.00022 
HexNAc(5)Hex(4)NeuAc(1) 1,035.43 (+4) 1, 954.70 -0.24191 
HexNAc(5)Hex(4)Fuc(1) 1,356.23 (+3) 1, 809.66 0.00052 
HexNAc(5)Hex(4) 980.91 (+4) 1, 663.60 -0.00032 
HexNAc(5)Hex(4)Fuc(2) 1,955.72 (+4) 1, 930.69 0.00039 
HexNAc(5)Hex(3)Fuc(1)Neu
Gc(1) 
1,404.24 (+3) 1, 954.70 -0.32956 
HexNAc(5)Hex(3)Fuc(1) 976.91 (+4) 1, 647.61 -0.00067 
HexNAc(4)Hex(7) 1,402.13 (+3) 1, 948.68 0.32814 
HexNAc(4)Hex(6)NeuGc(1) 1,450.25 (+4) 2, 091.72 0.33191 
HexNAc(4)Hex(6)NeuAc(1) 1,444.92 (+3) 2, 075.72 0.33262 
HexNAc(4)Hex(6)Fuc(2) 1,084.19 (+4) 2, 076.75 0.00188 
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HexNAc(4)Hex(6)Fuc(1) 1,047.93 (+4) 1, 930.69 0.2478 
HexNAc(4)Hex(6) 1,324.20 (+3) 1, 784.63 0.00147 
HexNAc(4)Hex(5)NeuGc(1) 1,047.18 (+4) 1, 926.67 0.00257 
HexNAc(4)Hex(5)NeuAc(1) 1,367.21 (+3) 1, 931.67 0.3165 
HexNAc(4)Hex(5)Fuc(3) 1,079.95 (+4) 2, 060.75 0.00052 
HexNAc(4)Hex(5)Fuc(2) 1,043.68 (+4) 1, 914.69 0.00044 
HexNAc(4)Hex(5)Fuc(1) 1,007.41 (+4) 1, 768.63 0.24923 
HexNAc(4)Hex(5) 970.65 (+4) 1, 622.58 -0.00094 
HexNAc(4)Hex(4)Fuc(2)Neu
Gc(1) 
1,061.69 (+4) 2, 059.73 -0.24548 
HexNAc(4)Hex(4)Fuc(2)Neu
Ac(1) 
1,057.69 (+4) 2, 043.74 -0.24382 
HexNAc(4)Hex(4)Fuc(1)Neu
Ac(1) 
1,021.17 (+4) 1, 897.68 -0.24484 
HexNAc(4)Hex(4)NeuAc(1) 1,003.16 (+4) 1, 751.62 0.2533 
HexNAc(4)Hex(4)Fuc(2) 1,003.17 (+4) 1, 752.64 0.00223 
HexNAc(4)Hex(4)Fuc(1) 901.58 (+5) 1, 606.58 0.00127 
HexNAc(4)Hex(4) 929.89 (+4) 1, 460.52 0.00082 
HexNAc(4)Hex(3)Fuc(3) 981.16 (+4) 1, 736.64 -0.00291 
HexNAc(4)Hex(3)Fuc(1) 926.14 (+4) 1, 444.53 0.00019 
HexNAc(3)Hex(6)Fuc(1)Neu
Gc(1) 
1,431.24 (+3) 2, 034.70 0.32942 
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HexNAc(3)Hex(6)Fuc(1)Neu
Ac(1) 
1,402.56 (+3) 2, 018.70 0.33363 
HexNAc(3)Hex(6)NeuGc(1) 1,037.41 (+4) 1, 888.64 0.24807 
HexNAc(3)Hex(6)Fuc(1) 996.91 (+4) 1, 727.61 0.00239 
HexNAc(3)Hex(6) 1,280.18 (+3) 1, 581.55 -0.01264 
HexNAc(3)Hex(5)Fuc(1) 956.39 (+4) 1, 565.56 0.00357 
HexNAc(3)Hex(5) 919.8 (+4) 1, 419.50 -0.00045 
HexNAc(3)Hex(4)Fuc(2) 915.88 (+4) 1, 549.56 0.00085 
HexNAc(3)Hex(4)Fuc(1) 915.64 (+4) 1, 403.50 0.00039 
HexNAc(3)Hex(3)Fuc(1) 875.37 (+4) 1, 241.45 -0.00017 
HexNAc(3)Hex(3) 838.85 (+4) 1, 095.39 0.00015 
HexNAc(2)Hex(5) 869.11 (+4) 1, 216.42 0.00035 
HexNAc(2)Hex(6) 909.62 (+4) 1, 378.47 0.00027 
HexNAc(2)Hex(7) 950.13 (+4) 1, 540.52 -0.00177 
HexNAc(2)Hex(8) 1,320.51 (+4) 1, 702.58 -0.01245 
Site 6: Asparagine 
177 (NLSK) 
Top of the head 
HexNAc(5)Hex(4)Fuc(1)Neu
Ac(1) 
1,553.65 (+2) 2, 100.76 -0.0034 
HexNAc(4)Hex(6) 1,166.17 (+3) 1, 784.63 0.00055 
HexNAc(2)Hex(8) 1,354.56 (+2) 1, 702.58 0.00196 
HexNAc(2)Hex(7) 1,273.53 (+2) 1, 540.52 0.00127 
HexNAc(2)Hex(6) 1,193.00 (+2) 1, 378.47 0.0015 
HexNAc(2)Hex(5) 1,111.98 (+2) 1, 216.42 0.00069 
HexNAc(2) 585.06 (+4) 406.15 -0.00064 
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Site 7: Asparagine 
303 (NSSL) 
Stalk 
HexNAc(6)Hex(4) 1,657.73 (+4) 1, 866.68 0.25101 
HexNAc(6)Hex(3) 1,621.22 (+4) 1, 704.63 0.25377 
HexNAc(4)Hex(5)NeuAc(1) 1,686.49 (+4) 1, 913.67 -0.24401 
HexNAc(4)Hex(4)NeuGc(1) 1,649.97 (+4) 1, 767.61 -0.25517 
HexNAc(3)Hex(6)NeuAc(1) 1,659.22 (+4) 1, 872.64 0.25161 
HexNAc(3)Hex(4)Fuc(1)Neu
Ac(1) 
1,614.70 (+4) 1, 694.60 0.2467 
Site 8: Asparagine 
498 (NGTY) 
Stalk 
HexNAc(8)Hex(8)Fuc(1) 1,342.18 (+3) 3, 067.11 -0.00606 
HexNAc(7)Hex(7)Fuc(1)Neu
Ac(2) 
1,414.88 (+3) 3, 284.17 0.3354 
HexNAc(6)Hex(6) 1,050.08 (+3) 2, 190.79 0.00079 
HexNAc(6)Hex(5)Fuc(1)Neu
Ac(2)NeuGc(1) 
1,341.19 (+3) 3, 064.07 0.02 
HexNAc(6)Hex(3)Fuc(2)Neu
Gc(1) 
1,471.89 (+3) 2, 303.84 -0.34158 
HexNAc(5)Hex(7) 1,415.21 (+3) 2, 149.76 -0.33692 
HexNAc(5)Hex(5)Fuc(1)Neu
Ac(1) 
1,458.23 (+3) 2, 262.81 -0.33147 
HexNAc(5)Hex(5)NeuGc(1) 1,409.55 (+3) 2, 132.75 -0.32933 
HexNAc(5)Hex(5)Fuc(1) 1,465.08 (+2) 1, 971.71 0.00223 
HexNAc(5)Hex(5) 1,307.84 (+3) 1, 825.66 0.00225 
HexNAc(5)Hex(4)Fuc(1)Neu
Ac(1) 
1,401.21 (+3) 2, 100.76 -0.32961 
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HexNAc(5)Hex(4)Fuc(1)Neu
Gc(1) 
1,409.55 (+3) 2, 116.75 -0.32763 
HexNAc(5)Hex(4)NeuGc(1) 1,384.87 (+3) 1, 970.69 -0.00099 
HexNAc(5)Hex(3)Fuc(1)Neu
Gc(1) 
1,355.53 (+3) 1, 945.70 -0.32857 
HexNAc(4)Hex(6) 1,293.83 (+3) 1, 784.63 -0.00351 
HexNAc(4)Hex(5)Fuc(1)Neu
Gc(1) 
1,390.54 (+4) 2, 075.72 -0.32938 
HexNAc(4)Hex(5)NeuGc(1) 1,366.19 (+3) 1, 929.67 0.00128 
HexNAc(4)Hex(5)Fuc(3) 1,386.20 (+3) 2, 060.75 -0.00084 
HexNAc(4)Hex(5)Fuc(2) 1,006.74 (+3) 1, 914.69 0.00054 
HexNAc(4)Hex(5)Fuc(1) 1,288.83 (+3) 1, 768.63 -0.00049 
HexNAc(4)Hex(5) 1,101.78 (+3) 1, 622.58 0.00172 
HexNAc(4)Hex(4)Fuc(2)Neu
Ac(1) 
1,385.21 (+3) 2, 043.74 -0.32697 
HexNAc(4)Hex(4)Fuc(1)Neu
Gc(1) 
1,360.86 (+3) 1, 913.67 0.32938 
HexNAc(4)Hex(4)Fuc(1)Neu
Ac(1) 
1,336.52 (+3) 1, 987.68 -0.33167 
HexNAc(4)Hex(4)Fuc(1) 943.87 (+4) 1, 606.58 -0.00836 
HexNAc(3)Hex(6)Fuc(1)Neu
Gc(1) 
1,382.18 (+3) 2, 034.70 -0.34415 
HexNAc(3)Hex(6)Fuc(1) 1,343.03 (+2) 1, 727.61 0.00136 
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HexNAc(3)Hex(5)NeuGc(1) 1,298.49 (+3) 1, 726.59 -0.00482 
HexNAc(3)Hex(4)Fuc(1)Neu
Ac(1) 
1,287.83 (+2) 1, 694.60 0.00233 
HexNAc(3)Hex(4)NeuAc(1) 1,239.15 (+3) 1, 548.54 0.00166 
HexNAc(3)Hex(4)Fuc(2) 1,239.15 (+3) 1, 549.56 -0.01108 
HexNAc(3)Hex(4) 1,107.95 (+2) 1, 257.44 0.00098 
HexNAc(2)Hex(8) 1,330.49 (+2) 1, 702.58 -0.02006 
 
The structural information obtained through CID fragmentation, albeit limited, still allows to 
discriminate between high mannose, complex or hybrid glycans in some cases. A high mannose 
structure can be assigned to the monosaccharide compositions in the form HexNAc(2)Hex(5-12), 
as long as the sequential fragmentation confirms the neutral loss of only hexose residues in the 
antennae from the glycopeptide Y ion series. Complex and hybrid glycans can be distinguished 
when diagnostic Y ions are detected, such as Pep+HexNAc(2)Hex(4), for compositions with more 
than 2 HexNAc residues. In such cases, at least one of the HexNAc residues must be in the 
antennae, thus ruling out a high mannose glycan. Additionally, the Pep+HexNAc(2)Hex(4) 
fragment confirms that one hexose must be attached to one glucose residue from the trimannosyl 
core. Both these features combined can only occur in hybrid glycans, since only HexNAc residues 
are attached to the trymannosyl core in complex glycans. Figure 3B shows a representative CID 
spectrum with two diagnostic ions (Pep+HexNAc(3)Hex(5)+3 and 
Pep+HexNAc(3)Hex(5)Fuc(1)+3) for a hybrid structure.  
Other diagnostic ions shed further structural information. A 512 m/z peak in the lower m/z range 
of the CID spectra corresponds to a Hex(1)HexNAc(1)Fuc(1) glycan B ion, characteristic of an 
outer arm fucose. Conversely, core fucosylation can be determined from the detection of Y ions 
such as Pep+HexNAc(1)Fuc(1) and Pep+HexNAc(2)Fuc(1). The latter fragments can also be 
observed in some HCD spectra to further confirm fucose attachment to the chitobiose core. Special 
consideration was given to glycans with a mass consistent with isobaric glycan compositions 
containing either Fuc+NeuGc or Hex+NeuAc. In these cases, not all spectra contained sufficient 
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information to derive the correct composition. Nonetheless, diagnostic ions (NeuAc (292.10 m/z), 
NeuAc-H2O (274.09 m/z), NeuGc (308.09 m/z), NeuGc-H2O (290.09 m/z)) were present in some 
HCD spectra and were used to identify the correct composition. Moreover, glycan B fragments 
corresponding to HexNAc-Gal-NeuAc (657 m/z) or HexNAc-Gal-NeuGc (673 m/z) detected in 
CID were also present in some spectra. 
Residues N142 and N498 displayed a great variety of glycan monomeric compositions. 
Conversely, for sites N28, N40, N71 and N104, only a very limited number of compositions were 
detected.  Overall, complex and hybrid glycans were predominantly found. Nonetheless, high 
mannose glycans are also present in N142 and N177, both located on the top of the globular head. 
Fucosylation was observed in most glycopeptides and was confirmed by the presence of fucose 
residues in the CID spectra or diagnostic ions in the HCD spectra. Core fucoses are predominant, 
but outer arm fucoses were also found in some glycoforms. Highly bulky complex glycans were 
found on N498. 
Discussion 
Sequence-based analysis has previously been employed by others to study the variation in the 
glycosylation profile of several strains during virus evolution [27, 28]. Although N-glycosylation 
prediction contributes greatly to the understanding of glycosite variation across strains, this method 
only provides a prediction that relies on primary sequence context, and the actual occupancy of 
glycosites must be confirmed experimentally. Moreover, it is known that the location of the sequon 
can affect glycan maturation, thereby resulting in different sets of glycoforms for each site 
depending on the accessibility of N-glycosyltransferases [29]. To this end, we used mass 
spectrometry analysis to confirm the occupancy of glycosites predicted by the NetNGlyc 1.0 
Server for the A/New Caledonia/20/1999 H1 protein. Others have shown that hemagglutinin from 
egg-grown viruses and human cell lines display the same occupancy profile [30]. Therefore, the 
results obtained in this study are relevant to the understanding of influenza virus adaptation in 
humans. 
The occupancy profile obtained through HCD/CID-MS/MS of tryptic glycopeptides was 
consistent with the prediction by the NetNGlyc 1.0 server. All eight sequons confirmed 
experimentally had been predicted by the server. Indeed, N28 (and not N27), was shown to be 
glycosylated as was predicted. The transfer of N-glycan precursors to asparagine residues in 
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endoplasmic reticulum (ER) bound ribosomes is affected by conformational constraints as well as 
inaccessibility due to steric hindrance from nearby residues. To this end, since N28 is occupied, it 
is unlikely that an olygosaccharyltransferase can act upon asparagine N27. The positive prediction 
for site N557 was not accurate, due to the location of the residue within the cytoplasmic domain 
of the protein. Nonetheless, such inaccuracies can easily be identified to prevent misleading 
interpretations when performing sequence-based analyses.  
Glycosites N142 and N177 are of particular relevance for the study of immunogenicity and 
virulence. These residues are both located on the receptor binding site (RBS) and the attachment 
of oligosaccharides can mask the antigenic Sa region. Remarkably, both acceptor sites were absent 
in the 1918 and 2009 pandemic strains. Wei et al. showed that mice display cross-neutralization 
of 1918 and 2009 pandemic viruses after vaccination with the 1918 strain, whereas such antibodies 
did not protect against seasonal strains – providing evidence that the introduction of N-
glycosylation sites on the vicinity of the RBS can mask antigenic recognition by pandemic 
antibodies [31].   
A vast heterogeneity of glycan compositions was found on N142 (Table 2), which is even more 
notable taking into account that the predicted compositions can encompass several glycan 
isoforms; meaning that the actual heterogeneity is presumably broader. Among the predicted 
oligosaccharides attached to N142 are glycan compositions consistent with complex, high 
mannose and hybrid glycans. The vast complexity encountered on this asparagine residue can be 
attributed to the high surface exposure, providing accessibility for N-glycan processing and 
maturation (Fig. 4).  
In the case of glycosite N177, a much narrower variety of glycoforms was detected. However, the 
intensities for these glycopeptides were much lower compared to those glycopeptides containing 
site N142. Therefore, many glycopeptides for N177 could have been suppressed and missed in the 
analysis, which constitutes a limitation of the method. Still, the MS/MS analysis predicted the 
occupancy of high mannose, hybrid and complex glycoforms. 
The presence of terminal sialic acid residues in several of the predicted glycoforms attached to 
both N142 and N177 could play an important role in the immunogenicity of the strain. Ohuchi et 
al. suggested that the presence of terminal NeuAc and NeuGc on HA glycans in the vicinity of the 
receptor binding sites may impair binding to sialic acid-containing receptors [32]. Although the 
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effect of the presence of sialic acid residues on immune cell recognition in this case is unknown, 
the bulkiness and negative charge of NeuAc and NeuGc would likely further impair an immune 
response. Overall, terminal sialylation of both cell surfaces and glycoproteins has been shown to 
decrease antigenicity [33, 34]. Therefore, the attachment of negatively charged terminal residues 
in embryonated-egg vaccine production could be a drawback in terms of HA antigenicity 
compared to other recombinant hemagglutinin based vaccines, where sialylation can be controlled 
or non-existent, as is the case in the baculovirus expression system [35].  
Glycosites N71 and N104 are located on the side of the globular head (Fig. 4). In the case of N71, 
only one glycan with a composition consistent with a non-fucosylated hybrid glycan was found 
(Table 2). For N104, one glycan with a complex-like composition was detected. Others have 
proposed that the occupancy of site N104 might be sterically hindered by glycan attachment on 
N71 due to their close proximity (Fig. 4) [20]. Moreover, it has been argued that since both 
glycosites are able to shield antigenic site Ca2, glycosylation on N71 could render the occupancy 
of N104 unnecessary to mask antigenic site Ca2 [20]. It was confirmed that both N71 and N104 
are indeed glycosylated in egg-grown viruses. It was unexpected, however, to find such a limited 
set of glycan compositions in these sites, in contrast to other positions such as N142, N177 and 
N498. As discussed previously, these results are potentially due to a limited detection of the 
glycopeptides containing these acceptor sites. However, the close proximity of both residues also 
suggests that glycan processing might be impaired due to steric hindrance. 
The detection of highly bulky complex glycans on N498 (e.g., HexNAc(8)Hex(8)Fuc(1) and 
HexNAc(7)Hex(7)Fuc(1)NeuAc(2)) suggests the presence of poly-N-acetyllactosamine groups, 
which are commonly found on membrane-proximal glycosites [36, 37]. The close proximity of 
N498 to the viral membrane (Fig. 4B) does not seem to decrease the degree of glycan maturation 
on this asparagine residue, resulting in a high complexity of structures. 
In this mass spectrometry setup, some tryptic glycopeptides produce considerably higher 
intensities than others. This causes that more information on glycan microheterogeneity can be 
gathered on those glycopeptides that ionize with a higher efficiency and whose m/z value is better 
detected under these experimental conditions, whereas only limited information can be derived 
from other regions. This was likely the cause of the limited glycopeptide detection for sites N28, 
N40, N71 and N104. Unfortunately, this drawback prevents an appropriate comparison of glycan 
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microheterogeneity among glycosites. Obtaining a more comprehensive profile is required to 
better understand the role of glycan structures on the biological properties of the virus. Still, these 
results allowed to confirm glycan attachment on these sites. 
An advantage of utilizing reducing SDS-PAGE as a preliminary fractionation step is that analysing 
HA0, HA1 and HA2 separately provides a more comprehensive characterization of glycan 
microheterogeneity, owing to the fact that the lower overall presence of non-glycosylated peptides 
in HA1 or HA2 isolated fractions (compared to HA0) could allow the detection of certain 
glycopeptides with low total ion current (TIC). In fact, most of the distinct glycan compositions 
detected on site N498 come from the analysis of HA2 and were not present in the analysis of HA0 
(band 4 in figure 2). This is likely due to the large presence of non-glycosylated peptides in HA0, 
which can suppress the signal of N498 glycopeptides.  
The experimental confirmation of glycosylation sites is highly important in the study of influenza 
viral evolution. Furthermore, there is evidence that egg and mammalian cell derived HA display 
the same occupancy profile [30]. Consequently, characterizing further egg-derived strains with 
this method would also yield site occupancy information relevant to other approved production 
platforms, such as cell-based and recombinant technologies. Currently, egg-based vaccines 
comprise the overwhelming majority of available influenza vaccine products. However, the FDA 
has recently approved the cell-based Flucelvax (Seqirus), produced in Madin-Darby Canine 
Kidney (MDCK) epithelial cells, and the recombinant Flublok (Protein Sciences Corporation), 
produced in insect cells [38-40]. It is noteworthy to mention that the glycan structures found on 
egg-derived viruses can differ significantly to those present on viruses that replicate in alternative 
cell substrates [30, 41, 42]. 
Conclusion 
The results presented in this study confirmed the glycan occupancy profile of A/New 
Caledonia/20/1999 hemagglutinin, validated the prediction by the NetNGlyc 1.0 Server and 
characterized the site-specific structural heterogeneity of the attached glycans. The mass 
spectrometry approach employed was able to furnish information on sequon occupancy and glycan 
structures in a single run. This efficient strategy can be extended to study further influenza 
glycoproteins in order to attain deeper knowledge of the role of N-glycosylation in viral adaptation 
mechanisms. Site-specific mass spectrometry methods, however, typically provide only partial 
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information on the structure of the oligosaccharides. To this regard, additional work should be 
carried out to elucidate more detailed structural features to assess the impact of glycoforms on 
parameters such as antigen masking, immunogenicity, SA receptor binding affinity and viral 
membrane resistance to surfactant treatment. The latter is highly relevant for split-virus vaccine 
manufacturing, where a surfactant is employed to disrupt the viral membrane. Gaining further 
insight into the glycosylation characteristics of influenza viruses can therefore potentially improve 
the manufacturing process of split-virus vaccines, the selection of strains for the composition of 
seasonal vaccines and the development of recombinant products. 
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Abstract 
It has been over four decades since the development of monoclonal antibodies (mAbs) using a 
hybridoma cell line was first reported. Since then more than thirty therapeutic antibodies have been 
marketed, mostly as oncology, autoimmune and inflammatory therapeutics. While antibodies are 
very efficient, their cost-effectiveness has always been discussed owing to their high costs, 
accumulating to more than one billion dollars from preclinical development through to market 
approval. Because of this, therapeutic antibodies are inaccessible to some patients in both 
developed and developing countries.  The growing interest in biosimilar antibodies as affordable 
versions of therapeutic antibodies may provide alternative treatment options as well potentially 
decreasing costs.  As certain markets begin to capitalize on this opportunity, regulatory authorities 
continue to refine the requirements for demonstrating quality, efficacy and safety of biosimilar 
compared to originator products.  In addition to biosimilars, innovations in antibody engineering 
are providing the opportunity to design biobetter antibodies with improved properties to maximize 
efficacy.  Enhancing effector function, antibody drug conjugates (ADC) or targeting multiple 
disease pathways via multi-specific antibodies are being explored. The manufacturing process of 
antibodies is also moving forward with advancements relating to host cell production and 
purification processes.  Studies into the physical and chemical degradation pathways of antibodies 
are contributing to the design of more stable proteins guided by computational tools.  Moreover, 
the delivery and pharmacokinetics of antibody-based therapeutics are improving as optimized 
formulations are pursued through the implementation of recent innovations in the field. 
Introduction  
Over the past twenty years, therapeutic antibodies have rapidly become the leading product within 
the biopharmaceutical market.  In 2013, therapeutic antibodies represented 50% of the $140 billion 
taken by the biopharmaceutical market with sales growing from $39 billion in 2008 to $75 billion 
in 2013 [1].  There are currently more than thirty therapeutic antibodies approved for established 
markets such as the United States and Europe with over three hundred antibody-based products in 
clinical development [1-3].  Therapeutic antibodies are no longer full-length, naked mouse 
antibodies; advancements in antibody engineering technologies, novel antigen discovery strategies 
and progress in deciphering disease pathways have all generated robust interest, resources and 
investment in antibody development.  In this review, we will discuss developments in the field of 
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therapeutic antibodies, the growth of biosimilars and pay particular attention to targeting 
degradation pathways of antibodies to produce more stable biobetter antibodies and formulations. 
Antibody discovery strategies 
The generation of early antibodies relied on the immunization of mice or other mammals with the 
desired antigen target. This resulted in multiple antibodies directed at different epitopes of the 
antigen secreted by a mixed population of B cells with each cell secreting only one specific 
antibody (i.e. polyclonal).  Unfortunately, secreting B cells can only replicate a limited number of 
times, therefore rendering mass production all but impossible.  The ground-breaking hybridoma 
technology developed by Kohler and Milstein allowed antibody secreting cells from the spleen of 
immunized animals to be fused with immortalized non-antibody secreting cells, thus resulting in 
cells that would divide continuously when cultivated in permissive conditions [4, 5].  Although 
the first recombinant antibodies were produced using this technology, including the first approved 
therapeutic antibody muromonab-CD3 (Orthoclone OKT®3) in 1986 for preventing kidney 
transplant rejection, hybridoma production presented some drawbacks.  Hybridomas can be labour 
intensive, low yielding or genetically unstable [6].  More importantly though, the antibody 
sequences originated from an immunized animal and consequently had the potential of triggering 
an immune response in humans.  Therefore, further improvements were needed to yield antibodies 
more human-like and safe.  These technologies have evolved from chimeric antibodies that is, 
grafting essential mouse amino acids needed for antigen binding onto a human antibody 
framework [7, 8] to both in vitro and in vivo techniques for generating humanized antibodies.   
The XenoMouse™ (Abgenix) and HuMab-Mouse® (Medarex) are transgenic mice developed in 
parallel and in both, the endogenous murine heavy and kappa light chain genes are inactivated and 
replaced with the equivalent human germline sequences [9, 10].  Injection of antigens into these 
mice leads to development of ‘fully human’ antibodies that have undergone mouse somatic 
hypermutation and selection to relatively high affinity.  Validation of this technology came with 
the regulatory approval of panitumumab (Vectibix®) in 2006; a fully human antibody directed 
against epidermal growth factor receptor (EGFR) as treatment for advanced colorectal cancer [11].  
Since then, RANK ligand-specific denosumab (Prolia®) has been approved for bone loss and 
TNFα-specific golimumab (Simponi®) for rheumatoid arthritis.   
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An in vitro method for generating fully human antibodies can be accomplished by cloning and 
screening large libraries of sufficiently diverse human antibody genes in combination with display 
technology.  The concept of display technology provides a direct physical link between a gene 
(genotype) and the encoding antibody fragment (phenotype) to allow selection of genes that 
encode a protein with the desired binding function.  Phage display technology remains the most 
widely used in vitro method for the display of large repertoires and for the selection of high affinity 
antibodies to biologically relevant targets [6].  Phage display involves the expression of proteins 
on the surface of filamentous phage via fusion with phage coat protein with the genetic sequence 
packaged within, linking phenotype to genotype selection.  When combined with antibody 
libraries, phage display allows for rapid in vitro selection of antigen-specific antibodies and 
recovery of their corresponding coding sequence [12-14].  This system is highly effective, robust 
and amenable to high throughput processes for screening of  >10+10 specificities [15].  The 
diversity of phage display libraries is distinguishable by source and design: naïve [16], immune 
[12], synthetic [17] and semi-synthetic [18].  The technology was first demonstrated for a single 
chain variable fragment (scFv) [13]. with screening of other formats also introduced including 
human antigen binding fragments (Fabs) [19], domain antibodies [20], camelid domain antibodies 
[21], single domain shark antibodies [22], diabodies [23] and even whole IgG [24].  The first 
approved human antibody isolated by phage display technology was adalimumab (Humira®) 
which binds the cytokine TNFα.  This antibody was first selected as a scFv expressed on the 
surface of phage and was further engineered in human IgG1 format, providing major validation 
for phage display technologies [25].  Adalimumab remains the most lucrative antibody product 
generating global sales of $11 billion in 2013 [1].  The number of phage display-derived candidates 
currently in clinical development further demonstrates the value of phage display as an established 
and reliable drug discovery platform [26].   
Other cell surface methodologies such as bacterial, baculovirus and yeast display present 
thousands of copies of the displayed protein on the cell surface thereby allowing for quantitative 
screening such as flow cytometry [27-29].  Yeast display has the additional feature of eukaryotic 
protein folding pathways and as a result, is perhaps the most ideally suited system for the surface 
display of mammalian secreted proteins such as antibodies.  Alternatively, ribosome display is 
used to screen large scFv and single variable domain libraries containing up to >10+13 mutant 
clones [30].  The main distinguishing feature of this method is that large libraries can be generated 
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because the entire procedure is performed in vitro without the need for cell transformations.  The 
genotype and phenotype are linked through ribosomal complexes, consisting of messenger RNA 
(mRNA), ribosome and encoded protein.  The in vitro selection of antibodies from antibody 
libraries based on target afﬁnity is termed as “panning”. The method is an iterative process 
whereby the population of target speciﬁc antibodies is enriched relative to the number of panning 
rounds. 
With the advent of next-generation sequencing (NGS), analysis of the natural and synthetic 
repertoires from which libraries have been constructed has become possible [31-33].  In one 
application, NGS was used to identify antigen-specific IgG antibodies from polyclonal serum of 
immunized rabbits and mice when used in combination with affinity chromatography coupled to 
LC-MS/MS [34].  The technology has been used to demonstrate its utility in selecting antibodies 
with favourable properties.  For example, Reddy et al. found that 21/27 (or 78%) of scFv they 
constructed could bind the target antigen with nanomolar afﬁnity after using NGS data to pair 
together the most abundant variable heavy (VH) and variable light (VL) genes from immunized 
mice [35].  Other studies have seen similar findings with natural VH:VL pairing limitations [36]. 
and without the limitation [37].  Interestingly, the method of repertoire mining of VH and VL 
abundances using NGS of splenocytes isolated from immunized mice was compared with a phage 
panning approach of the same cDNA [38]. While both methods provided completely different sets 
of antibodies, specificity and affinities of the antibody clones were comparable. 
Novel antibodies in approval and preclinical development stages 
In 2015, eight therapeutic antibodies were granted market approval by the US Food and Drug 
Administration (FDA) (Table 1). While full-length and IgG1 antibodies still dominate, a 
humanized Fab also gained approval.  Five of the eight approvals were to non-oncology indications 
with two antibodies entering ‘first-in-class’ for the treatment of hyperlipidemia.  The outlook for 
2016 has been positive with six antibodies approved (as of November 2016), including a first-in-
class antibody to bacterial target Bacillus anthraxis.  A number of full-length antibodies are 
currently under biologics license application (BLA) submission and awaiting FDA approval or 
have completed Phase III trials with endpoints met (Table 1).   
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Table 1. Novel full-length antibodies and fragments developed in recent years and their clinical 
status. 
Name Commerci
al Name 
Company Target Indication (FDA 
approved) 
Format 
APPROVED BY FDA IN 2015 
Secukinumab Costentyx
® 
Novartis IL-17 Psoriasis Whole IgG1 
(fully 
human) 
Dinutuximab Unituxin® United 
Therapeutics 
Corporation 
GD2 Neuroblastoma 
(pediatric 
patients) 
Whole IgG1 
(chimeric) 
Alirocumab Praulent® Sanofi PCSK9 Hyperlipidemia Whole IgG1 
(fully 
human) 
Evolocumab Repatha® Amgen PCSK9 Hyperlipidemia Whole IgG2 
(fully 
human) 
Idarucizumab Praxbind® Boehringer 
Ingelheim 
Dabigatran Anti-coagulation 
reversal 
Fab fragment 
(humanized) 
Mepolizumab Nucala® GlaxoSmithKline IL-5 Asthma Whole IgG1 
(humanized) 
Necitumumab Portrazza® Eli Lilly EGFR Non-small cell 
lung cancer 
(NSCLC) 
Whole IgG1 
(fully 
human) 
Daratumumab Darzalex® Janssen Biotech CD38 Multiple 
myeloma 
Whole IgG1 
(fully 
human) 
APPROVED BY FDA IN 2016 (as of November) 
Reslizumab Cinquil® Teva IL-5 Asthma Whole IgG4 
(humanized) 
Ixekizumab Taltz® Eli Lilly IL-17a Psoriasis Whole IgG4 
(humanized) 
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Obiltoxaximab Anthim® Elusys 
Therapeutics 
Bacillus 
anthrax 
Anthrax Whole IgG3 
(humanized) 
Atezolizumab Tecentriq
® 
Genentech PD-L1 NSCLC, Bladder 
cancer 
Whole IgG1 
(humanized) 
Olaratumab (+ 
Doxorubicin)  
Lartruvo® Eli Lilly PDGFRalph
a 
Soft tissue 
carcinoma 
Whole IgG1 
Bezlotoxumab Zinplava® Merck Clostridium 
difficile 
toxin B 
Clostridium 
difficile infection 
Whole IgG1 
(fully 
human) 
NOT YET APPROVED, TRIALS COMPLETED 
Brodalumab 
 
Valeant 
Pharmaceuticals 
IL-17R Psoriasis Whole IgG1 
(fully 
human) 
Bimagrumab 
 
Novartis ACVR2B Muscle loss and 
weakness 
Whole IgG1 
(fully 
human) 
MABp1 Xilonix XBiotech IL-1alpha Colorectal cancer, 
Cachexia 
Whole IgG1 
(‘true’ 
human) 
Catumaxomab Removab Trion Pharma EPCAM/CD
3 
Malignant ascites Whole 
hybrid of rat 
IgG2 
variable and 
mouse IgG2a 
Fc regions 
Guselkumab  Janssen Biotech IL-23/p19 Psoriasis Whole IgG1 
(fully 
human) 
Dupilumab  Sanofi/Regeneron IL-4R Atopic Dermatitis Whole IgG4 
(fully 
human) 
ONGOING PHASE III TRIALS 
Ocrelizumab Ocrevus Roche CD20 Multiple Sclerosis Whole IgG1 
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(humanized) 
Sirukumab 
 
GlaxoSmithKline IL-6 Rheumatoid 
arthritis 
Whole IgG1 
Sarilumab 
 
Sanofi/Regeneron IL-6R Rheumatoid 
arthritis 
Whole IgG1 
(fully 
human) 
Tildrakizumab 
 
Sun 
Pharmaceutical 
IL-23/p19 Psoriasis Whole IgG1 
(humanized) 
Romosozumab 
 
Amgen/UCB 
Pharma 
Sclerostin Osteoporosis Whole IgG2 
(humanized) 
Racotumomab Vaxira Recombio NGcGM3 NSCLC Whole IgG1 
(mouse) 
Clivatuzumab 
tetraxetan 
hPAM4-
Cide 
Immunomedics Mucin1 Pancreatic cancer Whole IgG1 
(humanized) 
Ublituximab 
 
TG Therapeutics CD20 Chronic 
Lymphocytic 
Leukemia 
Whole IgG1 
(chimeric) 
Benralizumab 
 
AstraZeneca IL-5R Asthma Whole IgG1 
(humanized) 
Caplacizumab 
 
Ablynx vWF Thrombotic 
thrombocytopenic 
purpura 
VH-VH 
(humanized) 
Lampalizumab 
 
Roche CFD Macular 
degeneration 
Fab fragment 
(humanized) 
Avelumab 
 
Merck/Pfizer PD-L1 Merkel Cell 
Carcinoma 
Whole IgG1 
(fully 
human) 
Aducanumab  Biogen Beta 
amyloid 
Alzheimer’s 
Disease 
Whole IgG1 
(fully 
human) 
Abbreviations: GD = disialoganglioside; PCSK = proprotein convertase subtilisin/kexin; EGFR = 
epidermal growth factor receptor; PD-L = programmed death-ligand; PDGFR = platelet-derived 
growth factor receptor; ACVR = activin receptor; EPCAM = epithelial cell adhesion molecule; 
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NGcGM = N-glycolyl (NGc) gangliosides; vWF = Von Willebrand factor; CF = complement 
factor. 
There is expected to be an influx of antibodies in the coming years for the treatment of 
inflammatory skin conditions including psoriasis that encompass various cytokine targets or their 
respective receptors; IL-17a, IL-17R, IL-1α, IL-4R and IL-23 (Table 1).  Other promising 
antibodies based on recent clinical trial results include ocrelizumab and atezolizumab.  
Ocrelizumab is a humanized antibody which selectively targets CD20-positive B cells which based 
on emerging evidence play a major role in activating T cells, the key cell type responsible for 
inflammatory damage within central nervous system lesions in multiple sclerosis (MS) [39].  Data 
from three Phase III studies (OPERA I, II and ORATORIO) show positive results in patients with 
relapsing MS and primary progressive MS (PPMS) with superiority to well-established therapy 
(Rebif®), by reducing the three major markers of disease activity.  Atezolizumab is a monoclonal 
antibody designed to target PD-L1 expressed on T cells and tumour-infiltrating immune cells, 
preventing binding to PD-1 and B7.1 to mediate T cell immune responses.  Positive results 
announced from two Phase II studies (POPLAR and BIRCH) in patients with advanced non-small 
cell lung cancer (NSCLC) show strong correlation between PD-L1 expression and response rates, 
suggesting that measuring PD-L1 may help identify people most likely to respond to antibody 
treatment.  Atezolizumab has since been granted FDA approval (after priority review) for 
treatment of a specific type of bladder cancer and NSCLC.   
A number of novel formats and treatment options are also likely to enter the market in 2017.  Of 
note based on novelty, are racotumomab, ublituximab, MABp1 and caplacizumab.  Racotumomab 
is an anti-idiotypic mouse monoclonal antibody that mimics N-glycolyl (NGc) gangliosides, thus 
triggering responses against tumor antigen NGcGM3 [40].  The idiotypic antibody acts as a 
therapeutic vaccine by inducing the immune system to elicit a specific response.  A Phase III 
clinical trial is ongoing in advanced NSCLC patients.  
Ublituximab is a chimeric monoclonal antibody which targets CD20 and has been fragment of 
crystallization (Fc) engineered with low fucose content to enhance affinity to all allelic variants of 
FcγIIIa receptors, demonstrating greater antibody dependent cell cytotoxicity (ADCC) than 
rituximab (Rituxan®) and ofatumumab (Arzerra®).  This will see the second glyco-engineered 
antibody to enter the market (discussed later in Fc engineered section).  Ublituximab is currently 
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being assessed in Phase III trials in combination with small molecule ibrutinib in patients with 
previously treated high-risk Chronic Lymphocytic Leukemia (CLL).  Indeed, 2015 witnessed the 
first FDA approval of a combination regime of anti-PD-L1 antibodies nivolumab (Opdivo®) and 
ipilimumab (Yervoy®) and is quickly becoming a focus of ongoing research with both emerging 
and established therapeutics.   
MABp1 is a ‘natural’ antibody cloned from an affinity-matured, in vivo human immune response, 
with no sequence modifications. The antibody was derived from Epstein-Barr-virus-immortalized 
B lymphocytes derived from an individual with circulating anti-interleukin-1α, a method 
previously described by Garrone and colleagues [41].  This potential breakthrough first-in-class 
‘true human™’ monoclonal antibody targeting IL-1α is being assessed in Phase III clinical trials 
for late stage colorectal cancer.  The safety results to date suggest a unique safety profile for this 
antibody, among the best tolerated therapies used in oncology making it ideally suited for treating 
advanced cancer patients with reduced tolerance for toxic therapy [42].  The antibody is also being 
investigated in a Phase II trial to correct the metabolic dysregulation underlying the wasting 
phenotype associated with malignancy by specifically targeting IL-1α signalling in the 
hypothalamus.   
A Phase III clinical trial (HERCULES) has been initiated for bivalent nanobody® (or VHH) 
caplacizumab targeting anti-von Willebrand factor (vWF) to treat acquired Thrombotic 
Thrombocytopenic Purpura (TTP).  This could see the first nanobody® to be approved and the 
smallest antibody fragment on the market at approximately fifteen kilodaltons (kDa).   
Biobetter antibodies 
Despite its success, antibody-based therapy still presents a long list of important shortcomings that 
need to be overcome to fully exploit their full therapeutic potential. Typical drawbacks in antibody-
based therapy include limited efficacy due to poor tissue and tumor penetration, low in vivo 
efficacy, cumbersome administration, antibody aggregation, solubility as well as high production 
costs [43]. The use of antibody engineering to improve the properties of therapeutic antibodies has 
advanced greatly in the last decades giving rise to a varied set of novel formats that offer enhanced 
attributes for therapeutic and research purposes. These novel molecules are often referred to as 
biobetters or next-generation antibodies and include platforms such as: engineered antibodies for 
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enhanced effector functions, antibody drug-conjugates (ADC), multi-specific antibodies and 
single-domain antibody fragments (sdAb or nanobodies®) [44, 45].  
A biobetter can have modifications to its chemical structure such as humanization, 
fusion/conjugation or be glyco-engineered to be less immunogenic or more efficacious. For 
instance, anti-CD20 ocrelizumab which is currently under review for FDA approval for MS is a 
humanized version of rituximab (Rituxan®).  A biobetter may be modified to have an improved 
formulation for improved treatment regimen so treatment is less evasive or have a simplified 
manufacturing process.  This was demonstrated with novel subcutaneous (SC) formulations of 
trastuzumab (Herceptin®) and rituximab (Mabthera®) developed by co-formulating the antibody 
with hyaluronidase, an enzyme that increases the absorption and distribution of the injected 
product [46].  A biobetter may be engineered to have higher target affinity, bind at a different 
epitope or stronger effector function to enhance efficacy and potentially reduce any off-target side 
effects.  Any such improvement means that the therapeutic has been modified and incomparable 
to the original therapeutic; it is therefore classified as a new biological therapeutic and requires 
more laborious testing to obtain regulatory approval before market entry.  In the next section, Fc 
engineering, ADC and multi-specific antibody-based therapies will be discussed. 
Fc engineered antibodies for enhanced effector functions 
Antibody engineering has sought to improve the effector function of antibodies via the Fc region; 
namely ADCC, complement dependent cytotoxicity (CDC) and PK profile. Specifically, this has 
been mostly explored through modifications in the amino acid sequence or the glycosylation 
pattern in the Fc region to enhance the affinity towards Fcγ receptors (FcγR) on effector cells [44, 
47]. The most prominent and successful technology so far has been the glycosylation approach, 
which has seen nearly twenty glyco-engineered antibodies enter clinical trials with two already 
approved for clinical use [48-50]. The first success came with the approval of mogamulizumab 
(Poteligeo®) in Japan in 2012, developed using the POTELLIGENT (Kyowa Hakko Kirin) 
platform which is indicated for CC-chemokine receptor 4 (CCR4)-expressing T cell leukaemia-
lymphoma and peripheral T cell lymphoma (PTCL) in adult patients [51].  
An ADCC enhanced version of rituximab, obinituzumab (Gazyva®) gained approval by the FDA 
in 2013 under breakthrough therapy designation [52]. Obinituzumab is an anti-CD20 monoclonal 
antibody that was originated by GlycArt Biotechnology (now GlycoMAb) and is approved for 
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CCL [49]. Both POTELLIGENT® and GlycArt platforms are based on the manufacture of 
products using engineered cell lines that yield defucosylated antibodies; a structural modification 
that removes the core 1,6 fucose from the N-glycans attached to asparagine at amino acid position 
297 of human IgG1 thereby greatly enhancing the affinity towards FcγRIII, and increasing ADCC 
induction by NK cells (Figure 1a) [53, 54].  NK cells are not abundant in the tumor site, and human 
endogenous IgG can inhibit the elicitation of ADCC by therapeutic antibodies [55] therefore, 
increasing the affinity towards FcγRIII to preferentially interact with the therapeutic antibody is a 
valuable approach to improve the efficacy profile. This approach was demonstrated by Zhang et 
al. by producing an anti-HER2 antibody with an identical sequence to trastuzumab but with 
superior binding affinity to FcyRIIIa and greater ADCC activity [56]. The antibody was produced 
using glyco-engineered Pichia pastoris and the differences were presumed to be due to absence of 
fucose in the N-glycans attached to the IgG1 product. 
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Figure 1. Schematic representation of biobetter antibody formats being pursued for clinical 
development. (a) Schematic structure of an IgG1 antibody with glycosylation sites at 
asparagine 297 (Asn-297) in CH2 domains indicated by hexagons.  The general structure of 
N-linked glycosylation is shown inset; core structures indicated by solid lines and variable 
structures by dotted lines.  Glyco-engineering of antibodies can involve defucosylation 
which refers to the removal of core fucose to enhance Fc-mediated effector functions.  (b) 
Schematic structure of an antibody drug conjugate (ado-trastuzumab emtansine; Kadcyla®) 
including N-maleimidomethyl cyclohexane-1-carboxylate (MCC) linker and maytansinoid 
1 (DM1) payload. (c) Prominent bispecific formats in development as discussed in the text 
including: Triomab or Trifunctional antibody, Dual variable domain immunoglobulin 
(DVD-Ig), Dock-and-Lock (DNL) antigen binding fragments (Fabs), Bispecific T cell 
engager (BITE), Dual affinity re-targeting (DART) molecule, Tandem diabody (tandAb) and 
Immune-mobilizing monoclonal TCRs against cancer (ImmTAC). 
Whereas the glyco-engineering approach generates defucosylated antibodies with FcγRIIIa-
specific affinity improvement, variants generated by mutagenesis of Fc amino acid sequence can 
be enhanced for multiple FcγR interactions.  A number of publications have identified specific Fc 
mutations to improve binding to the activating receptor FcγIIIa and reduce binding to the inhibitory 
receptor FcγIIb with corresponding improvement to ADCC activity [57-59].  The XmAb® concept 
is currently being investigated as an anti-CD30 in Phase I trials for Hodgkin lymphoma. 
In an alternative approach, aglycosylated antibodies (without glycan structures) can be engineered 
to display effector functions that are distinct from those of glycosylated counterparts [60-63].  The 
use of aglycosylated therapeutic antibodies offers manufacturing advantages by bypassing 
glycosylation and hence production can be performed in prokaryotic hosts.  On the other hand, the 
importance of glycosylation on the structural stability of antibodies has been demonstrated [64, 
65].  The first aglycosylated antibody to enter clinical trials, produced in yeast, is humanized rat-
derived IgG1 otelixizumab directed against CD3 which is being assessed in Phase II trials for type 
I diabetes mellitus. 
Antibody drug conjugates (ADC)  
ADC comprise one of the foremost antibody-based platforms currently being pursued for clinical 
implementation. Indeed, the FDA approval of brentuximab vedotin (Adcetris®) and a cytotoxin-
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conjugated biobetter of trastuzumab, ado-trastuzumab emtansine (Kadcyla®) in 2011 and 2013 
respectively, have eclipsed the clinical failures of first generation ADC. As of early 2016, in 
addition to the two ADC available in the market, over forty antibody drug conjugates are 
undergoing clinical trials and a plethora of such formats are in preclinical development [3]. (Table 
3). The achievement of such milestones has been facilitated by the advent of novel ADC 
technologies and designs.  
 
Table 3. Overview of ADC developed in recent years and their clinical status. 
ADC Format Target Payload Linker Lead 
indications 
FDA APPROVED 
Brentuximab 
vedotin 
(Adcetris®) 
IgG1 
(Chimeric) 
CD30 MMAE Valine-Citrulline Hodgkin 
Lymphoma, 
Anaplastic 
large cell 
lymphoma 
Ado-trastuzumab 
emtansine 
(Kadcyla®) 
IgG1 
(Humanized) 
HER2 DM1 Valine-Citrulline HER2+ breast 
cancer 
Gemtuzumab 
ozogamicin 
(Mylotarg® - 
withdrawn) 
IgG4 
(Humanized) 
CD33 Calicheamicin SS/hydrazone Acute 
Myeloid 
Leukemia 
Phase III 
Inotuzumab 
ozogamicin 
IgG4 
(Humanized) 
CD22 Calicheamicin SS/hydrazone Acute 
Lymphoblastic 
Leukemia  
Phase II 
Enfortumab 
vedotin 
(ASG-22ME) 
IgG1 
(Human) 
Nectin-4 MMAE Valine-Citrulline Bladder 
cancer 
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PSMA ADC IgG1 
(Human) 
PSMA MMAE Valine-Citrulline Prostate 
cancer 
Glembatumumab 
vedotin (CDX-
011) 
IgG2 
(Human) 
GPNMB MMAE Valine-Citrulline Breast cancer 
Lifastuzumab 
vedotin 
(DNIB0600A) 
IgG1 
(Humanized) 
NaPi2b MMAE Valine-Citrulline Ovarian 
cancer 
Pinatuzumab 
vedotin 
(DCDT2980S) 
IgG1 
(Humanized) 
CD22 MMAE Valine-Citrulline Non-
Hodgkin’s 
Lymphoma 
(NHL) 
Polatuzumab 
vedotin 
(DCDS4501A) 
IgG1 
(Humanized) 
CD79b MMAE Valine-Citrulline NHL, Diffuse 
large B cell 
lymphoma 
Lorvotuzumab 
mertansine 
(IMGN-901) 
IgG1 
(Humanized) 
CD56 DM1 SPP Hematological 
malignancies 
IMMU-130 
(Labetuzumab-
SN-38) 
IgG1 
(Humanized) 
CEACAM5 SN-38 Carbonate Colorectal 
cancer 
IMMU-132 
(hRS7-
SN38ADC) 
IgG1 
(Human) 
TROP-2 SN-38 Carbonate Breast cancer 
Milatuzumab 
doxorubicin 
(IMMU-110) 
IgG1 
(Humanized) 
CD74 Doxorubicin Hydrazone Multiple 
myeloma 
Indatuximab 
ravtansine (BT-
062) 
IgG1 
(Humanized) 
CD138 DM4 SPDB Multiple 
myeloma 
Rovalpituzumab 
tesirine 
(SC16LD6.5) 
Undisclosed Fyn3 D6.5 Undisclosed Small cell 
lung cancer 
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Depatuxizumab 
mafodotin 
(ABT-414) 
IgG1 
(Human) 
EGFRvIII MMAF Maleimidocaproyl Glioblastoma 
Abbreviations: MMAE = monomethylauristatin; DM = maytansinoid; PSMA = prostate-
specific membrane antigen; GPNMB = transmembrane glycoprotein NMB; NaPi = sodium-
dependent inorganic phosphate; CEACAM = carcinoembryonic antigen-related cell 
adhesion molecule; EGFR = epidermal growth factor receptor. 
While the targeted nature of ADC therapy is expected to reduce treatment side effects, toxicity still 
remains an important concern for ADC. In fact, gemtuzumab ozogamicin (Mylotarg®), a 
humanized anti-CD33 antibody conjugated to calicheamicin was the first ADC to receive FDA 
approval in 2000 for treatment of acute myeloid leukemia (AML).  However, Mylotarg® was 
voluntarily withdrawn from the market after results of a Phase III study raised toxicity concerns 
and showed no benefit compared to standard therapies [66].  Brentuximab vedotin and ado-
trastuzumab emtansine also present significant toxicity; both are required by the FDA to carry a 
black box warning due to the risk (although only seen in rare cases) of developing progressive 
multifocal leukoencephalopathy (brentuximab vedotin) and risk of hepatotoxicity, cardiac toxicity, 
and embryo-fetal toxicity (ado-trastuzumab emtansine). Consequently, there remains a challenge 
in the field to further validate the superior therapeutic index that ADC can deliver over traditional 
chemotherapy and other targeted therapies. In this regard, great efforts are being directed to 
implement refinements in each of the components (targeted antigen, targeting moiety, linker, 
payload and conjugation chemistry) to boost the therapeutic potential of ADC. 
While most conjugates in clinical and preclinical development target cell surface receptors that are 
overexpressed in solid tumours and B-cell malignancies (Table 3), novel approaches such as 
targeting antigens present in neovasculature or extracellular stromal tissue are being explored.  One 
main advantage of such approach is that perfusion into the tumor is not required since blood serum 
is in direct contact with vascular endothelial cells, with exposure of the conjugate to its target tissue 
considerably greater than for traditional ADC targeting neoplastic cells [67-69].  Another attractive 
feature is that vascular endothelial cells are less likely to develop resistance mechanisms. Others 
have also explored the possibility of targeting cancer stromal cells, aiming to suppress tumor 
proliferation, neovascularization, invasion, and metastasis which are typically promoted by the 
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tumor microenvironment [70, 71].  Overall, the factors affecting the internalization rate of ADC 
suggest that antigen selection is of high importance in determining the efficacy of the conjugate in 
a physiological environment.  
Conversely, the efficacy of a conjugate is predominantly determined by its affixed payload. 
Current ADC feature antineoplastic agents that have an extremely high potency, usually in the sub-
nanomolar range. Most of these molecules are derivatives of highly potent cytotoxic drugs that 
have exquisite potency but at the same time, make them unamenable for development as 
chemotherapeutic agents alone. The cytotoxic drugs being employed can be classified into three 
major groups namely, calicheamicins (DNA disruption), maytansinoids and auristatins (cell cycle 
interference) [72-75].  Monomethylauristatin E (MMAE) and monomethylauristatin F (MMAF) 
are the most widely used payloads in the current pipeline with another twenty auristatin conjugates 
under clinical development [76, 77].  Among the maytansine analogs, DM1 and DM4 are being 
pursued with more than ten ADC in clinical trials (Table 3; Figure 1b).  Alternative drug classes 
such as duocarmycins and pyrrolobenzodiazepines may also gain popularity due to their 
remarkable potency [78, 79]. 
The linker component is a major determinant of plasma stability of a conjugate, thus impacting on 
the efficacy and safety profile.  One of the main reasons for off-target effects is the premature 
release of cytotoxic activity outside of target cells.  A commonly used approach for coupling the 
conjugate to an antibody is via a linker that contains a lysosomal-specific protease cleavage site. 
In this format, the linker is intended to be cleaved in the lysosome by proteases such as cathepsin 
B, plasmin and β-glucoronidase [80, 81].  Indeed, the valine-citrulline (Val-Cit) dipeptide linker, 
recognized and cleaved by cathepsin B, is currently the most widely implemented linker 
technology [82, 83].  A novel approach using non-cleavable linkers has gained popularity since 
they could substantially increase blood serum stability. In this modality, the antibody is digested 
inside the lysosome upon internalization, releasing the payload attached to an amino acid residue, 
yet still retaining its cytotoxic activity [84, 85].  For example, ado-trastuzumab emtansine, employs 
the hetero-bifunctional crosslinker N-succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-
carboxylate (SMCC), creating a non-reducible thioether linker (MCC) as a spacer between the 
anti-HER2 antibody and the maytansine DM1 [86]. Presumably due to increased stability, reduced 
toxicity has been observed with non-cleavable linker design relative to conjugates with cleavable 
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linker [87].  Remarkably, ado-trastuzumab emtansine has displayed superior in vivo activity in 
mouse breast cancer models compared to a similar trastuzumab-DM1 conjugate that differs only 
in that it contains a disulphide reducible linker [88]. 
The chemical reactions used to couple ADC components can also play a role in the therapeutic 
index.  The first conjugation techniques developed to create ADC involved a chemical reaction 
between a functional group in the linker and a reactive moiety in native amino acid residues, 
predominantly the thiol side-chains of partially reduced cysteines and the epsilon-amino end of 
lysine residues [89, 90].  In these cases, the conjugation sites and the number of drug molecules 
affixed to the antibody are stochastic, resulting in heavily heterogeneous conjugates.  This 
heterogeneity undermines the clinical potential of ADC, since it impacts severely on their toxicity 
and safety profiles.  In terms of potency, the efficacy is compromised by the reduced subset of 
ADC with an optimal amount of attached drug to exert a significant cytotoxic effect. Besides the 
fact that conjugates with low drug-to-antibody ratios (DAR) have limited efficacy, high DAR also 
possess higher toxicity and reduced plasma stability due to increased clearance rates [91].  This 
clearly illustrates the critical importance of achieving an optimal ratio.  Despite the shortcomings 
of stochastic attachments methods, both cysteine and lysine conjugation techniques have been 
utilized in the development of brentuximab vedotin and ado-trastuzumab emtansine, respectively.  
A set of alternate novel techniques have been developed to allow for site-specific conjugation 
including the THIOMAB platform [92], introduction of unnatural amino acids or enzymatic 
modification of native amino acid side-chains [93-95] and even glycan attachment through glyco-
engineering [96]. 
Bispecifics 
The next novel wave of therapeutic antibodies is predicted to be in the format of bispecific 
antibodies.  The concept of bispecific antibodies was first demonstrated more than twenty years 
ago, initially by chemical conjugation of two antibodies [97] then by fusing two hybridoma 
cultures [98].  There are now more than fifty different bispecific formats in development, enabling 
researchers to adjust and control parameters such as size, half-life, stability, flexibility and 
orientation to achieve the desired therapeutic outcome.  The assembly of antibody chains to 
accomplish the various antibody formats has been made possible with antibody engineering 
techniques including variations of the general approach [99-101] to novel approaches such as 
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‘knobs-into-holes’ [102], CrossMab [103], ‘Dock-and-Lock’ (DNL) [104, 105] and even hybrid 
domains derived from other immunoglobulin antibodies, via a technology referred to as strand-
exchange engineered domain (SEED) [106].   
The majority of bispecific antibodies are currently being assessed in clinical trials and are detailed 
in Table 4 with a few examples discussed below based on their mode of action.  Referred to as a 
trifunctional or triomab is catumaxomab (Removab®), bispecific to tumor antigen EPCAM and T 
cell marker CD3 (Figure 1c).  The antibody acts by recruiting and activating immune cells; 
EPCAM targets the tumor, CD3 recruits T effector cells and the Fc region recruits and activates 
monocytes, macrophages, dendritic cells (DC) and NK cells by FcγR binding [107].  
Catumaxomab is a hybrid antibody comprised of rat IgG2b binding domains and mouse IgG2a Fc 
region.  Catumaxomab has not yet received FDA approval (BLA submitted) but has EMA approval 
for the treatment of malignant ascites since 2009.  The antibody is also in clinical trials for 
application in ovarian cancer (II), gastric cancer (II) and epithelial cancer (I).  Given that 
catumaxomab is a rat-mouse hybrid, some anti-rat or anti-mouse IgG responses are observed in 
patients, though treatment does not appear to be significantly affected.  In fact, development of 
human anti-mouse antibodies (HAMA) have been shown to contribute to greater clinical benefit 
[108]. 
Table 4. Bispecific antibodies developed in recent years and their clinical status. 
Name Company Targets Antibody 
type 
Mode of 
Action 
Indications 
FDA approved 
Blinatumoma
b Blincyto® 
Amgen CD19/CD
3 
BiTE T cell 
recruitment 
Philadelphia chromosome-negative 
precursor B-cell acute 
lymphoblastic leukemia 
Clinical Trials Completed 
Catumaxoma
b Removab® 
Trion Pharma EPCAM/
CD3 
Trifuncti
onal/ 
Triomab 
T cell 
recruitment/ 
Fc effector 
Malignant ascites 
Phase III 
Emicizumab/
RG6013/AC
E910 
Roche Factors 
XI/X 
CLC-IgG Two factor 
dimerisation 
Haemophilia A 
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MT111/ME
DI565 
MedImmune CEA/CD3 BiTE T cell 
recruitment 
Gastrointestinal cancer 
Phase II 
Vanucizuma
b 
Roche Angiopoie
tin2/VEG
F 
Crossmab Two ligand 
inactivation 
Colorectal cancer 
RG7716 Roche Angiopoie
tin2/VEG
F 
Crossmab Two ligand 
inactivation 
Macular degeneration 
TF2 IBC 
Pharmaceutical/ 
Immunomedics 
CEA/Hapt
en 
DNL 
Fab3 
Payload 
delivery 
Small cell lung cancer, Colorectal 
cancer, Thyroid cancer 
Duligotuzum
ab 
Genentech/Roch
e 
HER1/HE
R3 
DAF-IgG Two ligand 
inactivation 
Head and neck cancer, Colorectal 
cancer 
ABT122 Abbott 
Laboratories 
TNFα/IL-
17 
DVD-
IgG 
Two ligand 
inactivation 
Rheumatoid arthritis, Psoriatic 
arthritis 
ABT981 Abbott 
Laboratories 
IL-1α/IL-
1β 
DVD-
IgG 
Two ligand 
inactivation 
Osteoarthritis 
SAR156597 Sanofi-Aventis IL-4/IL-
13 
DVD-
IgG 
Two ligand 
inactivation 
Idiopathic pulmonary fibrosis 
Istiratumab/
MM141 
Merrimack 
Pharmaceuticals 
IGF1R/H
ER3 
IgG-scFv Two ligand 
inactivation 
Pancreatic cancer 
IMCgp100 Immunocore MHC 
peptide280-
88/CD3 
ImmTAC T cell 
recruitment 
Malignant melanoma 
AFM13 Affimed 
Therapeutics 
CD30/CD
16 
TandAb NK cell 
recruitment 
Hodgkin Lymphoma 
Phase I 
BI1034020 Boehringer 
Ingelheim 
Pharmaceuticals 
Beta 
amyloid 2 
epitopes 
Bi-
nanobody 
Undisclosed Alzheimer's Disease 
ALX0761 Merck Sereno IL-
17A/IL-
17F 
Bi-
nanobody 
Two ligand 
inactivation 
Psoriasis 
LY3164530 Eli Lilly HER1/cM
ET 
orthoFab-
IgG 
Two ligand 
inactivation 
Metastatic cancer 
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Pasotuxizum
ab 
Bayer PSMA/C
D3 
BiTE T cell 
recruitment 
Prostate cancer 
MGD006 Servier CD123/C
D3 
DART T cell 
recruitment 
Acute Myeloid Leukemia 
AFM11 Affimed 
Therapeutics 
CD19/CD
3 
TandAb T cell 
recruitment 
Acute Lymphoblastic Leukemia, 
Non-Hodgkin's Lymphoma 
MGD007 Servier GPA33/C
D3 
DART-
Fc 
T cell 
recruitment/ 
Fc effector 
Colorectal cancer 
Abbreviations: BiTE = bispecific T cell engager; CLC = common light chain; DNL= dock-
and-lock; Fab = antigen binding fragment; DAF = dual acting Fab; DVD-IgG = dual variable 
domain immunoglobulin, scFv = single chain variable fragment; ImmTAC = immune-
mobilizing monoclonal TCRs against cancer; TandAb = tandem diabody; DART = dual 
affinity re-targeting molecule; Fc = fragment of crystallization; EPCAM = epithelial cell 
adhesion molecule; CEA = carcinoembryonic antigen; VEGF = vascular endothelial growth 
factor; TNF = tumor necrosis factor; IGFR = insulin growth factor receptor; MHC = major 
histocompatibility complex; PSMA = prostate-specific membrane antigen; GP = 
glycoprotein; NK = natural killer.   
Another example that achieves effector cell recruitment via a conceptually different format without 
a Fc region is bispecific T cell engager (BiTE®).  BiTEs are variable regions in the form of two 
scFv connected by flexible linker peptides (Figure 1c)  [109, 110].  One scFv is directed at a cell 
surface tumor antigen (with higher affinity) and the other scFv binds CD3 (with lower affinity).  
The first marketed BiTE was blinatumomab (Blincyto®) which targets CD19 on acute 
lymphoblastic leukemia (ALL), approved by the FDA in late 2014 under the accelerated approval 
program.  Blinatumomab is currently undergoing multiple Phase II and Phase III clinical trials for 
other B-cell related malignancies [111].  A major setback for BiTEs is the requirement of 
continuous intravenous infusion due to the short half-life inherent to the small size of the molecule 
(55 kDa) and the lack of Fc region.  Additionally, the treatment produces significant side effects, 
notably neurotoxicity and symptoms of cytokine-release syndrome [112].  Despite the challenges, 
this strategy is being investigated for other targets (CEA, EPCAM, PSMA) and indications. Other 
examples of molecules with immune cell recruitment are dual affinity re-targeting (DART®) [113, 
114] and tandem diabodies (tandAb®) (Figure 1c) [115, 116].   
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Another novel class of bispecific molecules called immune-mobilizing monoclonal TCRs against 
cancer (ImmTAC) further expands the variety of potential tumor-specific antigens, by 
incorporating soluble T cell receptors (TCRs) that can target intracellular antigens through 
recognition of peptide-HLA antigen complexes on the cell surface (Figure 1c) [117].  Under 
current investigation in Phase II clinical trial for malignant melanoma is IMCgp100.  The 
engineered TCR portion of the molecule targets the gp100 peptide280-288 antigen, which is 
overexpressed and presented by HLA-A2 on the surface of melanoma cells. The anti-CD3 scFv 
portion captures and redirects T cells to kill the melanoma cells.  
 
With the knowledge gained on validated targets and receptor signalling of existing therapeutic 
antibodies, targeting two antigens to simultaneously interfere with two or more signaling pathways 
is being pursued to improve therapeutic efficacy.  The most advanced molecule in clinical 
development is dugliotuzumab, a human IgG which targets the combination of HER1 and HER3 
as a dual action Fab (DAF)-IgG [118].  Duligotuzumab is being evaluated in Phase II trial in 
patients with head and neck cancer.  The dual interference can also be applied to inflammatory 
conditions.  Dual variable domain immunoglobulin (DVD-Ig™) formats directed at TNFα + IL-
17 and IL-1α + IL-1β are undergoing assessment in Phase I studies in patients with rheumatoid 
arthritis (Figure 1c) [119].  Other formats being investigated to interfere with signaling pathways 
include CrossMabs [103] and bi-nanobodies [120].  
Bispecifics can also serve as vehicles to deliver payloads to tumor cells.  TF2 is a DNL(Fab3) 
bispecific antibody that binds to CEA present on the surface of many solid tumours (Figure 1c).  
The antibody comprises three Fab modules that are stably coupled to each other in a triangular 
fashion using the ‘dock-and-lock’ technology.  Without a Fc region, these molecules have a rather 
short serum half-life which is an advantage for pre-targeting approaches.  TF2 is being evaluated 
in a Phase I trial in patients with colorectal cancer using Lutetium-177 or Indium-111 payload for 
imaging. 
Physical and chemical degradation of antibodies 
During manufacturing and storage, therapeutic antibodies are at risk of degradation via a number 
of pathways.  Though these reactions may be kept under control by appropriate storage and 
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formulation conditions of the final product, degradation that occurs during culture, downstream 
processing and in vivo cannot be controlled sufficiently.  These degradation events may affect 
antigen recognition, hamper functionality and in severe cases lead to immunogenic responses [121-
125].  Each antibody molecule seems to have a unique personality related to its requirements for 
stability; a phenomenon derived from the fact that differences in the CDR between antibodies are 
primarily dictated by the surface exposed amino acids that define antigen specificity [124].  The 
identification of degradation prone or unstable regions early in the antibody development process 
would ideally permit re-engineering of these problematic areas [126-129].  This approach is aided 
by recent developments in computational modelling tools that predict regions of interest 
susceptible to physical, chemical degradation or influence other biophysical properties of 
antibodies.  In the next section, degradation pathways commonly observed in therapeutic 
antibodies and an overview of predictive tools are discussed. 
Aggregation  
Protein aggregation is the most common and significant type of physical degradation associated 
with therapeutic antibodies, often leading to reduced activity and in some cases, formation of 
immunogenic products [130, 131].  Initial preparations of therapeutic antibodies were administered 
by intravenous (IV) infusion formulated at protein concentrations (1-25 mg/ml).  As antibody-
based therapeutics have become more widely used, high concentration formulations that allow SC 
injection (>50 mg/ml) became desirable giving rise to aggregation issues.  Proteins are folded in 
such a way as to internalize hydrophobic domains and surface expose more hydrophilic domains.  
As protein-protein contact frequency increases at high concentrations, the opportunity for 
aggregation formation increases proportionally.  Changes in extrinsic conditions including 
temperature, pH, salt, shaking, viscosity and concentration can transiently expose hydrophobic 
domains which in doing so promotes protein-protein interactions that lead to aggregation events 
[132-135].  Non-covalent aggregates can be formed via hydrophobic and/or electrostatic 
interactions and may be reversible, while covalent aggregates are usually formed by disulphide 
bonds and are difficult to reverse. Mechanisms of protein aggregation include: (1) aggregation of 
native state monomers; (2) aggregation of monomers with a modified conformation (non-native); 
(3) aggregation of chemically-modified monomers; (4) aggregation via a nucleation-dependant 
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process; and (5) surface-induced aggregation via adsorption of protein to glass-liquid or air-liquid 
interfaces [136, 137]. 
Denaturation 
Protein denaturation refers to the partial or complete unfolding of the native three-dimensional 
folded protein structure.  A denatured antibody often loses its tertiary and perhaps secondary 
structure leading to loss of binding affinity and activity if an active site domain is affected, and 
may expose aggregation-prone regions leading to further degradation [133, 138, 139].  Several 
intermediate states may exist between the folded native structure of an antibody molecule and the 
denatured state, with some intermediates thought to act as precursors or ‘nuclei’, attracting other 
protein species to exposed hydrophobic sites and forming irreversible aggregates.  Denaturation 
may be induced by a number of stress conditions that arise during antibody manufacture including 
changes in solution pH or temperature, use of organic solvents or chaotropes, high salt 
concentrations, or shear force [132, 133, 140]. In general, the CH3 domain of an IgG antibody is 
often the most stable against denaturation at high temperatures (highest Tm) while the IgG CH2 
domain is least stable and denatures first (lowest Tm) [141]. 
Fragmentation 
Fragmentation of therapeutic antibodies can be a product of enzymatic or non-enzymatic 
hydrolysis that occurs at the peptide backbone of a number of regions, such as the hinge region, 
the CH2-CH3 interface or a region containing aspartic acid (Asp) or tryptophan (Trp) residues 
[132].  Asp-associated hydrolysis is affected by pH and the n+1 residue; for instance, a serine 
(Ser), valine (Val) or tyrosine (Tyr) adjacent to an Asp may increase the rate of Asp-hydrolysis.  
Hinge region hydrolysis can occur in the absence of Asp, and occurs most commonly in the IgG1 
isoform [132, 142, 143]. The rate of hydrolysis is dependent on the flexibility the peptide sequence 
at the hinge, and occurs within a narrow range of residues.  Hinge hydrolysis rates are affected by 
solution pH, with a minimum rate of hydrolysis observed near pH 6, and higher rates at a lower or 
higher pH [132, 143].  Fragmentation of full-length antibodies is a common occurrence and 
generally, cleaved forms are present in such low amounts that effect on efficacy would not likely 
be seen.     
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Deamidation 
 Deamidation is the most common chemical degradation pathway of therapeutic antibodies and 
results from the hydrolysis of the amide side-chain of amino acids glutamine (Gln) or asparagine 
(Asn) [132, 136, 144, 145].  Hydrolysis of the side-chain can occur at acidic pH (pH <4) resulting 
in the conversion of Asn to Asp and Gln to glutamic acid (Glu) [132]. However at higher pH, 
deamidation occurs predominantly (and more slowly) via the formation of a cyclic imide 
intermediate.  For Asn, the cyclic intermediate (succinimide) leads to either the formation of Asp 
or an isomer of Asp.  A similar process results in the deamidation of Gln to Glu; although Gln 
deamidation is much less frequent, due to the lower stability of the 6-membered cyclic intermediate 
formed.  In short, deamidation events lead to more acidic forms of the antibody through the 
acquisition of additional carboxylic acid groups.  Conversely, it is also possible for Asp residues 
to undergo modification to a succinimide intermediate that produces a basic form of the antibody 
by removal of a carboxylic acid group [144].   
A number of factors can affect the rate of deamidation.  For instance, Asn residues are more prone 
to deamidation if they are present in solvent-accessible or structurally-flexible regions, especially 
if followed by a small or flexible residue such as Gly, Ser, threonine (Thr) or Asn [132, 146].  
Deamidation rate is also affected by extrinsic conditions including pH, temperature, buffer 
composition and concentration [147].  Gln deamidation is thought to be less common than Asp 
deamidation due to the lower stability of the 6-membered cyclic ring intermediate, which results 
in a much slower reaction rate [132].  Although Gln deamidation occurs less frequently, a study 
found that following incubation at pH 9, 7.8% of Gln82 of a recombinant IgG1 mAb had 
undergone deamidation, despite no deamidation of this residue occurring at neutral pH [145]. 
Deamidation of therapeutic antibodies is well characterised both  and in vivo, and has been shown 
to decrease the potency, activity and stability of antibodies [144, 146-150].  The deamidation 
events appear to be highly selective for individual antibodies.  For example, Harris et al. performed 
accelerated stability studies at elevated temperatures with rhuMAB HER2 antibody and found 
three labile Asn residues in the CDR region (Asn55, Asn30 and Asn102) [144]. These residues 
either formed aspartate, isoasparatate or a stable succinimide intermediate, resulting in a total of 
seven species of the antibody being resolved. Deamidation of these Asn residues was shown to 
significantly affect the specific in vitro activity and potency of rhuMAb HER2. 
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Oxidation 
Oxidation is another common degradation pathway which can occur during antibody production, 
formulation or storage. A number of amino acid residues may be affected, including methionine 
(Met), cysteine (Cys), histidine (His), tyrosine (Tyr) and Trp [132]. Specific Met residues within 
the Fc region (up to four residues) are prone to oxidation resulting in production of methionine 
sulfoxide [136, 151, 152].  Oxidation of these residues may affect the stability of an antibody, Fc-
mediated effector function or Protein A binding affinity which is often used for purification from 
cell culture supernatant [153]. Wang et al. demonstrated that oxidation of Met252 can result in >4-
fold reduction in the half-life of an antibody in transgenic mice expressing human Fc neonatal 
receptor (FcRn). However, this was only observed when 80% of the antibody existed in the 
oxidized form, and not at 40% [154].   
Oxidation can be dependent on intrinsic factors such as the degree of surface exposed residues as 
well as extrinsic factors including buffer composition, light exposure and pH, although Met 
oxidation appears to be almost pH-independent [132, 153, 155]. Oxidative stress has been 
observed during antibody production in mammalian expression systems where the formation of 
reactive oxygen species as a result of hypoxic conditions caused fragmentation of an IgG1 
antibody [156]. 
Tryptophan oxidation of antibodies has been reported following light exposure. Sreedhara et al. 
found that light induced oxidation of surface exposed Trp residues (Trp53, Trp108 and Trp94) in 
the Fab region of an IgG1 antibody leading to a loss in potency accompanied with a solution colour 
change [151]. In another example, oxidation of Trp residue in the H3 CDR loop (Trp135) of a 
humanized anti-respiratory syncytial virus (RSV) therapeutic antibody resulted in loss of antigen 
binding and biological function [157]. 
Computational design tools 
In recent years, computational methods used to simulate and develop structural models of proteins 
have transformed into practical design tools for the development of biobetter and next-generation 
antibody therapeutics [127, 158]. Current computational design tools have evolved to allow rapid 
identification of specific amino acid sequences or regions on a protein of interest, that contribute 
to its observed in vivo properties such as binding affinity, efficacy, stability and half-life [158].  
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Some of the early computational tools used for protein modelling include TANGO, PAGE, 
AGGRESCAN, PASTA and Zyggregator all of which rely on the sequence of the protein of 
interest (Table 5) [128, 159-164]. These computational tools use force fields such as CHARMM 
or AMBER and exploit chemical properties of the amino acids such as hydrophobicity, β-sheet 
propensity, charge, and aromatic content to predict aggregation hot-spots and residues susceptible 
to chemical degradation. In some cases, multiple tools can be used in combination to improve the 
predictive power.  For example, Wang et al. combined TANGO and PAGE to identify aggregation-
prone motifs and residues susceptible to deamidation or oxidation of 22 commercial and 20 non-
commercial therapeutic antibodies [165]. 
Table 5. A representative list of computational tools for prediction of protein aggregation hot 
spots. 
Name Properties 
Sequence-based methods 
TANGO 
 [204]. 
Determines the secondary structure formation propensity 
Aggrescan 
 [205]. 
Uses amino acid aggregation propensity value 
Zyggregator 
 [207]. 
Compares a new peptide sequence to the database 
PASTA 
 [208]. 
Predicts amyloid structure aggregation by looking into sequences 
that are likely to stabilize the cross-beta core of fibrils 
PAGE 
 [209]. 
Uses physicochemical properties for prediction 
Structure-based methods 
SAP   
 [173]. 
Determines spatial effective surface accessible area 
LIP   
 [211]. 
Measures ratio of polar surface area to apolar surface area of buried 
interfaces 
AGGRESCAN3D  
[212]. 
Based of original AGGRESCAN server with input from 3D structure 
and spatial arrangement of residues 
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Some structure-based computational tools have also been developed. One such method, Spatial 
Aggregation Propensity (SAP), predicts surface exposed aggregation-prone regions of a protein 
based on hydrophobicity, dynamic fluctuations and solvent accessibility of residues and regions 
[127]. The tool has been used to simulate entire antibodies and develop IgG1 antibody variants 
with enhanced physical stability to the wild type, by performing single or multiple mutations in 
either the Fab or Fc regions [127, 129]. 
Another method developed by Angarica and Sancho predicts aggregation propensity based on the 
packing density and polarity ratio (ratio of polar surface area to apolar surface area) of buried 
interfaces [166]. The tool was designed to characterise “Light Interfaces of high Polarity” (LIPs) 
considered to be intrinsically unstable cores. The technology shows promise as a tool for 
engineering antibody variants with increased aggregation-resistance, especially as a 
complimentary method to surface- or sequence-based tools mentioned above.  
One of the most recent developments in computational modelling is the evolution of 
AGGRESCAN to AGGRESCAN3D (A3D), an improved server which addresses many of the 
limitations of AGGRESCAN and other sequence-based methods.  A3D takes into account the 
three-dimensional structure of the protein and the spatial arrangement of the residues when the 
protein is in its native folded state [167].  With the incorporation of a mutation module that allows 
the easy modelling of the detected aggregation-prone and surrounding residues, A3D looks to be 
a promising tool for predicting problematic regions and the same time, allowing for re-design of 
more stable proteins. 
Optimization of antibody bioavailability and delivery 
Antibody-based therapies are predominantly delivered intravenously (IV), though an increasing 
number are now being formulated and administered subcutaneously (SC). While the IV route 
offers 100% bioavailability, systemic distribution and physiological barriers greatly reduce the 
actual concentration of antibody achieved in target tissues [168]. What is more, IV infusions are 
time-consuming and inconvenient. Ideally, an antibody formulation should be non-invasive and 
increase local bioavailability.  Limited alternatives have been implemented in the clinic since 
formulation requirements for such delivery often pose significant hurdles. For other parenteral 
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administration routes, such as SC or intramuscular (IM), the most common limitation is poor 
antibody solubility at the high concentrations required, given that maximum volume of injection 
is restricted to 2 ml and 5 ml, respectively.  When compared to IV formulations which range from 
1-25 mg/ml, SC and IM products often require concentrations >100 mg/ml to deliver an effective 
dose [169].  Furthermore, these delivery routes involve an absorption step to enable systemic 
circulation. Two main approaches are being pursued to optimize bioavailability: 1) the design of 
aggregation-resistant antibodies with higher solubility to prevent precipitation at higher 
concentrations; 2) the use of polymer matrix systems to develop controlled release formulations 
and improve PK profile. 
As discussed in the previous section, the design of aggregation-resistant antibodies albeit 
challenging, has become possible with the implementation of computational tools and increasing 
understanding of antibody structure and degradation pathways. Formulation stability has also been 
improved by using stabilizing additives such as salts (e.g. citrates, sulfates), amino acids (e.g. 
glycine) and sugars (e.g. sorbitol, sucrose, trehalose) [132, 170-172]. The development of SC and 
IM products has been successful in the last decade because of the formulation of large doses in 
significantly smaller volumes without aggregation issues [46].  SC and IM formulations have 
significantly improved patient convenience enabling self-administration through the use of pre-
filled syringes, a feature that is highly advantageous for treatment of chronic diseases.  A novel 
approach to improving SC formulation and PK has been proposed by Yang et al. whereby, 
crystalline antibody preparations of infliximab (Remicade®) and trastuzumab (Herceptin®) were 
formulated at 200 mg/ml while maintaining low viscosities suitable for this delivery route [173].  
Animal studies in rats showed a 2-fold increase of antibody half-life compared to non-crystallized 
antibody, demonstrating the potential of crystalline preparations as controlled release systems.  
Alginate polymers have also been explored for controlled release.  Schweizer et al. developed two 
polyanionic alginate matrices loaded with antibody through electrostatic interactions [174].  Both 
matrices were delivered to rats subcutaneously as hydrogels. After comparison with its liquid 
antibody counterpart, no significant differences in bioavailability were reported.  
For many pathologies, local delivery could increase efficacy and reduce systemic exposure. In 
such cases, administration routes such as oral, topical, respiratory and intraocular become highly 
relevant. Controlled release systems based on polymer matrices are also being tested in preclinical 
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studies for these delivery routes [168, 175]. For instance, liposomes and chitosan-alginate 
microparticles have been employed for oral delivery in order to protect antibodies from gastric 
inactivation and allow release in the small intestine [176, 177]. This is being explored in 
combination with the conjugation of targeting ligands to improve delivery and absorption in the 
gastro-intestinal tract.  [178].  For topical application, a hydrofiber dressing/adhesive sheet has 
been used to apply infliximab as a gel formulation for wound healing with improvements in 7/8 
patients tested [179].  In another example, a Phase I trial has been completed with positive results 
for BIL-010t, a topically administered, sheep antibody therapy to treat Basal Cell Carcinoma 
(BCC).  BIL-010t ointment was self-applied for 28 days; it was noted that 13/20 patients had 
decreases in the sizes of their lesions with only mild localized skin reactions reported.  The 
respiratory route has been extensively studied for treatment of chronic obstructive pulmonary 
disease, lung cancer, asthma and other pulmonary pathologies. Liposomes and microspheres have 
shown potential to increase bioavailability of respiratory delivery by preventing proteolysis [180]. 
The PEGylation of antibody fragments was shown to increase lung lumen residence time in a 
murine model through decreased clearance of alveolar macrophages and increased mucoadhesion 
[181].  Other strategies being investigated to deliver antibodies via the respiratory tract include 
IgG-loaded lipid microparticles and nano-micelles [182-184]. The most advanced molecule in 
clinical development is ALX-0171, an anti-RSV nanobody administered through inhalation; 
demonstrating a positive safety and tolerability profile in a first-in-infant Phase I/II study with an 
anti-viral effect observed [185].   
Overall, the IV route will likely remain the most prominent administration route in development 
due to ease of formulation. Still, the improvement of local bioavailability is an obvious 
requirement to fulfil the potential of antibody-based therapy, both in terms of efficacy and patient 
convenience. As such, strategies such as pursuing alternative administration routes and developing 
appropriate controlled release systems will gain relevance as their therapeutic potential continues 
to be explored in preclinical studies. 
Conclusions 
Antibody-based therapeutics have evolved from murine antibodies to humanized and fully human 
antibodies, developed with innovative technologies such as transgenic mice and phage display.  In 
the coming years, next-generation antibodies with improved properties and formats including 
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ADC and bispecifics are expected to gain popularity as biobetter antibody therapeutics. Major 
hurdles are being overcome for biosimilar development following the marketing approval of the 
first biosimilar antibody by the FDA earlier this year.  The advancement of next-generation 
biobetters and biosimilars is critical to; 1) reduce the high cost of therapeutic antibodies 
encountered over the last thirty years, 2) address the shortcomings confronted with the use of these 
antibodies such as poor efficacy and stability and most importantly, (3) provide greater patient 
benefit. 
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Abstract 
Monoclonal antibodies (mAbs) are of high value in the diagnostic and treatment of many 
debilitating diseases such as cancers, auto-immune disorders and infections. Unfortunately, protein 
aggregation is one of the ongoing challenges, limiting the development and application of mAbs 
as therapeutic products by decreasing half-life, increasing immunogenicity and reducing activity. 
We engineered an aggregation-prone region of adalimumab, the top selling mAb product 
worldwide - with additional glycosylation sites to enhance its resistance to aggregation by steric 
hindrance as a next generation biologic. We found that the addition of N-glycans in the Fab domain 
significantly enhanced its conformational stability, with some variants increasing the melting 
temperature of the Fab domain by more than 6 °C. The mutations tested had minimal impact on 
antigen binding affinity, or affinity to Fcγ receptors responsible for effector function. Our findings 
highlight the significant utility of this rational engineering approach for enhancing the 
conformational stability of therapeutic mAbs and other next-generation antibody formats. 
Introduction 
Monoclonal antibodies (mAbs) are amongst the top-selling therapeutic prescription products 
worldwide. In 2017, Humira® (adalimumab) alone, generated over 18 billion US dollars, 
maintaining its position as the top-selling drug worldwide [1, 2]. Antibody therapeutics are 
revolutionary biopharmaceuticals used to treat cancers, auto-immune and inflammatory 
conditions, and even some types of asthma. Approximately 80 antibody products have been 
approved and marketed by the FDA and EMA with hundreds more in early and advanced clinical 
trials [3]. Advances in antibody engineering technology have led to the development of a multitude 
of novel, next-generation antibody-derived products often termed biobetters, which include 
bispecifics, nanobodies, antibody-drug conjugates, and nanoparticles functionalised with 
antibodies [3, 4].  
Despite the four-decade-long progress and ever-growing interest in antibody research, one of the 
major challenges in the development of antibody therapeutics remains unsolved: protein 
aggregation [4-7]. Protein aggregation is one of the most common form of antibody degradation, 
having significant implications for a therapeutic product under development; aggregation can 
result in reduced therapeutic efficacy, and may trigger severe immunogenic side effects when 
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administered [8, 9]. Formulations of biologics including mAbs and other protein products are 
stabilized with the use of additives such as salts, sugars, amino acids and surfactants [10-12]. Some 
novel formulation additives have also been investigated to inhibit protein aggregation, including 
deuterated solvents [13], hydrogels [14, 15], peptide dendrons [16] and ionic liquids [17]. 
However, the type and amount of additives allowed in any given formulation is limited, especially 
in parenteral formulations – which are often used to administer mAbs. Thus, other approaches to 
enhance the aggregation-resistance of mAbs are needed. 
Another approach to significantly enhance the stability of a mAb is to modify the antibody 
structure itself. A single amino acid mutation in an aggregation-prone region (APR) can be 
sufficient to significantly improve the stability of an antibody against aggregation and/or increase 
its melting temperature. Predictions of aggregation-prone regions are often aided by computational 
tools – these include TANGO, AGGRESCAN3D, SAP [18-20], docking studies and/or molecular 
dynamics simulations [21]. For instance, the spatial aggregation propensity (SAP) tool has 
previously been used to guide mutations of aggregation-prone motifs of rituximab. These motifs 
predicted by SAP were ‘neutralised’ by single-point mutations, and multiple mutations were then 
combined to increase the overall antibody stability [22]. 
A variation of this approach (single-point mutation of high SAP regions) involves engineering an 
additional N-glycosylation site in a spatially proximate region to an APR, to sterically hinder 
aggregation in that APR [23, 24]. This strategy involves the introduction of amino acid sequons 
containing the sequence N-X-S/T (N-glycosylation sequon), that can be recognised by 
oligosaccharyltransferases and result in the enzymatic attachment of a glycan to the asparagine (N) 
residue within the N-glycosylation sequon. Naturally occurring N-linked glycans in the Fc domain 
are known to significantly influence antibody stability and effector function and to increase half-
life in patient serum. The introduction of extra N-linked glycosylation sites in the Fab domain may 
not only improve resistance to aggregation, but also enhance solubility and conformational 
stability of the antibody, offering additional benefits to a single-point mutation in a hydrophobic 
region. 
Courtois, Agrawal [23] recently tested a series of Fab-glycosylated bevacizumab variants and 
reported significant improvements in overall stability. Nakamura, Oda-Ueda [24] also tested a 
glycan-introducing mutation in the Fab of adalimumab expressed in Pichia pastoris and found that 
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it inhibited protease digestion and precipitation under pH stress. However, its impact on soluble 
aggregation of the full antibody is not clear. 
Table 1. Surface exposed amino acid (AA) residues identified in adalimumab Fab region for 
substitution. 
AA 
Residue Position Region Mutation Proposed Function 
L 178 CH1 
K Remove APR by introducing polar amino acid  [23]. 
N 
Remove APR and introduce glycosylation site  
[23]. 
Q 160 Ckappa 
Sterically hinder APR by introducing 
glycosylation site  [23]. L 116 
Cjoin 
T 118 
A 122 
CH1 
Improve solubility by introducing 
glycosylation site  [25]. 
Q 179 Sterically hinder APR by introducing 
glycosylation site  [23, 25]. 
L 183 
T 199 
Improve solubility and sterically hinder self-
association by introducing glycosylation site  
[25, 26]. 
 
In this study, we report on and discuss the stability of Fab-glycosylated adalimumab variants that 
have spatial proximity to a previously determined APR in the IgG1 CH1 region of rituximab [22] 
and bevacizumab [23]. Specifically, the amino acid of the APR transposed to the adalimumab 
IgG1 peptide sequence is leucine 178. The substitution of this hydrophobic amino acid to lysine 
in bevacizumab [23], or to serine in rituximab [22] in the equivalent position, had experimentally 
demonstrated increased stability. This amino acid can also be substituted with asparagine (e.g. 
L178N) to introduce an N-linked glycosylation site. For this study, surface exposed amino acids 
were identified that can be substituted to asparagine to introduce N-linked glycosylation sites i.e. 
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Asn-X-Ser/Thr, where X is any amino acid except proline (Fig. 1). All substitutions except T199N, 
were previously identified to have 10 Angstrom spatial proximity to the APR of interest [22, 23]. 
T199N was specifically chosen as it had been reported to dramatically increase the solubility of a 
poorly soluble antibody [25], however it does not have spatial proximity to the APR. This 
particular substitution also has the potential to sterically hinder reversible self-association [26] 
which warranted further investigation through this study. The substitutions that were identified 
and pursued for this study are listed in Table 1. 
 
Figure 1. Crystal structure 3wd5 of adalimumab Fab fragment complexed to partial TNF-α 
fragment. Adalimumab VH/CH1 (green), VL/CL (aqua), TNF-α fragment (orange), APR 
site (purple) and surface exposed amino acids identified for substitution to an N-linked 
glycosylation site (pink). 
In addition to studying the effect of these Fab N-linked glycosylations on the aggregation 
propensity of adalimumab, we also investigated the conformational stability of the variants, and 
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characterised their binding affinity to TNF-α, and Fcγ receptors (FcγRs) responsible for effector 
function, to understand the broader impact of these additional glycans. 
Materials and Methods 
Cloning and mutation of AdmAb WT and variants 
The blank gWiz expression vector (Genlantis, P000200) was used to construct separate AdmAb 
IgG1 and kappa chain expression vectors. Firstly, secretion peptide genes, IgG1 and kappa chain 
genes were sourced from genes contained in vector pVITRO1_trastuzumab_IgG1/κ (Addgene 
plasmid # 61883), a kind donation from Andrew Beavil. These genes were cloned separately into 
the empty gWiz vector through conventional restriction cloning techniques (all materials from 
GeneSearch). The variable regions of AdmAb genes were designed and synthetically produced 
(Integrated DNA Technologies). These genes were exchanged with the trastuzumab variable 
regions in the gWiz vectors through In-Fusion cloning (Scientifix, 639648) to produce gWiz 
AdmAb IgG1 and gWiz AdmAb kappa vectors. 
Mutations were then introduced to the gWiz AdmAb IgG1 and kappa vectors through high fidelity 
inverse PCR to produce a library of AdmAb mutant expression vectors. AdmAb WT and mutant 
variants were confirmed through sequencing and expressed through transfection of vector pair 
combinations. 
Expression and Purification of AdmAb WT and variants 
AdmAb WT and mutants were transiently expressed in suspension HEK293F culture. HEK293F 
culture was maintained and transfected in Freestyle 293F media (Life Technologies, 12338-018), 
120 rpm, 37 °C, 5% CO2, humidified incubation conditions. 24 hours prior to transfection, 
HEK293F culture was seeded to 6 - 7 x 10+5 cells/mL in a 60 mL culture and the culture was 
adjusted to 1 x 10+6 cells/mL on the day of transfection.  
The complexing DNA for transfection was prepared as 1 µg total DNA per 1 x 10+6 cells. The 
gWiz AdmAb IgG1 and kappa vectors were combined in a w/w ratio of 1:1, and the complexing 
w/w ratio of PEI (BioScientific, 23966-2 (POL)) to total DNA was 2:1. The vector DNA and PEI 
were separately diluted in OptiPRO SFM (Life Technologies, 12309-050). The dilutions were 
combined and left to complex for 15 minutes before adding dropwise to the transfection culture. 
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After 24-hour incubation of the transfection culture, the culture was scaled up to 120 mL with 
Freestyle 293F media and supplemented to a total concentration of 0.5% tryptone w/v. After a 
further 24 hours of incubation, the culture was scaled up to 240 mL with Freestyle 293F media 
and supplemented to a total concentration of 0.5% tryptone w/v. The transfection culture remained 
in incubation for a total of 8 days before the media containing secreted antibody was harvested by 
centrifugation, and the culture supernatant was clarified by filtration. 
AdmAb WT and variants were purified from the culture supernatants using protein A affinity with 
a 1 mL HiTrap MabSelect SuRe column (GE Healthcare, 29-0491-04). PBS pH 7.4 was used as 
the binding and wash buffer, and glycine-HCl pH 3 was used to elute bound antibody. Eluted 
antibody samples were neutralized in 1 M Tris-HCl pH 8 and concentrated to <1 mL using 50 kDa 
centrifugal filters (Sigma-Aldrich, Z740193). To purify the samples from any aggregates and 
obtain pure monomer samples, concentrated samples were fractioned using SE-HPLC (see SE-
HPLC section) and the monomer fractions were collected and concentrated in 150 mM potassium 
phosphate buffer, pH 6.5, for analysis. 
LC-MS/MS analysis of AdmAb variants 
Successful mutation and introduction of glycosylation motifs of the AdmAb variants was 
confirmed through site-specific liquid chromatography tandem mass spectrometry (LC-MS/MS). 
Briefly, AdmAb variants were separated on reducing SDS-PAGE and digested with trypsin 
(Sigma-Aldrich, T6567) and chymotrypsin (Sigma-Aldrich, 11418467001). A fraction of the 
digestions was further treated with PNGase F (GeneSearch, P0708S) for glycan release. The 
digestion products were analysed by LC-MS/MS using higher-energy collisional dissociation 
(HCD), collision induced dissociation (CID) and electron transfer dissociation (ETD) methods. 
The AdmAb variants (10 μg) were run on a reducing SDS-PAGE, in-gel trypsin digestion was 
performed on the heavy chain band (50 - 60 kDa) of variants L116N, T118N, A122N, L178K, 
L178N, Q179N, L183N, T199N and the light chain band (25 - 30 kDa) of Q160N. The bands were 
excised, diced and washed with 50% (v/v) acetonitrile in 100 mM NH4HCO3. The gel pieces were 
then reduced with 10 mM dithiothreitol at 56 °C for 45 minutes, followed by alkylation by addition 
of 55 mM iodoacetamide in 100 mM NH4HCO3, and incubation at 25 °C for 30 minutes. The 
samples were subsequently washed with 50% (v/v) acetonitrile in 100 mM NH4HCO3. 
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The alkylated polypeptides were incubated with trypsin (1 μg trypsin per 50 μg antibody) in 50 
mM NH4HCO3, pH 6.8 at 37 °C overnight. The resulting tryptic peptides were further digested 
with chymotrypsin in 100 mM Tris-HCl, 10 mM CaCl2, pH 7.8 at room temperature, overnight. 
Glycan release was performed to confirm amino acid substitution; a fraction of the chymotryptic 
peptides (excluding L178K) was incubated with recombinant PNGase F (400 units per 1 μg of 
peptide) in 50 mM sodium phosphate buffer pH 7.5 at 37 °C, overnight. The chymotryptic peptides 
and the de-glycosylated fractions were desalted with C18 ZipTips (Millipore, ZTC18S096), eluted 
in 80% (v/v) acetonitrile, dried by vacuum centrifugation then re-dissolved in 0.1% formic acid 
for LC-MS/MS analysis. 
Glycopeptides and de-glycosylated peptides were separated on an in-house packed 20 cm × 75 μm 
Reprosil-Pur C18AQ (3 μm, 120 A; Dr. Maisch GmbH) column using a Dionex 3500RS HPLC 
over a 90-minute 0-40% solvent B gradient at a flow rate of 300 nL/min, at 60°C (solvent A was 
0.1% (v/v) formic acid; solvent B was 80% (v/v) acetonitrile and 0.1% formic acid). MS analysis 
was performed on an Orbitrap Fusion MS (Thermo Scientific) in positive mode. Instrument 
parameters were set up as follows: source voltage = 2.3 kV, S-lens RF level = 68%, and capillary 
temperature = 275 °C. The initial MS scan was acquired in the Orbitrap mass analyser (350–2000 
m/z; MS AGC = 6 × 10+5) with a resolution of 60,000 at 400 m/z. MS1 was followed by data-
dependent HCD using top speed, where as many dependent scans as possible are acquired in a 
specified time. HCD fragmentation was followed by re-isolation of the top two most intense 
precursors, and fragmentation with CID and ETD MS/MS. HCD parameters were as follows: 
activation time = 0.1 ms, resolution = 30,000, maximum injection time = 200 ms, dynamic 
exclusion = enabled with repeat count 1, normalized energy = 40, exclusion duration = 20 s, default 
charge state = 2, and MSn AGC 2.0e5. CID parameters were as follows: 30,000 resolution in 
orbitrap, activation time = 10 ms, max injection time = 300 ms, dynamic exclusion = enabled with 
repeat count 1, normalized energy = 35, exclusion duration = 20 s, default charge state = 2, and 
MSn AGC 5.0e4. ETD parameters were as follows: 30,000 resolution in orbitrap, 5.0e4 AGC, 
ETD reaction time = 50 ms, Max injection time = 300 ms. 
Peptide spectrum matches (PSM) were generated through a search against the corresponding 
FASTA file (wild-type or variant Adalimumab amino acid sequence) utilizing the search engine 
Byonic (Protein Metrics Inc.). Annotation of the HCD and ETD spectra were automated through 
105 
 
Byonic and the PSM assignments were validated by manually annotating the aforementioned 
spectra and the complementary CID spectrum. Further confirmation of the identity assignment was 
achieved through analysis of the de-glycosylated chymotryptic peptides utilizing the same LC-
MS/MS approach as for the glycosylated fraction. 
Accelerated stability at elevated temperatures 
We performed accelerated studies at an elevated temperature as previously described [7]. Humira® 
40 mg/0.8 mL subcutaneous injections (Symbion) were used for reference. Briefly, 20 µL of each 
AdmAb variant (1 mg/mL) was transferred to a 0.2 mL PCR vial and incubated at 65 °C for 1, 2 
or 3 hours in a Thermal Cycler with heated lid (Applied Biosystems, CA, USA) to induce 
aggregation. Each experiment was repeated in triplicate. A thermal cycler was used to minimize 
sample amount and prevent evaporation of the sample and consequent changes in antibody 
concentration during incubation (lid/cover of thermal cycler is heated above incubation 
temperature). Following incubation, samples were immediately transferred to an ice bath as to halt 
aggregation. The aggregated samples were then characterized by size exclusion-high performance 
liquid chromatography (SE-HPLC). 
SE-HPLC analysis of monomer loss 
Size exclusion-high performance liquid chromatography (SE-HPLC) was used to quantify AdmAb 
monomer loss following incubation at elevated temperature as previously described [7]. Analysis 
was performed using an Agilent 1200 Liquid Chromatography system (Agilent Technologies) with 
a Zorbax GF-250 column (Agilent Technologies, 884973-701) coupled to a guard column (Agilent 
Technologies, 82095-911) at 22 °C, using a 150 mM potassium phosphate pH 6.5 mobile phase, 
and a flow rate of 0.5 mL/min. 5 μL of each incubated sample was injected in triplicate. Monomer 
peaks were detected using an in-line UV signal detector set at 280 nm. The area under the curve 
(AUC) of the monomer peak was averaged over the three runs. The percentage mean relative 
monomer was calculated for each sample by setting the monomer AUC of the non-incubated 
samples as 100% and calculating the change in monomer AUC accordingly. The standard 
deviations (SD) were plotted as error bars in the figures. 
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AdmAb melting temperature (Tm) and onset temperature of aggregation (Tagg) 
The Tm and Tagg of Humira®, AdmAb WT, and variants were simultaneously measured using 
intrinsic tryptophan fluorescence and static light scattering (SLS), respectively, on the UNcle 
system (Unchained Labs). A linear temperature ramp from 15 to 95 °C at a 1 °C/minute scan rate 
was performed whilst measuring tryptophan fluorescence and SLS simultaneously through laser 
excitation at 266 nm. 8.5 µL of each AdmAb sample (1 mg/mL) was transferred undiluted in 
triplicate, into the UNcle sample holding unit. A holding time was not used as to maximize the 
frequency of measurements. Tm and Tagg were determined by the UNcle Analysis software. The 
barycentric mean (BCM) was used to plot the Tm curves, which is defined by the following 
equation: 
𝜆𝜆𝐵𝐵𝐵𝐵𝐵𝐵 = ∑ 𝜆𝜆𝜆𝜆(𝜆𝜆)𝜆𝜆∑ 𝜆𝜆(𝜆𝜆)𝜆𝜆  
The equation is defined over the range 300 - 450 nm; each wavelength value (λ) is multiplied by 
the tryptophan fluorescence intensity (I) at that wavelength, and the sum of that value for all 
wavelengths from 300 - 450 is divided by the sum of the intensities at those wavelengths. This 
results in an ‘averaged’ peak wavelength (λBCM) for a given spectrum. 
Binding kinetics to TNF-α and Fcγ receptors (FcγRs) 
The binding kinetics of Humira®, AdmAb WT and variants were assessed to TNF-α and FcγR1A, 
2B and 3A through surface plasmon resonance (SPR) to confirm that the mutations did not 
contribute to a loss of biological function. Briefly, a Biacore T200 system (GE Healthcare) was 
used, running single cycle kinetic assays. Monomeric AdmAb samples were captured on a ProA 
chip (GE Healthcare, 29-1275-55) and increasing dilutions of TNF-α (Sigma-Aldrich, H8916) 
were injected, with a 60-minute dissociation. HIS-tagged FcγR1A (Life Technologies, 10256-
H08H-5), FcγR2B (Sigma-Aldrich, SRP6396) and FcγR3A (Sigma-Aldrich, SRP6436) were 
captured on an anti-HIS chip and increasing dilutions of monomeric AdmAb samples were 
injected, with a 30-minute dissociation. The sensograms were analysed to determine association 
rate (Ka), dissociation rate (Kd) and equilibrium dissociation constants (KD). All runs were 
performed at 25 °C with 10 mM HEPES, 150 mM NaCl, 0.05% v/v Tween 20 running buffer, pH 
adjusted to 7.4. 
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Soluble homotrimeric TNF-α was assayed against monomeric AdmAb samples on a ProA chip 
under continuous flow rate of 20 µL/min. Monomeric AdmAb samples were prepared to 10 nM 
and captured on the sensor chip surface with a contact time of 10 seconds. TNF-α was injected in 
2-fold increasing concentrations (2.5 – 40 nM) with a contact time of 120 seconds at each 
concentration, then a dissociation time of 60 minutes. The chip surface was regenerated with 50 
mM NaOH for 30 seconds at a flow rate of 30 µL / min. 
Monomeric AdmAb samples were assayed against HIS tagged FcγRs. Anti-HIS antibody was 
covalently attached to a CM5 biosensor chip (GE Healthcare, 29-1049-88) using an amine 
coupling kit (GE Healthcare, BR-1000-50) and HIS capture kit (GE Healthcare, 28-9950-56). HIS 
tagged FcγR1A, 2B and 3A were prepared to 4 nM and captured to the sensor chip surface with a 
contact time of 300 seconds at 5 µL/min flow rate. AdmAb samples were injected on FcγR1A 
coated surface in 2-fold increasing concentrations (2.5 – 40 nM) at a flow rate of 20 µL/min with 
a contact time of 120 seconds at each concentration, followed by 30-minute dissociation time. 
AdmAb samples were injected on FcγR2B and FcγR3A-coated surfaces in 2-fold increasing 
concentrations (25 – 400 nM unless otherwise stated) at a flow rate of 10 µL/min with a contact 
time of 120 seconds at each concentration, followed by 1800 second dissociation time. The chip 
surface was regenerated with 10 mM glycine-HCl, pH 1.5 for 60 seconds at a flow rate of 30 
µL/min. 
The sensograms were analysed globally using a Langmuir 1:1 binding model to determine Ka, Kd 
and KD. All samples were conducted in duplicate to obtain average values and standard deviation. 
Kinetic rate and equilibrium constants determined from sensograms were accepted if the goodness 
of fit value (χ2) was within 5% of the maximum response level (Rmax) of the sensograms and KD 
was calculated as Kd/Ka. 
Results 
Confirmation of mutation and glycan attachment through LC-MS/MS 
Detailed analysis of LC-MSMS data confirmed that all AdmAb variants had successful amino acid 
substitution. Incorporation of HCD, ETD and CID fragmentation techniques further provided 
compositional glycan information of the new N-glycosylation sites. Except for Q160N mutant, all 
other AdmAb glycosylation-site variants were found to contain an N-glycan (data not shown). 
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Here, we show the characterization of glycan site-engineered AdmAb variant T199N as a 
representation of the analysis performed for all AdmAb variants. 
 
Figure 2. (A) HCD, (B) ETD and (C) CID spectra of chymotryptic T199N glycopeptide 
observed at m/z 909.65 (4+). Peptide sequence SLSSVVTVPSSSLGNQTY and attached 
complex type N-glycan HexNAc5Hex4Fuc1 are shown. Blue square; N-acetylglucosamine, 
red triangle; fucose, green circle; mannose, yellow circle; galactose, Hex; hexose, HexNAc; 
N-acetylhexosamine, M; precursor ion. 
HCD spectrum of SLSSVVTVPSSSLGNQTY peptide observed at m/z 909.65(4+) showed b- and 
y-ion series confirming amino acid sequence and the asparagine substitution was shown 
specifically by y4-y11 fragment ions (Fig. 2A). HCD of T199N mutant also contained diagnostic 
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HexNAc (m/z 204.09) and HexNAcHex (m/z 366.14) oxonium ions, strongly indicating 
glycosylation on the mutant peptide (Fig. 2A). ETD further confirmed the structure of T199N 
glycopeptide by multiple fragment ions corresponding to dissociated peptide backbone with intact 
glycan (Figure 2B, c-15, c-16, c-17 and z-16 ions). Theoretical monosaccharide composition of 
the N-glycan was derived using Byonic (Protein Metrics) search results and GlycoMod 
(https://web.expasy.org). CID data in Figure 2C shows sequential loss of monosaccharides from 
glycopeptide fragments of T199N mutant and contains complementary oxonium ions m/z 366.14, 
m/z 528.19, and m/z 569.22 of the observed glycan in the low mass region. Extensive glycosidic 
bond cleavages (Fig. 2C, y-ions, m/z 1616.2(2+), m/z 1535.19(2+), m/z 1461.67(2+)) observed in 
CID confirmed that SLSSVVTVPSSSLGNQTY peptide is occupied by a complex type N-glycan 
with HexNAc5Hex4Fuc1 composition. CID spectra of deglycosylated T199N peptide m/z 
609.64(3+) showed enhanced peptide backbone fragmentation and provided additional 
information for the expected mass shift from threonine to asparagine (y4-y18 ions and b17 ion, 
Fig. 3). Same ion series also displayed deamidation (+1Da) of the new asparagine residue which 
is a characteristic result of PNGaseF treatment of a formerly N-glycosylated peptide. 
 
Figure 3. CID spectrum of de-glycosylated chymotryptic T199N mutant peptide 
SLSSVVTVPSSSLGNQTY observed at m/z 609.64(3+). b- and y- ions show CID fragments 
of the peptide. 
Monomer loss following accelerated studies at elevated temperature 
Incubation at 65 °C revealed modest differences in aggregation propensity between the reference 
Humira®, WT and single-mutant variants (Fig. 4). Variants L116N and T118N were completely 
degraded after an hour of incubation and were therefore not included in the figure (Fig. 4). Variant 
Q160N had very similar monomer loss data at all incubation temperatures to the WT, while L183N 
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had a noticeably higher monomer loss. Variants A122N, Q179N and T199N retained higher 
monomer content than the control at most incubation conditions, with A122N having the least 
monomer loss (Fig. 4). While Q179N had comparable monomer loss after 1 hour, monomer loss 
was lower at 2 and 3 hours, when compared to the WT. Interestingly, variants L178N and L178K 
had comparable monomer loss profiles which were not significantly different to the WT (Fig. 4). 
Humira® reference had slightly lower monomer loss than the WT. 
 
Figure 4. Monomer loss of Humira®, AdmAb wild-type (WT) and variants following 
incubation at 65 °C for 1, 2 and 3 hours. Error bars represent the SD. 
Tm and Tagg 
The WT AdmAb had a very similar Tm1 and Tm2 to the Humira® reference product; a slightly 
lower Tm1 was measured at 69.6 °C (WT) compared with 70.8 °C (Table 2). The Tm2 was 
comparable at 82 °C compared with 82.5 °C for Humira®. Variant Q160N had a similar melting 
profile to the WT, with an identical Tm1 and comparable Tm2 of 69.6 and 82 °C, respectively. 
Variants T118N and L116N had a significantly lower Tm1 at 59.7 and 63.6 °C, respectively; the 
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Tm2 was also lower at 68 and 78.6 °C, respectively. Interestingly, a third Tm was recorded for 
variants T118N and L116N at 87.8 and 88.3 °C, respectively. Variants L178K, A122N and Q179N 
had similar Tms and were comparable to the WT. Variants T199N and L178N had similar Tm1 
values to the WT (70.6 and 69.9 °C, respectively), but significantly higher Tm2 values (88.2 and 
89.3 °C, respectively). Variant L183N had a similar Tm1 to the WT, but had a consistent minor 
unfolding event at ~65 °C (not shown); Tm2 was higher than the WT (88.3 °C, Table 2). The Tagg 
of the WT and variants ranged from 70.6 to 72.5 °C, except for variants T118N and L116N, which 
had significantly lower Tagg values (61.7 and 64.7 °C, respectively; Table 2). Most variants had 
a slightly higher Tagg than the WT (70.7 °C) by approximately 1-2 °C, while the Tagg of Q160N 
and L178K were unchanged. Compared with L178K, the Tagg of glycosylated variant L178N was 
1.7 °C higher. 
Table 2. The melting (Tm) and onset of aggregation temperatures (Tagg) of the AdmAb variants 
compared with the wild-type (WT) and reference Humira® product (± SD). ^see discussion 
AdmAb Tm1 (°C)  Tm2 (°C) Tm3 (°C) Tagg @266 nm 
Humira® 70.8 ± 0.2 82.5 ± 0.8 - 71.3 ± 0.4 
WT 69.6 ± 0.5 82 ± 1.4 - 70.7 ± 0.1 
Q160N 69.6 ± 0.3 81.1 ± 1.4 - 71 ± 0.4 
T199N 70.6 ± 0.2 88.2 ± 2.2 - 71.7 ± 0.1 
T118N 59.7 ± 0.5 68 ± 0.7 87.8 ± 2.5 61.7 ± 0.6 
L178K 68.4 ± 0.6 83.5 ± 0.5 - 70.6 ± 0.3 
L178N 69.9 ± 0.5 89.3 ± 0.2 - 72.3 ± 0.3 
A122N 69.7 ± 0.5 83.4 ± 0.7 - 71.8 ± 0.4 
Q179N 69.4 ± 0.2 82.7 ± 0.9 - 71.7 ± 0.5 
L118N 63.6 ± 0.5 78.6 ± 0.5 88.3 ± 1.2 64.7 ± 0.3 
L183N 70^ ± 0.5 88.3 ± 1.1 - 72.5 
 
Binding kinetics of AdmAb to TNF-α and FcγRs 
The binding kinetics of reference Humira®, monomeric AdmAb WT and variants to TNF-α and 
FcγR1A, 2B and 3A were assessed using SPR single cycle kinetic analysis. Samples were run in 
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duplicate and sensograms were fitted to a Langmuir 1:1 binding model to obtain Ka, Kd and KD 
values for comparison as per previous studies [27, 28]. It was determined that in general, the 
majority of AdmAb variants did not experience a significant loss of biological activity. 
The KD range determined for monomeric AdmAb variants binding to soluble homotrimeric TNF-
α spanned 36.69 – 110.27 pM, while Humira® had a mean KD of 30.77 pM (Table 3). Monomeric 
AdmAb WT had a KD of 66.43 ± 2.37 pM which lies within the range, with no significant outlier 
(Table 3). Of all variants tested, T199N had the strongest KD to TNF- α (36.69 pM) - 
approximately 1.8-fold stronger than the WT - while Q179N had the weakest KD (110.27 pM). 
Table 3. Kinetics and binding affinity of reference (Humira®) and monomeric AdmAb mutants 
to soluble homotrimeric TNF-α (± SD). 
AdmAb 
TNF-α 
Ka (x 10+5) M-1.s-1 Kd (x 10-5) s-1 KD (pM) 
Humira® 11.7 ± 0.01 3.59 ± 0.80 30.77 ± 6.83 
WT 6.08 ± 0.07 4.04 ± 0.10 66.43 ± 2.37 
L178K 4.84 ± 0.01 4.61 ± 0.64 95.33 ± 13.3 
L178N 5.33 ± 0.03 5.42 ± 0.67 101.7 ± 12.1 
Q160N 6.2 ± 0.07 2.86 ± 0.05 46.05 ± 1.31 
L116N 5.19 ± 0.09 2.84 ± 0.1 54.77 ± 2.87 
T118N 5.04 ± 0.02 3.59 ± 0.21 71.19 ± 4.50 
A122N 6.47 ± 0.03 2.87 ± 0.05 44.32 ± 0.57 
Q179N 5.02 ± 0.40 5.53 ± 0.1 110.3 ± 6.56 
L183N 5.58 ± 0.14 3.05 ± 0.03 55.37 ± 0.86 
T199N 7.15 ± 0.69 2.62 ± 0.01 36.69 ± 3.54 
 
The KD range determined for FcγR1A binding to monomeric AdmAb variants spanned 2.1 – 6.81 
nM, while Humira® had a mean KD of 1.84 nM (Table 4). Monomeric AdmAb WT had a KD of 
4.4 ± 0.01 nM which lies within the range with no significant outlier (Table 4). Of all variants 
tested, the strongest KD was recorded for mutant T118N (2.1 nM), while the weakest KD was 
recorded for L178N (6.81 nM).  
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Due to sample limitations, monomeric AdmAb Q160N was not tested for the cycle assays against 
FcγR2B (Table 4).  
The KD range determined for FcγR2B binding to monomeric AdmAb variants spanned 1.81 – 
9.61 nM, while Humira® had a mean KD of 2.55 nM. Monomeric AdmAb WT had a KD of 4.47 
± 0.1 nM which lies within the range with no significant outlier (Table 4). T199N had the strongest 
KD to FcγR2B (1.81 nM), while T118N had the weakest KD (9.61 nM). However, due to the large 
variation in KD values for the WT and several mutants, most differences were not deemed 
significant.  
The KD range determined for FcγR3A binding to monomeric AdmAb variants spanned 1.48 – 
18.01 nM, while Humira® had a mean KD of 1.84 nM. Monomeric AdmAb WT had a KD of 5.96 
± 1.62 nM which lies within the range with no significant outlier (Table 4). The strongest KD was 
recorded for L183N (1.48 nM), while the weakest KD was recorded for A122N (18.01 nM) with 
large ranges. Overall, all differences in KD recorded compared to the WT, were no larger or 
smaller than 3-fold for TNF-α and all receptors tested. 
Table 4. Binding affinity of reference Humira® and monomeric AdmAb mutants to FcγR1A, 
FcγR2B and FcγR3A. 
AdmAb 
KD (nM) 
FcγR1A FcγR2B FcγR3A 
Humira® 1.84 ± 0.18 2.55 ± 1.67 1.84 ± 0.68 
WT 4.4 ± 0.01 4.47 ± 1.00 5.96 ± 1.62 
L178K 4.14 ± 0.06 9.16 ± 6.86 2.37 ± 1.19 
L178N 6.81 ± 0.45 3.67 ± 0.93 2.15 ± 0.73 
Q160N 5.3 ± 0.01 N.D. 16.2 ± 3.05 
L116N 3.87 ± 0.14 6.15 ± 1.10 6.71 ± 1.91 
T118N 2.1 ± 0.01 9.61 ± 1.38 13.3 ± 0.45 
A122N 5.58 ± 0.18 7.53 ± 2.74 18.01 ± 7.4 
Q179N 2.74 ± 0.01 5.27 ± 0.11 2.92 ± 0.16 
L183N 2.6 ± 0.04 2.52 ± 2.05 1.48 ± 0.84 
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T199N 6.49 ± 0.06 1.81 ± 1.25 11.80 ± 0.2 
 
Discussion 
We rationally designed and produced a library of glycan-engineered AdmAb variants to enhance 
stability through steric hindrance of an APR. Successful mutation and glycan addition was 
confirmed for all mutants aside from Q160N, through LC-MS/MS. Consequently, the stability and 
binding kinetics results for the Q160N variant are directly related to the amino acid substitution 
alone. Since Q160N had similar stability and antigen binding affinity to the WT, it was concluded 
that the amino acid substitution did not have any significant impact on the antibody properties 
tested. The KD values for the AdmAb WT produced in our study (Table 3 and 4) are comparable 
to Humira® KD values observed, and as reported in the literature; TNF-α (30-110 pM), FcγR1A 
(15-23 nM), FcγR2B (4.3-14.2 nM) and FcγR3A (5.8-7.9 nM) [29, 30]. 
Likewise, most measured KD values for the mutants tested lay within a close range to reported 
literature values for the reference AdmAb, showing that these mutations had minimal impact on 
binding properties.  
The highest improvement in resistance to aggregation was observed in mutant A122N with a slight 
increase in Tagg and reduction in monomer loss (Table 2 and Fig. 4). The A122N mutation resulted 
in 1.5-fold increased binding affinity to TNF-α with slightly reduced binding to FcγRs tested and 
with no impact on conformational stability. Pepinsky, et al [25] reported that a mutation equivalent 
in position to AdmAb variant A122N significantly improved the solubility of an anti-LINGO 
antibody, with no impact on binding affinity or conformational stability. Improvements in 
solubility often correlate with reduced precipitation and insoluble aggregate formation. 
This may explain the minor improvement in Tagg we observed with mutant A122N which reflects 
a higher resistance to precipitation at higher temperatures. Although only a minor improvement in 
monomer loss, the improvement is consistent at higher concentrations tested (15 mg/mL, data not 
shown) and is significant in a clinical setting, where typically no more than 5% of aggregates are 
considered acceptable by regulatory standards. 
No significant improvements in monomer loss were observed with other mutants (e.g. T199N and 
Q179N). Courtois, et al [22] hypothesised that a mutant equivalent in position to Q179N in 
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bevacizumab could not be glycosylated as it was inaccessible to glycosylases. However, we 
confirmed that Q179N was glycosylated; likewise, Pepinsky, et al [25] were able to express a 
glycosylated variant with a mutation in an equivalent position to Q179N which mildly improved 
antibody solubility. Accessibility to glycosylases does not determine whether the initial glycan is 
added or not, as this addition occurs in the endoplasmic reticulum prior to the folding of the protein. 
Thus, it may have been possible to introduce a glycan in this position with bevacizumab as well. 
Nevertheless, with the additional N-glycan, Q179N was expected to sterically hinder Fab-mediated 
aggregation in the targeted APR; while T199N was reported to significantly improve solubility 
[25] and sterically hinder self-association [26], however this was not observed for AdmAb. The 
Q179N mutation also mildly reduced antigen binding affinity by ~1.6-fold. 
Interestingly, Pepinsky, et al [25] reported no change in the Tm of the mutation equivalent in 
position to AdmAb variant T199N, while we observed a significant improvement in Fab Tm with 
variant T199N (~6 degrees higher). Additionally, T199N had 1.8-fold improved KD to TNF-α 
with minimal differences in KD to FcγRs. The lack of improvement in resistance to aggregation, 
despite the improvement in Fab stability, may be related to the mechanism of aggregation in 
AdmAb. Since the CH2 has the lowest Tm in most IgG1s, it is expected that most aggregation 
steps are at least initiated with unfolding of the CH2; thus, an improvement in Fab stability may 
not significantly impact overall resistance to soluble aggregation.  
Similarly, we observed an improvement in Fab Tm for mutants L178N and L183N. L178N is an 
interesting example, because when compared to the non-glycosylated variant L178K, there is an 
improvement in Tagg and Fab Tm through glycosylation. This emphasises the impact of the N-
glycans added via mutation on the conformational stability of the Fab and its resistance to 
precipitation, and highlights that these changes are not due to the amino acid substitution. The 
mutation significantly improved the conformational stability of the Fab domain. Furthermore, 
despite suppressing pH-induced precipitation when tested on the Fab alone [24], the L178N 
mutation had minimal impact on soluble aggregation when tested on the full AdmAb. Surprisingly, 
the non-glycosylated variant L178K which was reported to significantly suppress aggregation in 
bevacizumab [23], but enhance aggregation in rituximab [22], also had minimal impact on the 
stability of AdmAb. This finding highlights that framework regions differ significantly between 
IgG1 antibodies despite having identical sequences. 
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Variants L116N and T118N had multiple Tms, with a lower Tm1, higher Tm3 and a significantly 
reduced Tagg; additionally, they were completely degraded at 65 °C. The Tms of these mutants 
are harder to interpret, and do not necessarily represent the CH2, Fab and CH3 in that order. As 
previously reported [31], disturbances in the joining region between the Fab domains can create 
additional Tms for each separate domain. Thus, we expect that the Tm1 value of these mutants is 
representative of only part of the Fab (for e.g. the CH1 or VL); since the Tm of this part of the Fab 
is now less stable than the CH2, aggregation proceeded more rapidly at 65 °C. Again, our results 
do not correspond with findings reported for the mutation equivalent to AdmAb L116N in 
bevacizumab, which showed improved resistance to aggregation with no destabilization of the Fab 
[23]. Some perturbation in Fab stability was also observed with mutant L183N, resulting in 
increased monomer loss. The perturbation was minor and hard to detect; however consistently 
appeared in temperature ramps for Tm measurement. It is likely that the amino acid substation in 
this position impaired the conformational stability of part of the Fab domain as observed with 
mutants L116N and T118N. 
Conclusion 
Protein aggregation is a complex challenge hindering the development and long-term stability of 
therapeutic mAbs. Using advanced computational tools, we identified aggregation prone regions 
and engineered adalimumab, a marketed therapeutic mAb, with additional N-glycans in the Fab 
domain, with the aim to sterically hinder aggregation and increase long-term stability. Our glycan-
engineered variants displayed a range of different stabilities, with some mutations increasing 
susceptibility to aggregation, others enhancing the conformational stability of the Fab domain, and 
one showing minor improvements in resistance to aggregation.  This approach has potential 
application for other antibodies where the Fab domain has poor stability or is a pre-cursor to 
aggregation.  We demonstrated that the conformational stability of blockbuster therapeutic 
antibodies such as AdmAb can still be improved with glycan-engineering without compromising 
its antigen and Fc receptor binding affinity; these findings highlight the significant value of this 
engineering approach in the quest for developing more stable therapeutic mAbs with improved 
half-lives and therapeutic outcomes. 
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Abbreviations 
AdmAb adalimumab 
APR  aggregation-prone region 
AUC  area under the curve 
BCM  barycentric mean  
CID  collision induced dissociation 
ETD  electron transfer dissociation 
HCD  higher-energy collisional dissociation 
Ka  association rate constant 
Kd  dissociation rate constant 
KD  equilibrium dissociation constant 
LC-MS/MS liquid chromatography tandem mass spectrometry 
mAb   monoclonal antibody 
PEI  polyethylenimine, linear, 25 kDa 
PSM  peptide spectrum matches 
rpm  rotations per minute 
SAP  spatial aggregation propensity 
SD  standard deviation 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SE-HPLC size exclusion-high performance liquid chromatography  
SLS  static light scattering 
SPR  surface plasmon resonance 
Tagg  onset temperature of aggregation 
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 Tm  melting temperature (protein) 
UV  ultraviolet 
v/v  volume for volume 
WT  wild-type 
w/v  weight for volume 
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Abstract 
Protein aggregation constitutes a recurring complication in the manufacture and clinical use of 
therapeutic monoclonal antibodies (mAb) and mAb derivatives. Antibody aggregates can reduce 
production yield, cause immunogenic reactions, decrease the shelf-life of the pharmaceutical 
product and impair the capacity of the antibody monomer to bind to its cognate antigen. A common 
strategy to tackle protein aggregation involves the identification of surface-exposed aggregation-
prone regions (APR) for replacement through protein engineering. Others have shown that the 
insertion of N-glycosylation sequons on amino acids proximal to an aggregation-prone region can 
increase the physical stability of the protein by shielding the APR, thus preventing self-association 
of antibody monomers. We recently implemented this approach in the Fab region of full-size 
adalimumab and demonstrated that the thermodynamic stability of the Fab domain increases upon 
N-glycosite addition.  Previous experimental data reported for this technique has lacked 
appropriate confirmation of glycan occupancy and structural characterization of the ensuing glycan 
profile. Here, we mutated previously identified candidate positions on the Fab domain of 
trastuzumab and employed tandem mass spectrometry to confirm attachment and obtain the N-
glycosylation profile of the mutants. The trastuzumab glycomutants displayed a glycan profile 
with significantly higher structural heterogeneity compared to the WT antibody, which contains a 
single N-glycosylation site per heavy chain located in the CH2 domain of the Fc region. These 
findings suggest that Fab N-glycosites have higher accessibility to enzymes responsible for glycan 
maturation, shedding light into mAb glycobiology and potential implications in the application of 
this technique for the development of “biobetter” antibodies.  
Introduction 
The advent of therapeutic monoclonal antibodies (mAb) reshaped the pharmaceutical industry and 
has enabled a wide array of therapeutic avenues. Antibody therapeutics have dominated the market 
for the past two decades, featuring seven mAbs or mAb-based therapeutics in the top-10 list of 
best-selling drugs in 2018; and are now implemented in the treatment of an extensive range of 
pathologies, including oncological, inflammatory, cardiovascular, neurodegenerative and 
infectious diseases [1-3]. Moreover, mAbs comprise the largest class of molecules undergoing 
clinical development, thus it is forecasted that their market size will grow further as their clinical 
applications expand [3]. 
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The coming of age of mAbs as therapeutics entailed substantial efforts aimed at addressing pitfalls 
of first-generation molecules, most notably the immunogenicity caused by their non-human origin 
[4]. Yet, despite the myriad advancements in antibody technology, protein aggregation is a 
recurring complication that continues to hinder their manufacture and clinical properties [2]. 
Furthermore, the physicochemical factors determining thermodynamic and colloidal stability 
remain poorly understood. Aggregation can have a negative impact on the therapeutic efficacy of 
monoclonal antibodies by compromising their biological function, increasing clearance rates, and 
triggering immunogenic reactions. Moreover, the shelf-life of the pharmaceutical product can be 
severely reduced by the accelerated formation of protein aggregates [5, 6].  
Although it is believed that evolution has yielded improvements in the thermodynamic states of 
native antibodies relative to aggregated species, the manufacturing process and storage exposes 
recombinant therapeutic mAbs to a combination of “non-physiological” stress factors that hamper 
their physical and chemical stability [7, 8]. These factors include high protein concentrations, 
mechanical stress, exposure to air-water interfaces, and variations in pH, temperature, and ionic 
strength. To tackle this issue, numerous strategies have been developed and are the subject of 
intense exploration. These approaches can be broadly classified into two main categories: those 
that enhance the intrinsic stability of the protein to prevent aggregation throughout the 
manufacturing process [9-11], and those that improve the formulation of the final product by the 
optimization of pH, ionic strength and the incorporation of stabilizing agents [12, 13].   
Excipients commonly used in protein stabilization include surfactants, sugars, amino acids, 
polymers, and other proteins. Recently, ionic liquids have emerged as promising additives in this 
context [14, 15]. Whilst highly valuable, formulation strategies are limited in their applicability in 
that the amount of excipient added is restricted by several factors, including toxicity and increases 
in viscosity and tonicity [14]. Furthermore, optimizing formulation conditions for particular 
proteins is challenging, given the lack of understanding of aggregation mechanisms and how 
excipients impact these processes. In light of these limitations, strategies to improve the intrinsic 
physical stability of mAbs become highly valuable as a way to avoid physical degradation in the 
manufacturing process and/or decrease the necessity to incorporate excipients in the final 
formulation. This has been particularly relevant in recent times due to the growing trend to 
formulate antibody therapeutics as sub-cutaneous (SC) syringes for self-injection, wherein high 
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protein concentrations are required to deliver effective doses in the limited injection volumes 
allowed by the SC route [2, 16].  
Approaches to improve intrinsic aggregation resistance rely on rational modifications of the 
antibody structure. It is widely believed that surface-exposed hydrophobic regions in proteins can 
lead to self-association and initiate the formation of larger aggregates [5, 9]. Considering this, in 
silico methods have been developed to screen and identify aggregation-prone regions (APR). 
Exposed hydrophobic amino acids in APRs can then be replaced with more hydrophilic or charged 
residues through mutagenesis [7, 9, 10]. Pepinsky et al. introduced an innovative variation to this 
approach, wherein the mutations pursued inserted an N-glycosylation sequon (Asn-X-Ser/Thr) in 
the Fab region of an anti-LINGO antibody, enabling the attachment of an additional glycan on the 
antibody molecule – IgG1 molecules possess a conserved N-glycosylation motif in the Fc region 
[17]. The substantial increments (50-fold) in solubility obtained with two such mutants were 
attributed to the large hydrodynamic size and hydrophilic character of the glycan, preventing self-
association through steric hindrance. Later, Courtois et al. employed an advanced computational 
tool, called Spatial Aggregation Propensity (SAP), that performs full antibody molecular dynamic 
simulations to identify APRs in bevacizumab; and proposed a panel of residues that could be 
mutated to insert a glycosylation site where the glycan can shield an aggregation prone region and 
deter protein-protein interactions [18]. In the latter study, significant enhancements were reported 
in accelerated stability studies with the glyco-engineered bevacizumab variants, reporting up to 3-
fold improvements in monomer preservation. More recently, our group implemented several of 
the identified mutations in adalimumab and demonstrated improvements in thermodynamic 
stability, reflected by increments in the second melting temperature (Tm2).  
Altogether, the experimental results obtained with the glycosylation site insertion approach have 
highlighted the potential of this technique to improve shelf-life and pharmacokinetic profiles of 
approved therapeutic antibodies and mAbs in preclinical development. Notwithstanding, crucial 
aspects neglected in the aforementioned studies have been the appropriate confirmation of glycan 
attachment; and more importantly, the structural analysis of the glycans attached to the engineered 
site. The latter is essential in the context of regulatory approval and in elucidating the molecular 
mechanisms that drive improvements in stability. In view of the foregoing, we sought to ascertain 
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differences in the glycosylation profiles of a wild-type antibody compared to its glycoengineered 
mutants.  
Herein, we implemented several glycosite insertions in the Fab region of the blockbuster antibody 
trastuzumab and characterized the full glycan profile of the trastuzumab variants by glycan 
enzymatic release followed by LC-MS/MS analysis. In addition, we employed algorithms for 
prediction of successful glycan attachment to compare with experimental data in order to gain 
insight into structural features governing glycan transfer during translation. Furthermore, we 
evaluated the binding kinetics of the trastuzumab variants to its biological target (HER2) and to 
Fc receptors involved in eliciting effector functions to assess potential effects on therapeutic 
efficacy.  
Materials and methods 
Materials 
Herceptin® was a generous donation from Genentech (San Francisco, California). The pVITRO-
1-trastuzumab-IgG1/κ expression vector (containing trastuzumab heavy and light chain genes) was 
a generous gift from Andrew Beavil (Addgene plasmid # 61883). The gWiz expression vector was 
purchased from Genlantis (San Diego, USA). The primers utilized for mutagenesis and sequencing 
were acquired from Geneworks (Adelaide, Australia). The DpnI enzyme (R0176S) and the 
Phusion high-fidelity PCR kit (E0553S) were purchased from Genesearch (Gold Coast, Australia). 
StellarTM competent E. coli cells were purchased from Scientifix (Melbourne, Australia). Tryptone 
(LP0042B) was purchased from Thermo Fisher Scientific (Melbourne, Australia). Sodium 
chloride (S9888) and Kanamycin solution (K0254) were purchased from Sigma-Aldrich (Sydney, 
Australia). The miniprep (PLN70) and maxiprep (NA0310) kits were obtained from Sigma-
Aldrich (Sydney, Australia).  
Freestyle 293F cells were provided by Dr. Mario Torrado del Rey of Prof. Joel Mackay’s research 
group, School of Life and Environmental Sciences, The University of Sydney. FreeStyleTM 293 
media (12338018), RPMI media (21870-076), OptiPROTM serum free media (SFM) (12309050) 
and other reagents used for tissue culture were purchased from Life Technologies (Melbourne, 
Australia). 25 kDa linear polyethylenimine (PEI) (23966-2) was purchased from BioScientific 
(Sydney, Australia). Disposable baffled tissue-culture flasks (CLS431405), glycine hydrochloride 
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(G2879), and HiTrap® Protein A HP affinity column (GE17-0403-01) were obtained from Sigma-
Aldrich (Sydney, Australia). The Reprosil-Pur C18AQ (3µm, 120 A) was purchased from Dr. 
Maisch (Amerbuch, Germany). 
PBS tablets (09-2051-100), 1 M Tris-HCl pH 9 (BIOSD814), and all chemicals employed for SDS-
PAGE were acquired from Astral Scientific (Sydney, Australia). Precision Plus Protein™ Dual 
Color Molecular Weight Marker (1610374) was obtained from Bio-Rad Laboratories (Sydney, 
Australia). Trypsin (T6567), Chymotrypsin (1141847001) were purchased from Sigma-Aldrich 
(Sydney, Australia). C18 ZipTip® pipette tips (ZTC18S096) were obtained from Merck Millipore. 
PNGase F (P0708) was purchased from Genesearch (Gold Coast, Australia).  
HEPES (54457), Tween 20 (P9416) and the HIS-tagged HER2 (SRP6405), FcγR2B (SRP6396), 
and FcγR3A (SRP6436) receptors were purchased from Sigma-Aldrich (Sydney, Australia). HIS-
tagged FcγR1A (10256-H08H-5) were obtained from Life Technologies (Melbourne, Australia). 
The CM5 chips (29-1049-88), anti-HIS capture kit (28-9950-56), and amine coupling kit (BR-
1000-50) were purchased from GE Healthcare (Sydney, Australia). 
Cloning and mutation of Tmab WT and glycosylation mutants 
A section of the pVITRO-1-trastuzumab-IgG1/κ expression vector containing the secretion signal 
and Tmab heavy chain gene, and another section containing the secretion signal and Tmab light 
kappa chain gene were amplified separately employing high fidelity PCR (Phusion High Fidelity 
PCR kit) with a 2-step PCR cycling method. These amplified sections were then inserted separately 
into the blank gWiz vector through restriction enzyme cloning to produce separate vectors for 
trastuzumab heavy chain (HC) and light chain (LC) expression. Mutagenesis was performed 
through high fidelity inverse PCR to obtain mutated trastuzumab expression vectors. Successful 
mutation was confirmed by sequencing. HEK-293F cells were co-transfected with heavy and light 
chain vectors for transient expression.  
Expression and purification of Tmab WT and glycosylation mutants 
The trastuzumab variants were expressed transiently in HEK-293F cells in suspension at 120 rpm, 
using Freestyle 293F media. The cell culture was maintained at 37 °C, 5% CO2. Transfection was 
performed at a cell density of 1 x 10+6 cells/mL (60 mL cultures). Vector DNA and PEI in OptiPRO 
SFM were added to the cells in a 2:1 PEI/DNA w/w ratio. Total DNA added per 1 x 10+6 cells was 
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1 µg (1:1 w/w HC to LC ratio). Following 24 hours after transfection, the cultures were scaled up 
to 120 mL with Freestyle 293F media containing tryptone (0.5% w/v final concentration). At 48 
hours post transfection the cultures were further scaled up to 240 mL with Freestyle 293F media 
containing tryptone (0.5% w/v final concentration). The cell culture supernatant was harvested by 
centrifugation at day 8 following transfection and subsequently clarified by filtration (0.22 µm).  
Purification of the secreted antibody was performed employing a HiTrap® Protein A HP affinity 
column. PBS was used for the binding and washing steps. Elution of bound antibody was 
performed with 0.1 M glycine HCl pH 2.7 and the eluted fractions were immediately neutralized 
with 1 M Tris-HCl pH 9. Eluted fractions containing antibody were pooled and buffer exchanged 
to PBS using 50 kDa molecular weight cutoff (MWCO) centrifugal filters. Antibody 
concentrations were derived from absorbance readings at 280 nm using a molar extinction 
coefficient ε = 2.25 x 10+6 M-1 cm-1. 
LC-MS/MS analysis of Tmab variants 
Glycopeptide analysis 
Tmab WT, Herceptin and Tmab mutants were run on a reducing 10% SDS-PAGE. The HC bands 
(Tmab WT, Herceptin and all mutants except Q160N) and the LC band (Q160N) were excised 
from the gel and diced. The proteins in the gel were reduced by incubation with 10 mM DTT at 
56 °C for 45 minutes and then alkylated with 55 mM iodoacetamide (IAA) in 100 mM NH4HCO3 
at 25 °C for 30 minutes. The alkylated proteins were then digested with trypsin (1 µg per 50 µg of 
protein) in 50 mM NH4HCO3 (pH 6.8) at 37 °C overnight. The tryptic peptides were subsequently 
treated with chymotrypsin in 100 mM Tris-HCl and 10 mM CaCl2 (pH 7.8) at 25 °C overnight. 
C18 ZipTips were used for desalting the tryptic/chymotryptic peptides, using 80% (v/v) 
acetonitrile in 0.1% TFA for elution. Solvent was removed by vacuum centrifugation and the 
peptides were dissolved in 0.1% formic acid for LC-MS/MS analysis. 
Free glycan analysis 
The glycans were released from the antibody and analysed through tandem mass spectrometry as 
described before [19]. Briefly, antibody aliquots were reduced and alkylated using 1 M DTT and 
500 mM IAA, respectively. Subsequently, 10 µg of protein was blotted on a PVDF membrane 
previously wetted with ethanol and left to dry overnight. The membrane was then washed with 
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methanol, followed by a wash with water to remove salts. The membrane was then stained briefly 
with Direct Blue 71 solution (1 part 0.1% direct blue 71 stain (w/v) in MilliQ water and 12 parts 
wash solution (40% ethanol (v/v), 10% acetic acid (v/v)) to visualize the spots. The spots were 
then briefly destained using wash solution and washed with water. The spots were cut from the 
membrane and transferred to 96-well plates and blocked with 1% (w/v) polyvinylpyrrolidone 40 
(PVP40). The spots were washed three times with water and placed in new wells containing water. 
PNGase F was subsequently added to the wells (1 unit per 5 ug of protein) and the plate was 
incubated overnight at 37 °C. The resulting solution containing the released glycans was collected 
and transferred to a low-protein binding tube. 10 µL of 100 mM ammonium acetate pH 5 was 
added and incubation was done for 1 hour at 25 °C to remove glycosylamines from the reducing 
end. The samples were dried by vacuum centrifugation followed by reduction with 1 M NaBH4 in 
50 mM KOH for 3 hours at 50 °C. The reaction was neutralized with 1 µL glacial acetic acid.  
An AG 50W X8 cation exchange resin loaded onto a ZipTip C18 tip for packing and was used for 
desalting the reduced glycans. Prior to sample loading, the columns were washed three times with 
50 µL of 1 M HCl followed by three washes with 50 µL of methanol. The columns were then 
transferred to new collection tubes and washed three times with 50 µL of water. The samples were 
loaded onto the column and eluted with water. The eluted glycans were dried with a SpeedVac 
concentrator and redissolved in 100 µL methanol to remove residual methyl borate and dried once 
more. Methanol redissolution was performed three times.  
Finally, a carbon cleanup step was performed with a carbon solid-phase extraction (SPE) slurry 
packed into a TopTip. The carbon SPE columns were initially washed three times with 50 µL of 
acetonitrile in 0.1% (v/v) TFA. The columns were then washed three times with 50 µL of 0.1% 
(v/v) TFA in water. The desalted reduced glycans were then dissolved in 0.1% (v/v) TFA in water 
and loaded onto the column. The columns were washed three times with 50 µL of 0.1% (v/v) TFA 
in water and the glycans were eluted with 50% (v/v) acetonitrile in 0.1% (v/v) TFA. The glycans 
were dried in a SpeedVac concentrator and dissolved in 10 mM NH4HCO3 for LC-MS/MS 
analysis. 
Mass Spectrometry 
Glycopeptide analysis was done using an in-house packed 20 cm x 75 µm Reprosil-Pur C18AQ (3 
µm, 120 A) coupled to an Orbitrap Fusion MS (Thermo Scientific) was used for LC-MS/MS. 
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HPLC solvent A was 0.1% (v/v) formic acid and solvent B was 80% (v/v) acetonitrile in 0.1% 
formic acid. The peptides were separated running a 90-minute 0-40% solvent B gradient at 300 
nL/min at 60 °C. The Orbitrap Fusion mass spectrometer was used in positive mode, with source 
voltage = 2.3 kV, S lens RF level = 68%, and a capillary temperature of 275 °C. Initial MS scan 
was acquired from 350-2000 m/z at a resolution of 60000 at 400 m/z (MS AGC = 6 x 105). 
Following MS1, data-dependent higher-energy collisional dissociation (HCD) was used at top 
speed. HCD parameters were set up as: activation time = 0.1 ms, maximum injection time = 200 
ms, dynamic exclusion = enabled with repeat count 1, resolution = 30000, normalized energy = 
40, exclusion duration = 20 s, default charge state = 2 and MSn AGC = 2.0 x 105. The two most 
intense precursors were re-isolated and subjected to collision induced fragmentation (CID). CID 
parameters were: resolution = 30000 in orbitrap, activation time = 10 ms, dynamic exclusion = 
enabled with repeat count 1, normalized energy = 35, exclusion duration = 20 s, default charge 
state = 2, MSn AGC = 5.0 x 104. 
MS analysis of the free glycans was done on a VelosPro (Thermo) mass spectrometer with an 
Agilent 1260 HPLC using a Hypercarb porous graphitised carbon capillary column (3 µm particle 
size, 100 mm x 180 µm, pore size 250 Å, Thermo). The glycans were separated using a 60 min 5-
45% (v/v) solvent B (80% (v/v) acetonitrile in 10mM NH4HCO3) gradient on a flow rate of 2 
μl/min. Column was washed with 100% solvent B and equilibrated with solvent A (10mM 
ammonium bicarbonate) after each run. ESI–MS was performed in negative ion mode at a 
resolution of 30000 with a mass range of m/z 500–2000. Transfer capillary temperature was at 275 
°C and the capillary voltage was at 3 kV. MS2 of the top 9 most intense ions was done using 
collusion induced dissociation (CID) at a normalized collision energy of 35 in the ion trap with an 
activation time of 10 ms.   
Data Analysis 
The analysis of the peptide and glycopeptide data was done using Byonic (Protein Metrics Inc.) 
software. Peptide spectrum matches (PSM) were obtained through a search against the FASTA 
files of the wild-type trastuzumab and its variants. CID spectra annotation was automated using 
Byonic and the spectral matches were inspected manually. The Byonic search was conducted with 
a semi specific digestion specificity allowing two missed cleavages. The fragment mass tolerance 
was 0.05 Dalton (Da). A maximum of two common modifications (Asparagine and glutamine 
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deamidation +0.984016 Da, Cysteine carbamidomethylation +57.021464) and one rare 
(Methionine oxidation +15.994915) modifications were enabled.   
Free glycans were analysed manually using Thermo Xcalibur Qual Browser version 3.0.63. The 
theoretical monosaccharide compositions were determined using the monoisotopic masses of the 
detected ions using GlycoMod (http://web.expasy.org/glycomod/) with mass tolerance of ±0.5 Da. 
The glycan structures were manually assigned using PGC retention time and MS2 diagnostic 
fragment ion information. The percentage relative quantitation of each glycan structure per Tmab 
variant was calculated using the extracted ion chromatogram (EIC) areas upon peak smoothing 
using Gaussian Algorithm (15 points). The area values for the glycan structures were summed and 
normalised to 100% and each glycan peak was expressed as percentage of the total.  
Binding affinity to HER2 and Fc receptors 
The wild type trastuzumab references (Tmab WT and Herceptin) and the hyperglycosylated 
mutants were tested for their capacity to bind their molecular target (HER2) and Fc receptors 
(FcγR1A, FcγR2B, and FcγR3A). A Biacore T200 instrument (GE Healthcare, Australia) was used 
to obtain the binding kinetic constants through surface-plasmon resonance (SPR) using single-
cycle kinetic analysis.  
For HER2 binding experiments, a CM5 sensor chip was functionalized with an anti-HIS antibody 
through amine coupling chemistry. The HIS-tagged HER2 receptor (4 nM) was then bound to the 
anti-HIS at 5 µL/min flow rate for 5 minutes. The trastuzumab variants were assayed in single-
cycle kinetic titrations in 2-fold serial dilutions spanning 0.5 – 8 nM using HBS-T running buffer 
(10 mM HEPES, 150 mM NaCl, 0.05% (v/v) Tween 20, pH 7.4). Analyte runs were performed at 
20 µL/min for 2 min with 60 min dissociation times. All experiments were conducted in duplicate. 
HIS-tagged Fc receptors were bound to the anti-HIS antibody on the CM5 sensor following the 
same procedure as for HER2. The analyte runs were performed as described above for HER2, with 
the exception of a 30 min dissociation time and that analyte concentrations ranged from 2.5 – 40 
nM for FcγR1A, and from 25 – 400 nM for FcγR2B and FcγR3A. 
The sensorgrams were fitted to a Langmuir 1:1 binding model to derive the binding kinetic 
constants (Ka, Kd, and KD). The fit was deemed acceptable if χ2 was lower than 5% of the maximum 
response level (Rmax). 
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Results 
Engineered glycosylation sites 
Table 1 lists the surface exposed amino acid residues that were mutated herein in trastuzumab with 
the respective proposed mechanism to increase physical stability. One residue (L115) lies on the 
variable region of the heavy chain (VH), five (A121, L177, Q178, L182 and T198) on the constant 
heavy (CH1) and one on the constant region of the light kappa chain (Ck). The amino acid 
substitutions L115N, Q160N, Q178N and L182N were derived from previous studies by Courtois 
et al. that identified sites on the tertiary structure of the Fab region of IgG1 antibodies where the 
incorporation of a glycan could shield hydrophobic surface-exposed regions. These aggregation-
prone regions (APRs), or aggregation hotspots, were mapped with the Spatial Aggregation 
Propensity (SAP) technology, wherein individual amino acids are assigned an aggregation 
propensity value based on side chain hydrophobicity, dynamically-exposed solvent accessible 
surface area (SASA), and the hydrophobic contributions of adjacent amino acids within a given 
radius [18]. For more details on this technique see [20].  
Table 1. Surface exposed amino acid (aa) residues identified in Tmab Fab region for glycosylation 
sequon addition. 
aa Substitution 
(Position) 
Region Proposed function 
L115N VH Mask APR by introducing glycosylation site [18]. 
A121N 
CH1 
Improve solubility by introducing glycosylation site [17]. 
L177N 
Mutate aa with high spatial-aggregation propensity and introduce 
glycosylation site [18, 21]. 
Q178N 
Sterically hinder self-association by introducing glycosylation site and 
increase solubility [18, 17]. 
L182N Mask APR by introducing glycosylation site [18]. 
T198N 
Improve solubility and sterically hinder self-association by introducing 
glycosylation site [17]. 
Q160N Ck  Mask APR by introducing glycosylation site [18]. 
 
Aside from T198, all other aforementioned substitutions were engineered to shield the APR 
generated by the high SAP residue L177. Mutations L115N and Q160N have previously 
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demonstrated to improve resistance to aggregation through accelerated stability studies in 
bevacizumab – a therapeutic monoclonal antibody with a pronounced tendency to aggregate 
through self-association [18]. Q178N and L182N were identified in the same study as positions in 
the vicinity of L177N that can be mutated to generate an N-glycosylation sequon (Asn-X-Ser/Thr) 
through a single amino acid substitution, however these were excluded from experimental tests in 
bevacizumab due to Q178 having reduced SASA and L182 not being oriented on the same face as 
the APR. In this work, L177 was also mutated to substitute the high SAP residue with an 
asparagine within a consensus motif for glycan addition. The latter mutation was recently tested 
in an adalimumab Fab expressed in Pichia pastoris, conferring improved resistance to aggregation 
and proteinase K digestion relative to wild-type adalimumab Fab. 
A121N, Q178N and T198N were identified by Pepinsky et al. [17] as glycosite additions that could 
prevent self-association through steric hindrance in an anti-LINGO antibody with reduced 
solubility. In this case, all three modifications granted a dramatic improvement in solubility.   
Glycan occupancy prediction 
To assess the validity of employing existing algorithms for the prediction of glycan attachment, 
the primary sequence of the trastuzumab variants was subjected to an in-silico analysis using two 
available N-glycosylation prediction servers. Both servers, NetNGlyc 1.0 and NGlycPred, assign 
a 0-1 score, wherein values greater than 0.5 indicate a predicted glycosylated asparagine residue. 
Figure 1 depicts the location and surface exposure of the amino acid substitutions and the high 
SAP L177. Table 2 reports the predicted potential for glycan occupancy obtained with the 
NetNGlyc 1.0 server, which relies on adjacent primary sequence to assign a probability for N-
glycan transfer during protein translation. This server has been employed successfully in various 
studies to predict glycosylation in identified Asn-X-Ser/Thr motifs within primary amino acid 
sequences [22-24]. NetNGlyc predicted all residues, except Q178N, to undergo glycosylation. 
Further, an additional algorithm (NGlycPred) that incorporates structural features (e.g., adjacent 
secondary structure, surface accessibility, local contact order) into the analysis was utilised for 
prediction based on fundamentally distinct inputs [25]. NGlycPred assigned a negative value 
(<0.5) to L115N and Q178N.  Herein, all listed mutations were implemented and expressed in 
HEK-293F human embryonic kidney cells. The attached glycans were subsequently released by 
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PNGase F digestion and analysed by capillary/nanoLC-ESI-MS/MS to confirm glycan attachment 
and obtain structural features of the oligosaccharides. 
 
Figure 1. Location of the mutated amino acid residues for glycosite addition. Crystal 
structure of the HER2 extracellular domain complexed with the Fab of trastuzumab (1N8Z) 
visualised in PyMOL. The mutated amino acids are highlighted in red. The high SAP L177 
is displayed in yellow. VH and CH1 domains are shown in light grey and dark grey 
respectively. VL and CL domains are shown in light green and dark green respectively. The 
HER2 ECD is displayed in blue. 
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Table 2. Estimated glycosylation potential and solvent accessible surface area (SASA) of the 
targeted N-glycan sequons. 
aa Substitution (Position) Region Sequon NetNGlyc NGlycPred SASA (Å^2) 
Q160N CK 160 NESV 0.647 0.834 62.478 
L115N VH 115 NVTV 0.679 0.462 43.709 
A121N CH1 121 NSTK 0.547 0.686 85.338 
L177N 
CH1 
177 NQSS 0.537 1.000 96.039 
Q178N 178 NSSG 0 0.157 20.5 
L182N 182 NYSL 0.568 0.999 30.123 
T198N 198 NQTY 0.592 1.000 141.149 
 
Glycan attachment confirmation 
Glycan attachment on the mutated sites was analysed through electrophoretic mobility shifts in 
SDS-PAGE and MS/MS glycan profile analysis. Figure 2 shows a reducing SDS-PAGE of the 
mutants and the in-house wild-type trastuzumab (Tmab WT) produced in the same cell line (HEK-
293F) under identical expression conditions. The heavy chain (HC) band (~50 kDa) mobilities of 
the L115N, A121N, L177N, Q178N, L182N, and T198N mutants were retarded relative to that of 
WT, commercial Herceptin (Herc) and Q160N (mutated on the light chain), indicating higher 
levels of glycosylation on these HC mutants. 
Interestingly, no matches were found for glycopeptides containing the L177N, Q178N and L182N 
residues. Conversely, peptides containing the non-mutated L177, Q178 and L182 amino acids 
were detected in WT and Tmab variants with mutations outside the region (Figures S31-S33). 
Assuming no missed cleavages, the tryptic/chymotryptic peptide containing L177N, Q178N or 
L182N has a mass of 2206.11 Da (Table 3). It is likely that glycan attachment on the side chain 
hindered enzymatic digestion, thus producing peptides with missed cleavages and m/z values too 
large for detection – glycan attachment increases the m/z further. It has also been suggested that 
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large glycopeptides can be missed in the workflow utilized for this analysis during peptide 
extraction following SDS-PAGE, as the large size could prevent them from extraction due to gel 
shrinkage caused by the organic solvents employed [19]. Similarly, glycan attachment in the 
vicinity of the cleavage sites has been shown to prevent enzymatic activity of the serine protease 
proteinase K in the L177N mutant in adalimumab Fab [21]. Still, successful glycosylation of 
L177N, Q178N, and L182N was confirmed by mobility shifts in SDS-PAGE and an increased 
heterogeneity observed in the released glycan profile compared to WT as discussed in the next 
section. 
 
Figure 2. Reducing SDS-PAGE of the trastuzumab mutants for confirmation of glycan 
attachment. Commercial Herceptin (Herc) and the wild-type (non-mutated) trastuzumab 
produced in-house were run together with the mutants to compare electrophoretic mobility 
shifts in the ~50 kDa band corresponding to the heavy chain. 
Despite the positive prediction from the algorithms (NGlycPred score of 0.834 (Q160N), Table 2), 
the light chain (LC) band (~25 kDa) of Q160N showed no apparent mobility shift compared to 
WT LC region, suggesting a lack of glycosylation on the mutated asparagine residue. Although 
the glycan profiling of the Q160N showed very similar structures to WT Tmab, the glycan release 
was performed on the whole protein but not on the light chain only and therefore provided an 
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overall glycoprofile of the protein (figure 3, table 4). While the visual similarity of the light chain 
gel mobilities of WT Tmab and Q160N and the information of the overall glycan profile of Q160N 
do not entirely exclude the possibility of glycan occupancy on the 160N, the MS analysis of the 
Q160N light chain peptide clearly showed the presence of a non-glycosylated LC region. To 
confirm the lack of glycan attachment, the Q160N mutant was subjected to trypsin and 
chymotrypsin digestion to generate the corresponding peptides for nanoLC-ESI-MS/MS analysis. 
Spectral matches were found for non-glycosylated peptides encompassing the Q160N residue, thus 
confirming successful Q to N conversion and reaffirming the lack of glycan attachment (Figure 
S34). This apparent lack of glycan attachment was also observed in the corresponding Q160N 
mutant when expressed in adalimumab (Q161N) (data to be published). 
Table 3. Peptide sequences after trypsin/chymotrypsin digestion allowing one missed cleavage 
(MC) site 
Mass (Da) Position MC Sequence 
4000.01 162-201 1 NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY 
3248.63 153-183 1 FPEPVTVSWNSGALTSGVHTFPAVLQSSGLY 
3148.59 184-213 1 SLSSVVTVPSSSLGTQTYIC NVNHKPSNTK 
2206.11 162-183 0 NSGALTSGVHTFPAVLQSSG LY 
1812.92 184-201 0 SLSSVVTVPSSSLGTQTY 
 
Glycan profile analysis 
To analyse the global glycan profile of the trastuzumab variants, the proteins were immobilized 
on PVDF membranes and treated with PNGase F to release glycans attached to both the conserved 
WT N297 and the added glycosylation site. The released oligosaccharides were run on capillary 
LC-ESI-MS/MS, wherein a PGC column was used for separation of distinct glycoforms and 
MS/MS analysis (CID fragmentation) was performed to elucidate glycan structure. Figure 3 shows 
the annotated full MS spectra of Tmab WT, Herceptin, Q160N, and L177N displaying the 
identified glycan structures found on each variant. The global glycan profile reflects contrasting 
differences in glycoform heterogeneity and the relative abundance of the glycans found on the 
glycomutants. MS1 and MS2 (where possible) spectra of all the glycomutants can be found in 
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supplementary materials. The released glycan profiles displayed in figure 3 and figures S1-S9 
come from both the conserved Fc N-glycosylation sequon and the added N-glycosylation site. 
Table 4 lists the glycan structures found on all Tmab variants through this MS methodology; and 
Figure 4 reports the glycan relative abundances on specific Tmab variants determined by 
quantifying the area under the curve (AUC) of the extracted ion chromatograms.  
 
Figure 3. Full MS spectra of N-glycans released from Tmab WT, Q160N, L177N and 
Herceptin contrasting the heterogeneity found on the mutant. 
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Glycan microheterogeneity at the conserved N297 in Tmab WT is similar to that reported in 
previous analysis of commercial Herceptin and other monoclonal therapeutic antibodies, where 
complex G0F, G1F and G2F glycoforms (Figure 4 and table 4) are predominant [26, 27]. Minor 
species (i.e., Man5, G0 and G2S1) were detected in commercial Herceptin but not in Tmab WT 
(Figure 3). An important difference between commercial Herceptin and Tmab WT lies in the 
relative abundance of the three main glycoforms (G0F, G1F and G2F), where the originator 
contained the pattern G0F>G1F>G2F (60%, 31%, and 2%) and Tmab WT possessed 
G1F>G0F>G2F (26%, 57%, and 17%) (Figure 4). Glycosylation differences are expected between 
these two samples, as the originator is produced in CHO cells and our in-house Tmab in HEK-
293F. Moreover, sialic acid-containing species (17a table 4) were present in the originator and not 
detected in Tmab WT. This observation is consistent with previous studies reporting higher 
sialylation of N-glycans in recombinant proteins expressed in CHO when compared to HEK cells 
[28].  
The G1F>G0F>G2F distribution observed in Tmab WT was conserved in all the glycomutants 
(Figure 4), although the abundance of G1F seemed to decrease in comparison to that observed for 
Tmab WT. Figure 5 shows the relative abundances considering only the main complex glycoforms 
found on the Fc domain (G0F, G1F, and G2F). The decrease in G1F and concomitant increase in 
G0F was more pronounced in the Q178N mutant where G1F (40.47%) was only slightly less 
abundant than G0F (42.98%) (Figure 5).  
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Figure 4. Relative abundances of the glycan found on each specific mutant. Highlighted in 
blue are G0F, G1F and G2F which were also found on the WT tmab. High mannose glycans 
are displayed in greed, hybrid glycans in yellow and sialic acid containing glycans in red. 
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Figure 5. Relative abundances of the main glycoforms found on all Tmab variants. 
Remarkably, a much wider heterogeneity of glycan structures were detected on most Tmab 
variants relative to wild type trastuzumab (Tmab WT and Herceptin) (Figures 3 and 4). The fact 
that G0F, G1F, and G2F were still the most abundant structures in all samples indicates that the 
increased variety of glycans come from the Fab region. The wider array of structures included high 
mannose, hybrid, and complex biantennary, triantennary and tetrantennary glycans with varied 
degrees of galactosylation and sialylation (Table 4). Variants L177N and L182N displayed the 
most varied sets of glycoforms with 16 and 12 different structures detected, respectively. 
Importantly, sialic acid-containing glycans were particularly abundant in L115N, L182N, and 
T198N. Q178N had a significant presence of high mannose glycans.  
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Table 4. Full list of glycans found on all mutants 
# 
Structure 
Type Composition Structure 
[M-
2H]2- 
Mutants 
containing 
the glycan 
1a 
high 
mannose 
HexNAc(2)Hex(5) 
 
617.22 
Q178N 
 
1b 
high 
mannose 
HexNAc(2)Hex(5) 
 
617.22 
L177N 
Q178N 
L182N 
2a (G0) complex HexNAc(4)Hex(3) 
 
658.24 
L177N 
Herceptin 
2b (G0) complex HexNAc(4)Hex(3) 
 
658.24 L177N 
3 
high 
mannose 
HexNAc(2)Hex(6) 
 
698.25 
Q178N 
L182N 
4 (G0F) complex HexNAc(4)Hex(3)Fuc(1) 
 
731.27 
All Tmab 
variants 
 
5 complex HexNAc(5)Hex(3) 
 
759.78 
L177N 
 
6a hybrid 
HexNAc(3)Hex(4)Man(2) 
Fuc(1) 
 
791.79 L177N 
6b hybrid 
HexNAc(3)Hex(4)Man(2) 
Fuc(1) 
 
791.79 L177N 
6c hybrid 
HexNAc(3)Hex(4)Man(2) 
Fuc(1) 
 
791.79 L177N 
7 hybrid HexNAc(3)Hex(5)Man(1) 
 
799.79 
Q178N 
L182N 
144 
 
8a (G1F) complex 
HexNAc(4)Hex(3)Man(1) 
Fuc(1) 
 
812.3 L177N 
8b (G1F) complex 
HexNAc(4)Hex(3)Man(1) 
Fuc(1) 
 
812.3 
All Tmab 
variants 
9 complex HexNAc(5)Hex(3)Man(1) 
 
 
840.81 L177N 
10 
high 
mannose 
HexNAc(2)Hex(8) 
 
 
860.3 
L115N 
 
11 hybrid 
HexNAc(3)Hex(4)Man(1) 
NeuAc(1) 
 
 
864.31 L182N 
12 hybrid 
HexNAc(3)Hex(5)Man(1) 
Fuc(1) 
 
872.81 L177N 
13 (G2F) complex 
HexNAc(4)Hex(3)Man(2) 
Fuc(1) 
 
893.33 
All Tmab 
variants 
14a complex 
HexNAc(5)Hex(3)Man(1) 
Fuc(1) 
 
913.84 
A121N 
L177N 
Q178N 
L182N 
T198N 
14b complex 
HexNAc(5)Hex(3)Man(1) 
Fuc(1) 
 
913.84 
A121N 
L177N 
Q178N 
L182N 
T198N 
15 
high 
mannose 
HexNAc(2)Hex(9) 
 
941.33 
L115N 
 
16 hybrid 
HexNAc(3)Hex(5)Man(1) 
NeuAc(1) 
 
944.84 
A121N 
L177N 
L182N 
T198N 
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17a complex 
HexNAc(4)Hex(3)Man(2) 
NeuAc(1) 
 
965.84 
L177N 
L182N 
17b complex 
HexNAc(4)Hex(3)Man(2) 
NeuAc(1) 
 
965.84 L177N 
18 complex 
HexNAc(5)Hex(3)Man(1) 
Fuc(2) 
 
986.87 
A121N 
L177N 
19a complex 
HexNAc(5)Hex(3)Man(2) 
Fuc(1) 
 
994.87 
L115N 
A121N 
L177N 
Q178N 
L182N 
T198N 
19b complex 
HexNAc(5)Hex(3)Man(2) 
Fuc(1) 
 
994.87 L177N 
20a complex 
HexNAc(4)Hex(3)Man(2) 
Fuc(1)NeuAc(1) 
 
1038.87 
L115N 
A121N 
L177N 
Q178N 
L182N 
T198N 
20b complex 
HexNAc(4)Hex(3)Man(2) 
NeuAc(1) 
 
1038.87 
A121N 
L177N 
Q178N 
L182N 
T198N 
21a complex 
HexNAc(5)Hex(3)Man(1) 
NeuAc(1) 
 
1059.39 
A121N 
L177N 
T198N 
21b complex 
HexNAc(5)Hex(3)Man(1) 
NeuAc(1) 
 
1059.39 L177N 
21c complex 
HexNAc(5)Hex(3)Man(1) 
NeuAc(1) 
 
1059.39 L177N 
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Binding affinity to HER2 and FcγR1A 
To assess potential alterations in biological activity caused by the structural modifications of 
glycan addition, we tested the binding affinity of the Tmab variants on biologically relevant 
receptors in vitro. Surface-plasmon resonance (SPR) single-cycle kinetic assays were performed 
to determine binding kinetic constants of the Tmab variants to their molecular target HER2, and 
to Fc receptors FcγR1A, FcγR2B, and FcγR3A (Table 5 and Table 6). Sensorgrams displaying 
typical curvatures with satisfactory curve fitting were obtained across all receptors tested with the 
exception of mutants A121N, Q178N, L182N, and T198N on FcγR2B, thus the corresponding 
binding kinetic constants to this receptor were not determined (Figures S35-S38). Chi-square 
values and residuals were inspected to validate curve fitting.  
Table 5. Binding kinetic constants of the Tmab variants to HER2 and FcγR1A 
 
HER2 FcγR1A 
Ka Kd KD Ka Kd KD 
(x 10+6) M-
1.s-1 
(x 10-5) s-1 pM 
(x 10+5) M-
1.s-1 
(x 10-4) s-1 nM 
Tmab WT 2.50 ± 0.03 3.03 ± 0.72 12.11 ± 2.72 2.11 ± 0.03 10.64 ± 0.56 5.05 ± 0.33 
L115 > N 3.82 ± 3.80 
18.16 ±  
9.14 
47.56 ± 
25.89 
1.79 ± 0.20 4.20 ± 0.06 2.34 ± 0.26 
A121 > N 4.40 ± 1.71 23.84 ± 4.35 
54.24 ± 
10.24 
3.83 ± 0.36 8.77 ± 1.14 2.29 ± 0.08 
Q160 > N 0.83 ± 0.02 2.78 ±  1.26 
33.53 ± 
15.86 
2.55 ± 0.02 6.62 ± 0.11 2.59 ± 0.02 
L177 > N 1.84 ± 0.13 6.32 ± 0.08 34.28 ± 2.01 5.01 ± 0.18 15.04 ± 1.27 3.00 ± 0.15 
Q178 > N 1.35 ± 0.27 4.29 ± 0.67 31.88 ± 2.11 7.38 ± 0.11 9.23 ± 0.30 1.25 ± 0.02 
L182 > N 1.1 * 3.2 * 29.1 * 3.67 ± 0.55 12.37 ± 2.64 3.37 ± 0.22 
T198 > N 6.11 ± 1.17 50.97 ± 3.23 
83.44 ± 
77.77 
4.71 ± 0.02 8.09 ± 0.10 1.72 ± 0.03 
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Table 6. Binding kinetic constants of the Tmab variants to FcγR2B and FcγR3A 
 
FcγR2B FcγR3A 
Ka Kd KD Ka Kd KD 
(x 10+4) M-
1.s-1 
(x 10-4) s-1 nM 
(x 10+4) M-1.s-
1 
(x 10-4) s-1 nM 
PBS-Herc 3.05 ± 0.04 1.99 ± 0.13 6.55 ± 0.35 10.51 ± 0.29 
1.90 ± 
0.54 
1.81 ± 0.47 
Tmab WT 5.76 ± 1.01 4.75 ± 0.41 8.25 ± 0.69 11.41 ± 2.06 
1.29 ± 
0.64 
1.13 ± 0.32 
L115 > N 0.65 ± 0.26 0.78 ± 0.44 11.92 ± 3.57 3.35 ± 0.85 
2.74 ± 
0.23 
8.17 ± 1.60 
T117 > N ND ND 
A121 > N ND 2.78 ± 1.99 1.95 ± 0.43 7.01 ± 3.84 
Q160 > N 4.01 ± 0.32 1.85 ± 0.27 4.62 ± 0.32 21.17 ± 4.95 
8.01 ± 
2.95 
3.78 ± 0.46 
L177 > N 2.95 ± 1.82 6.88 ± 4.26 
23.28 ± 
44.62 
2.83 ± 0.22 
3.02 ± 
0.05 
10.67 ± 1.03 
Q178 > N ND 1.95 ± 0.20 
0.98 ± 
0.20 
5.04 ± 1.47 
L182 > N ND 3.12 ± 0.25 
1.95 ± 
0.20 
6.24 ± 1.30 
T198 > N ND 2.25 ± 0.14 
0.86 ± 
0.15 
3.81 ± 0.41 
 
SPR-derived binding kinetic parameters of the mutants on immobilized HER2 displayed a modest 
decrease in the binding affinity constant (KD) compared to wild-type trastuzumab (Table 5). KD 
values for the Tmab variants ranged from 29.10 – 83.44 pM compared to 12.11 ± 2.72 pM for 
Tmab WT, which represents a 2.4 – 6.9-fold reduction in binding affinity. Most variants displayed 
a decrease in binding rate constant (Ka) and an increase in dissociation rate constant (Kd), with 
the exception of A121N and T198N that had higher Ka values, yet they also possessed the highest 
increase in Kd constants. Thus, the A121N and T198N mutations displayed the lowest binding 
affinity constants to HER2. 
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Conversely, binding affinity to captured FcγR1A was improved for all mutants relative to both 
Tmab WT and Herceptin, exhibiting KD values 1.5 – 4 times lower than Tmab WT. Mutants 
Q178N and T198N recorded the highest binding affinity to FcγR1A, with KD constants of 1.25 
and 1.72 nM respectively. SPR assays with immobilized FcγR2B yielded curves with lower 
similarity to the wild-type references. Dissociation times for mutants A121N and Q178N were too 
long to obtain reliable kinetic binding affinity parameters. L182N showed a drastic decrease in 
binding affinity. Mutants L115N, Q160N, and L177N exhibited modest increases in binding 
affinity constants to FcγR2B. Binding affinity to FcγR3A was reduced across all mutants, 
displaying 3.35 – 9.44-fold increases in KD values. 
Discussion 
The insertion of novel N-glycosylation sites on the primary structure of IgG1 molecules is a highly 
promising approach to enhance the physicochemical properties of therapeutic proteins, having 
previously demonstrated important enhancements in solubility and physical stability in 
bevacizumab, adalimumab, and the Li33 anti-LINGO antibody. However, implementation of this 
approach in clinical development could be challenging due to the concomitant increase in 
structural heterogeneity. This is especially relevant when considering mAbs whose therapeutic 
efficacy relies, at least partially, on eliciting effector functions; given that the technique entails the 
incorporation of a relatively large molecule that should not alter detrimentally the binding affinity 
towards the various receptors involved in its biological activity (i.e., cognate antigen, Fc receptors, 
C1q). Further considerations include potential modifications in immunogenicity and 
pharmacokinetic profiles. Moreover, elucidation of the underlying mechanisms that drive 
improvements in stability demands thorough structural analysis of the glycan structures attached 
to the engineered site. In light of this, we inserted N-glycosylation motifs in trastuzumab in several 
amino acid positions previously identified by others on conserved regions of the IgG1 molecule 
and performed a detailed structural analysis of the ensuing glycan profile. 
Preliminary prediction and confirmation of glycan attachment 
N-glycosylation is a complex biochemical process, for which the requirements for glycan 
attachment are not yet fully understood. Three key factors determining glycan occupancy have 
been identified: (1) location of the asparagine residue within the consensus motif Asn-X-Ser/Thr, 
(2) location of the N residue in the ER lumen during translation, and (3) the adjacent secondary 
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structure of the protein must enable glycan transfer. Based on these, numerous servers have been 
developed to map N-glycosylation sequons and predict the probability of glycan attachment, and 
have been instrumental in the study of the glycosylation profile of proteomes. We thus employed 
two such servers to assess the validity of their prediction values applied to this antibody 
engineering strategy. This is particularly important considering the fact that previous studies have 
not pursued potential APR shielding regions experimentally due to low glycan transfer probability. 
Specifically, residue Q178 was deemed ineligible by Courtois et al. based on low solvent 
accessible surface area obtained from MD simulations. Our preliminary evaluation of glycan 
attachment probability on trastuzumab shed similar results (Table 2) to those obtained by Courtois 
et al. on their panel of glycosylation sites identified through SAP, wherein Q178N had negative 
predictions by both NetNGlyc and NGlycPred, and SASA was amongst the lowest calculated (20.5 
Å2). Importantly, L115N also obtained a negative prediction value from NGlycPred. It was thus 
remarkable that our experimental data contradicted the negative prediction for residues L115N and 
Q178N. The Q178N mutant had previously been implemented by Pepinsky et al. in the anti-
LINGO IgG1 antibody with important improvements in solubility, although no compelling data to 
confirm glycan attachment was reported.  Moreover, our data strongly suggest that Q160N does 
not undergo glycan attachment, despite the high SASA and prediction values calculated for the 
residue. This was equally observed in the equivalent mutation in adalimumab (data to be 
published). These results emphasize the importance of confirming glycan attachment and 
performing structural analysis of the resulting structural modifications, to better interpret the 
results derived from aggregation experiments. Furthermore, they reveal a conspicuous need for 
further understanding of the factors that determine successful glycan transfer to refine this antibody 
engineering approach. 
Glycan profile analysis 
Compared to plasma proteins and other recombinant therapeutic proteins, monoclonal antibodies 
display limited heterogeneity in their Fc N-glycan profile, as reported herein. This observation is 
ascribed to the decreased surface exposure of Asn N297 and the attached glycan as it engages in 
several interactions with the protein backbone and residue side chains at the inner face of the 
domain [28, 29]. Although most plasma IgG molecules possess only the conserved N-
glycosylation sequon in the Fc region, roughly 15-25% also express additional glycosylation sites 
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on the variable domain of the Fab region [30, 31]. Glycan profiling of Fab-glycosylated serum 
IgGs has revealed contrasting structural characteristics between Fc-derived and Fab-derived 
glycans, most notably higher overall heterogeneity and sialylation [32, 33]. All mutations 
evaluated in this study are located in the Fab region, although only L115N lies on a variable domain 
– in close proximity to the VH-CH1 interface. The global glycan profile acquired through 
capillary/nanoLC-ESI-MS/MS demonstrated that increased structural heterogeneity is similarly 
obtained when engineered glycosylation sites are incorporated through mutagenesis in the Fab 
region of a recombinant mAb.  
There was no evident association between the degree of heterogeneity or apparent glycan 
maturation and the solvent accessible surface area calculated. For instance, low-SASA mutant 
L115N possessed a relatively high abundance of sialylated glycans, indicative of higher glycan 
processing. Remarkably, high mannose glycans (HexNAc(2)Man(8) and HexNAc(2)Man(9)) 
were also detected in L115N. Similarly, residue Q178N displayed high glycoform heterogeneity 
despite having the lowest SASA among the mutants, including sialylated and triantennary glycans. 
As the en bloc transfer of the dolichol oligosaccharide precursor occurs on nascent proteins 
undergoing translation, low surface exposure calculated from the WT structure might not preclude 
glycan attachment and the resulting orientation of the glycan could be surface-exposed for enzyme 
accessibility. Ideally, SASA would be calculated from the crystal structure of the mutated protein, 
but performing such analyses for all mutations entails prominent experimental challenges.  
Overall, the degree of sialylation was markedly higher in most engineered mutants relative to both 
wild-type references, i.e., Tmab WT and Herceptin. Similar findings have consistently been 
reported for both polyclonal and recombinant monoclonal IgG proteins containing naturally-
occurring N-glycosylation sequons in the Fab region [34]. The higher abundance of sialic acid 
glycans in Fab glycosites has been attributed to increased accessibility to enzymes involved in 
glycan maturation relative to the Fc glycan. In this case, however, we also found various high 
mannose and hybrid glycans not detected in Tmab WT. In the seminal exploration of SAP 
reduction by Courtois et al., a G0 glycan was selected for molecular dynamic simulations of the 
Fab region to shed light into the factors driving resistance to aggregation upon glycosite insertion 
[18]. Here, it was posited that the added glycans on some of the mutated sites produce limited APR 
shielding and hence the improvements in physical stability could stem from steric hindrance due 
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to the large hydrodynamic size and hydrophilic character of the added glycans. The diversity of 
glycoforms reported here indicates that this structural heterogeneity must be accounted for when 
performing these analyses, particularly considering the important presence of negatively charged 
sialic acid residues on some of the mutants. 
HEK-293F cells were chosen for transient expression of the Tmab variants due to high transient 
transfection efficiency and yield relative to CHO cells. Comparison of the glycan profile of CHO-
produced Herceptin with HEK-derived Tmab WT shows that galactosylation was more abundant 
in HEK-293F expression. This observation was also consistent across the mutant panel when 
considering uniquely Fc glycans. Galactosylation of the conserved Fc glycan is not considered to 
affect significantly mAb binding to FcγR receptors, yet there is consistent evidence that the 
presence of terminal galactose promotes activation of the classical complement route [35]. Hence, 
the higher content of G1F and G2F glycoforms could lead to potency advantages in mAbs with 
significant modulation of complement activity.  
Alterations in HER2 and Fc receptor affinity 
A crucial consideration in this engineering approach must be the conservation of biological 
activity. The proximity of the mutations to the CDRs and to regions involved in Fc receptor binding 
warrants examination of alterations in receptor binding affinity. Taking this into consideration, we 
evaluated the binding kinetics of the panel of mutants to their molecular target (HER2) and to Fc 
receptors involved in effector function, using single-cycle SPR.  
The kinetic constants obtained indicate that HER2 binding affinity is moderately diminished for 
all mutants, reflected by 2.4 – 6.9-fold reductions in the binding affinity constant (KD). All KD 
values, however, were subnanomolar – demonstrating that strong binding to HER2 is retained 
despite modest decreases in affinity. Remarkably, the highest reduction in affinity was obtained 
with T198N, which is located farthest from the HER2 binding region. This reduction in binding 
affinity could have resulted from conformational changes affecting the antigen binding region. KD 
values derived herein for wild-type Tmab binding to HER2 were in agreement with those reported 
in previous literature, spanning 19 pM – 5.48 nM [36-38]. 
Overall, the mutant library exhibited minor modifications in Fc receptor binding affinity. Binding 
to FcγR1A was marginally improved in all Tmab variants. Curve fitting was less reliable for 
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FcγR2B, and it was not possible to calculate these parameters for mutants A121N, Q178N, L182N, 
and T198N. Still, sensorgram interpretation suggests that L182N binding to FcγR2B was 
drastically disrupted. Binding affinity to FcγR3A also showed moderate disruption across all Tmab 
variants, with 3.35 – 9.44-fold increases in KD values. 
The affinity screening to biologically relevant receptors performed in this work served as a proof-
of-principle that N-glycosylation sites can be incorporated in the Fab region of therapeutic 
monoclonal antibodies without major modifications in antigen and Fc receptor binding. 
Nonetheless, evaluation of ADCC, CDC and inhibition of cell proliferation is still required to 
ascertain potential variations in biological activity. 
Concluding remarks 
The rational addition of N-glycosylation sequons represents a highly promising strategy to 
improve the physical stability of therapeutic antibodies, as is highlighted by the important 
enhancements in physical stability obtained in previous studies with bevacizumab, adalimumab 
Fab, and the Li33 anti-LINGO antibody. Moreover, we have previously performed the panel of 
mutations reported here in full-size adalimumab and demonstrated enhancements in 
thermodynamic stability through this approach. However, our data established that for this strategy 
to move forward in the clinical development pathway, there is an evident need to control or 
minimize the structural heterogeneity that results from glycan addition. The latter is also required 
to obtain further insight into the conferred physicochemical properties responsible for the 
improvements in stability. Native Fc glycosylation, albeit less diverse than most glycoproteins, 
already constitutes a challenge concerning the assessment of critical quality attributes. This, 
however, could be overcome with glyco-engineering strategies to curtail glycoform heterogeneity. 
Technologies to reduce glycan diversity in recombinant expression are being pursued in the 
context of refining the production of biopharmaceuticals. Prime examples of these include 
engineered Pichia pastoris (GlycoSwitch) and human (GlycoDelete) cell lines. We foresee great 
value in combining these two glyco-engineering strategies towards the development of therapeutic 
antibodies with enhanced physicochemical and biological properties. Albeit introducing 
heterogeneity, molecular engineering approaches such as this one offer a great deal of flexibility 
and control over preparation of new generation therapies. This glycoengineering strategy can also 
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be employed to enhance the biophysical stability of other protein-based therapies with short half-
life and low formulation stabilities. 
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Abstract 
Abstract: Monoclonal antibodies (mAbs) have become a cornerstone in the therapeutic guidelines 
of a wide range of solid tumors. The targeted nature of these biotherapeutics has improved 
treatment outcomes by offering enhanced specificity to reduce severe side effects experienced with 
conventional chemotherapy. Notwithstanding, poor tumor tissue penetration and the 
heterogeneous distribution achieved therein are prominent drawbacks that hamper the clinical 
efficacy of therapeutic antibodies. Failure to deliver efficacious doses throughout the tumor can 
lead to treatment failure and the development of acquired resistance mechanisms. Comprehending 
the morphological and physiological characteristics of solid tumors and their microenvironment 
that affect tumor penetration and distribution is a key requirement to improve clinical outcomes 
and realize the full potential of monoclonal antibodies in oncology. This review summarizes the 
essential architectural characteristics of solid tumors that obstruct macromolecule penetration into 
the targeted tissue following systemic delivery. It further describes mechanisms of resistance 
elucidated for blockbuster antibodies for which extensive clinical data exists, as a way to illustrate 
various modes in which cancer cells can overcome the anticancer activity of therapeutic antibodies. 
Thereafter, it describes novel strategies designed to improve clinical outcomes of mAbs by 
increasing potency and/or improving tumor delivery; focusing on the recent clinical success and 
growing clinical pipeline of antibody-drug conjugates (ADC), immune checkpoint inhibitors and 
nanoparticle-based delivery systems. 
Introduction 
Therapeutic monoclonal antibodies (mAbs) successfully entered the clinic over 25 years ago and 
have become one of the central components of the healthcare system [1, 2]. Their arrival brought 
about a therapeutic revolution due to their capacity to target specific molecular components, with 
a large number of mAbs already approved in oncology, autoimmune disorders, chronic diseases 
and many more conditions. Currently, over 80 antibody therapeutics have received regulatory 
approval in Europe and/or the United States and just in 2017 sales of therapeutic antibodies 
exceeded $100 billion worldwide [3].  
In oncology, therapeutic antibodies offer the possibility to treat tumors in a targeted fashion and 
reduce the severe side effects of conventional chemotherapy. Recent developments in cancer 
161 
 
biology have aided the discovery of molecular biomarkers in a wide range of solid malignancies 
that can be used as targets with beneficial therapeutic outcomes. At present, over 15 distinct 
monoclonal antibodies are indicated for the treatment of solid tumors [4]. Notwithstanding, in spite 
of their remarkable clinical success some patients do not benefit from the treatment due to intrinsic 
resistance mechanisms or the emergence of acquired resistance following treatment initialisation 
[5, 6]. 
In solid tumors, the development of acquired resistance mechanisms is thought to emerge primarily 
from continuous genetic alterations that modify the cellular phenotype and undermine the initial 
therapeutic efficacy. This capacity of cancer cells to overcome the anticancer effect of the antibody 
is facilitated by the exposure to subtherapeutic concentrations of the drug [7, 8]. The tumor 
microenvironment poses physical barriers, most notably a markedly increased hydrostatic 
pressure, that hinder penetration of macromolecules into the tumor following systemic 
administration [9, 10]. This reduces the overall amount of antibody molecules that reach the target 
tissue and exposes areas of the tumor that are difficult to penetrate to marginal doses of the 
antibody, leading to acquired resistance and treatment failure [8]. In fact, therapeutic mAbs in 
oncology are more commonly administered as combination therapy in conjunction with 
chemotherapeutics due to relatively limited efficacy as single agents [11]. 
Identifying and understanding primary and acquired resistance mechanisms and overcoming the 
barriers that impair efficient delivery of the drug into the tissue is critical to enhance therapeutic 
outcomes. Most of the understanding regarding primary and acquired resistance comes from the 
evaluation of clinical data available for early-approved blockbuster antibodies, such as 
trastuzumab and cetuximab. This review gives an overview of the key factors affecting tumor 
distribution upon systemic delivery and describes relevant mechanisms of resistance identified in 
trastuzumab (anti-HER2) and cetuximab (anti-EGFR) therapy. Additionally, it describes recent 
developments in the implementation of novel antibody-based therapeutics, such as antibody-drug 
conjugates, immune checkpoint inhibitors, and antibody-targeted nanoparticles that have the 
potential to increase therapeutic outcomes of solid tumors. 
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Limitations that impact clinical efficacy 
Poor penetration and heterogeneous distribution in solid tumors 
Therapeutic IgG antibodies must overcome pronounced physical and physiological obstacles in 
order to penetrate and distribute uniformly throughout the tumor. In solid malignancies, impaired 
lymphatic drainage due to the sparse presence of lymphatic vessels leads to the accumulation of 
macromolecules in the interstitial tissue and a consequent increase in hydrostatic pressure [9, 12-
14]. Hence, the altered pressure differential from vascular vessels to the interstitial compartment 
limits convection and extravasation of macromolecules from the vascular lumen into the tumor 
(Figure 1) [15]. Moreover, antibody distribution following extravasation is further impeded by 
cellular internalization and subsequent endocytic clearance at the tumor edge (an effect coined the 
“binding-site barrier”), leading to poor penetration and regions of marginal antibody 
concentrations [10, 16, 17]. The binding-site barrier suggests that higher affinity and higher 
antigen expression, especially at the tumor edge, can retard mAb tumor percolation and impair 
homogeneous distribution; although this barrier can be overcome by increasing the administered 
dose.  
163 
 
 
Figure 1. Structural features of the tumor microenvironment that increase interstitial 
pressure and hinder mAb extravasation and distribution. (A) Blood vessels that irrigate 
healthy normal tissue possess a continuous inner lining of endothelial cells, enveloped by 
perivascular cells called pericytes that grant integrity to the vascular tube. The extracellular 
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matrix (ECM) contains a lax network of collagen and proteoglycan fibers, and the presence 
of macrophages and fibroblasts is scarce. Lymph vessels efficiently remove and prevent the 
accumulation of macromolecules and interstitial fluid. (B) Increased demand of oxygen and 
nutrients in tumor tissues causes blood vessels to form defectively and irregularly shaped. 
The lack of pericytes makes the vascular tube unstable and leakier. The abundant presence 
of fibroblasts and infiltrating macrophages promote the formation of a dense extracellular 
matrix, with a condensed network of collagen and proteoglycan fibers. The paucity of lymph 
vessels leads to the accumulation of macromolecules and an increase in interstitial fluid 
pressure (IFP). The fibrotic nature of the ECM and the altered pressure differential between 
the vascular lumen and the tumor hinder antibody convection into the targeted tissue. 
A vast body of research studying some of the blockbuster therapeutic mAbs has highlighted the 
significance of increasing tissue penetration to improve the outcome of antibody therapy [15, 18]. 
A study on cetuximab and trastuzumab in mouse xenografts confirmed that tumor distribution can 
be improved with an increase in dose; however, hypoxic areas remained difficult to reach even at 
higher doses. Moreover, xenografts expressing intermediate levels of ErbB1 (cognate antigen for 
cetuximab) displayed more homogeneous distribution of cetuximab compared to xenografts with 
higher ErbB1 expression [19]. 
An alternative approach consists in improving diffusion by employing smaller antibody fragments, 
such as Fab fragments (~50 kDa), single-chain variable fragments (scFv ~30 kDa) and single-
domain antibodies (sdAb 12-15 kDa). Yet, while these formats indeed possess higher diffusion 
rates, the tumor distribution achieved in physiological settings is poor because the clearance rates 
for smaller fragments is markedly higher relative to full size antibody molecules [15, 20]. IgG 
immunoglobulins undergo salvage recycling through interaction of the Fc region with the neonatal 
Fc receptor (FcRn), leading to prolonged half-lives of more than 20 days for most therapeutic 
mAbs [21]. Conversely, antibody fragments lacking an Fc region display half-lives of hours, or 
even minutes for formats below the glomerular filtration cutoff (30-50 kDa). The high elimination 
rates upon systemic delivery prevent most antibody fragments from saturating the tumor and 
achieving uniform distributions [22, 23]. Increasing tumor tissue penetration thus poses significant 
challenges given the intricate pharmacokinetic properties of IgGs.  
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Resistance to monoclonal antibody therapy 
Understanding the resistance mechanisms that affect monoclonal antibody therapy in cancer has 
proven to be a strenuous task, insofar as the antitumor activity of mAbs stems from a multiplicity 
of molecular mechanisms – eg, signaling pathway disruption, antibody dependent cellular 
cytotoxicity (ADCC), antibody dependent cellular phagocytosis (ADCP) and complement 
dependent cytotoxicity (CDC). To this day, the clinical contribution of the various modes of action 
involved in the anticancer activity of most mAbs remains controversial [24-26]. On that account, 
intrinsic phenotypic variations in tumor cells or tumor-related cells affecting any of the involved 
modes of action can compromise treatment efficacy. Moreover, adaptive phenotypic modifications 
can arise following repeated exposure to sub-optimal doses of the biotherapeutic resulting in 
acquired resistance [27, 28]. 
Most of the current understanding of the contributing factors in the development of intrinsic or 
acquired resistance and their clinical significance comes from preclinical and clinical trials of 
benchmark therapeutic antibodies. Notwithstanding that the modes of action of different mAbs are 
not identical, the vast clinical data available for these benchmark antibodies are pivotal to 
comprehend host response and optimize monoclonal antibody therapy. The next sections briefly 
discuss resistance mechanisms identified in clinical settings for trastuzumab in HER2 positive 
breast cancer, and for cetuximab in colorectal cancer as archetypes of solid tumor treatment. 
Resistance to trastuzumab (anti-HER2 therapy) 
Trastuzumab was the first therapeutic monoclonal antibody to be approved for a solid carcinoma 
(FDA approval in the year 1998) [29]. Trastuzumab targets the extracellular domain of the human 
epidermal growth factor receptor 2 (HER2/Neu or ErbB2) that is overexpressed in a broad range 
of malignancies. HER2 overexpression is detected in 15-20% of breast cancers and this subset is 
associated with poor prognosis and higher rates of recurrence [30, 31]. 
HER2 exists primarily as a monomeric receptor that can form heterodimers with other members 
of the ErbB family of receptors (HER1, HER3 and HER4) upon ligand-mediated activation of the 
latter. Heterodimerization activates the MAPK and PI3K/AKT/mTor intracellular pathways, 
inducing cell proliferation and inhibition of apoptosis, respectively [32, 33]. Direct binding of 
trastuzumab with HER2 can hinder heterodimerization and promote proteolysis of the receptor 
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through receptor-mediated endocytosis. This interaction inhibits downstream signaling and causes 
cell cycle arrest by accumulation of the cyclin-dependent kinase (CDK) inhibitor p27 [34]. 
Additionally, trastuzumab can mediate antibody-dependent cellular cytotoxicity (ADCC) [35, 36] 
and antibody-dependent cellular phagocytosis (ADCP) [36-38]. Induction of complement 
dependent cytotoxicity (CDC) has also been documented in in vitro experiments, but it is thought 
to contribute only minimally to the anticancer effect in patients [36, 39]. 
Intrinsic alterations of the HER2 receptor involving regions associated with the binding epitope of 
trastuzumab have been linked to intrinsic (or primary) resistance mechanisms. For instance, 
alternate transcription initiation sites can result in the expression of a truncated variant of the 
receptor (p95-HER2) that lacks the cognate epitope for trastuzumab [40]. Insertions and point 
mutations in the tyrosine kinase domain of HER2 have been identified in various cancers, some of 
them associated with resistance to trastuzumab and lapatinib, however evidence of such mutations 
in HER2 overexpressing breast cancers has not been reported to date [41, 42]. A further alteration 
resulting in impaired target binding comes from the overexpression of mucin-4, which has been 
shown to induce association with HER2 causing steric hindrance to abrogate trastuzumab binding 
to HER2 [43]. 
Additional intrinsic and acquired resistance mechanisms predominantly involve alterations in the 
P13K/Akt/mTOR axis, activation of other ErbB receptors (especially EGFR and HER3) by 
increased ligand production, and circumvention of HER2 binding by activation of the PI3K 
cascade through alternative pathways. Mutations in PIK3CA and function impairment of PTEN 
(both downstream of HER2 signaling) have been implicated in bypassing HER2 blockade [44, 45]. 
Overexpression of the insulin-like growth factor (IGF-IR) has been documented as an adaptive 
response to trastuzumab by some tumors, resulting in resistance to the antibody. IGF-IR can form 
heterodimers and heterotrimers with HER2 and HER3 in breast cancer cells resistant to 
trastuzumab [46, 47]. Similarly, increased levels of EpoR, EpHA2 and RTK MET can activate 
P13K/Akt/mTOR by interacting with other members of the ErbB family or through activation of 
intracellular kinases [47-49]. 
Resistance to cetuximab (anti-EGFR therapy) 
The epidermal growth factor receptor (EGFR; HER1; ErbB1) forms part of the ErbB family of 
receptors. EGFR is pivotal in modulating proliferative mechanisms and has been implicated in a 
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broad range of cancers [50-52]. Cetuximab (chimeric IgG1) was the first anti-EGFR mAb to 
receive regulatory approval in 2004 [53]. Since then, two more anti-EGFR mAbs (panitumumab 
and necitumumab) and six anti-EGFR small molecule inhibitors (gefitinib, erlotinib, lapatinib, 
neratinib, vandetanib and osimertinib) have obtained regulatory approval for various cancers [4].  
The anticancer activity of cetuximab partially resembles that of trastuzumab in that it targets 
another member of the ErbB family of receptors with intrinsic protein tyrosine kinase activity. 
Accordingly, dimerization of EGFR can activate the PI3K/AKT/mTOR, RAS/RAF/MAPK and 
JAK/STAT signaling pathways to promote cell growth and proliferation [54, 55]. In contrast to 
HER2, EGFR can undergo a conformational transition triggered by binding of specific ligands, 
predominantly EGF and TGFα, that promotes the formation of homodimers and heterodimers with 
other members of the HER family [56]. Cetuximab can block ligand activation of EGFR by binding 
directly to the extracellular domain III of the receptor and inducing receptor internalization and 
proteolysis [57]. A further contributing mechanism of action involves suppression of VEGF (a 
pro-angiogenic factor) production resulting in impaired angiogenesis [58]. Moreover, ADCC and 
CDC are also believed to contribute to cetuximab efficacy in EGFR over-expressing cancers [59, 
60]. 
There is vast documentation of primary and acquired resistance to anti-EGFR therapy in patients 
with colorectal and head and neck cancer. Indeed, roughly 80% of metastatic colorectal cancer 
patients do not display susceptibility to EGFR blockade [61]. This low response rate has been 
linked to a broad spectrum of alterations in several of the components of the downstream signaling 
pathways. Specifically, mutations in the PIK3CA [62], NRAS, BRAF and KRAS [63]. genes that 
confer constitutive activation of the EGFR are amongst the best studied contributing factors in 
intrinsic and acquired resistance. Further alterations such as low EGFR copy numbers or low 
expression of specific EGFR-ligands (eg, EREG and AREG) have been implicated in resistance 
to EGFR therapy [64, 65]. 
EGFR downregulation and structural modifications in the binding region can also compromise 
treatment efficacy [66]. The role of mutations in the extracellular domain (ECD) of EGFR in 
cetuximab resistance remains unclear. Recent publications have identified several point mutations 
that abrogate cetuximab binding to the receptor [67]. Still, RAS mutations are found more 
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frequently in refractory patients than ECD mutations and have been associated with worst clinical 
outcomes [68]. 
Novel approaches to enhance efficacy 
Increasing the therapeutic index with antibody drug-conjugates 
Antibody drug conjugates (ADCs) were conceived as an approach to enhance the therapeutic 
window of its primary components, namely the targeted antibody and a cytotoxin or an 
immunotoxin covalently attached to the antibody. Endowing the drug with specificity towards a 
molecular target – by virtue of the attachment of an antibody – allows for the utilization of highly 
potent cytotoxic compounds, that otherwise display intolerable systemic toxicity.  
ADCs increase the intrinsic potency of the targeted treatment – relative to the antibody agent, 
therefore lower doses are required to reach the tumor to effectively destroy the targeted cells. 
Moreover, depending on the chemical nature of the drug and its release in the tumor (either 
intracellular or extracellular), some payloads can subsequently diffuse and kill surrounding cells 
(‘bystander killing’) [69, 70]. Consequently, these features could ameliorate the drawbacks of the 
heterogeneous tumor distributions of therapeutic antibodies and decrease the risk of developing 
resistance. 
Despite the potential of the concept, the clinical implementation of ADCs has met with significant 
challenges, mostly regarding off-target toxicity. To date, only four ADCs (Mylotarg, Adcetris, 
Kadcyla and Besponsa) have received regulatory approval. Gemtuzumab ozogamicin (Mylotarg) 
(anti-CD33) was the first to enter the market in 2000 under an accelerated approval process [71]. 
It was originally approved as stand-alone treatment for refractory CD33-positive acute myeloid 
leukemia (AML), but it was voluntarily withdrawn in 2010 after failure to display benefits relative 
to standard therapies in a phase III comparative controlled clinical trial (NCT00085709 or SWOG-
0106) [72]. Moreover, Mylotarg caused a significantly higher rate of fatal induction toxicity in this 
confirmatory trial. Gentuzumab ozogamicin had previously raised hepatotoxicity concerns due to 
high incidence (~20%) of Grade 3 or 4 liver transaminitis and hyperbilirubinemia, and reports of 
hepatic veno-occlusive disease [73]. Mylotarg received FDA approval once again in 2017 
following a careful review of the dosing regimen, whereby fractionated lower-dose regimens 
demonstrated a decrease in early mortality without compromise in complete remission rate [74, 
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75]. Brentuximab vedotin (Adcetris) (anti-CD30 for Hodgkin lymphoma and anaplastic large cell 
lymphoma) and ado-trastuzumab emtansine (Kadcyla) (anti-HER2 for HER2-positive metastatic 
breast cancer) gained approvals in 2011 [76] and 2013 [77], respectively. More recently, the FDA 
granted approval to inotuzumab ozogamicin (Besponsa) (anti-CD22) for treatment of relapsed or 
refractory B-cell precursor acute lymphoblastic leukemia (ALL) in 2017 [78]. 
The clinical development of ADCs has been hampered predominantly by systemic toxicity due to 
off-target release of the payload. Most adverse effects reported in clinical reports are ascribed to 
the potent cytotoxicity of the payload, underlining the importance of improving ADC design to 
enhance therapeutic index [79, 80]. On that account, the linker chemistry plays a crucial role in 
determining plasma stability to prevent premature release.  
Linker chemistry 
Earlier ADC formats carried mostly chemically-labile linkers, such as pH-labile moieties intended 
to be released within the cell. These linkers should be stable at the neutral pH of the blood (pH 
7.3-7.5) and undergo hydrolysis once they are internalized within the cell by receptor-mediated 
endocytosis, where the more acidic environment of the endosome (pH 5.0-6.5) or the lysosome 
(pH 4.5-5.0) trigger the release of the payload [81-83]. Both Mylotarg and Besponsa employ a pH-
labile hydrazone linker. Other early constructs bore reducible disulfide linkers that enable payload 
delivery in the intracellular reducing environment. The higher concentrations of glutathione in the 
intracellular compartment induce disulfide bond reduction and cytotoxin release [84]. 
Since then, plasma stability has been improved by the implementation of alternative release 
strategies. Most commonly, the linker is designed to possess a dipeptide sequence that is 
recognized and cleaved by lysosomal proteases following receptor-mediated endocytosis. Most 
ADCs currently in development employ this approach [83, 85].  Specifically, the dipeptide valine-
citrulline group – recognized and cleaved by cathepsin B (lysosomal protease) – is the most widely 
implemented technology in the current clinical pipeline [85]. A further approach consists in 
utilizing non-cleavable linkers, whereby release of the drug requires cellular uptake and proteolysis 
(Figure 2). 
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Figure 2. Structural components of an antibody drug conjugate. Trastuzumab emtansine is 
a commercially approved anti-Her2 antibody with a potent maytansinoid payload attached 
to lysines in the mAb polypeptide chain through a non-cleavable linker. 
Conjugation methods 
Most of the ADC formats that have entered clinical trials employ stochastic conjugation methods 
to lysine residues in the antibody, or to free SH groups in cysteines obtained by partial reduction 
of the interchain disulfide bonds. These techniques, although widely used, suffer from several 
disadvantages. In IgG molecules, lysine side chains are abundant and lysine conjugation yields 
consequently highly heterogeneous drug attachments, some of them occurring on residues where 
attachment can be detrimental to the physicochemical stability of the antibody [86]. Additionally, 
highly heterogeneous drug-to-antibody-ratios (DAR) are obtained, where the ADCs with high 
DARs (>8) show more narrow therapeutic indices [87]. Conjugation to free SH groups offers 
greater homogeneity as the maximum amount of available SH groups after partial reduction of the 
interchain disulfide bonds is limited to 8. Nonetheless, the disruption of these bonds can result in 
alterations in the quaternary structure of the IgG molecule [88]. The impact of these conjugation 
techniques on the physicochemical stability of ADCs is thoroughly described in [89]. 
 Novel developments in linker technologies intend to enhance the homogeneity of ADCs by 
providing site-specific attachment of the drug-linker to the antibody, thereby controlling the 
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number of drugs affixed as well as preventing attachment to regions in the antibody that may 
impair binding to the cognate epitope or to Fc receptors on immune effector cells. The THIOMAB 
platform, developed by Genentech, was the first site-specific technique to be implemented and it 
consists in the insertion of engineered unpaired cysteines on protein surface [90]. Site-specific 
methods also include recombinant techniques to introduce unnatural amino acids – eg, p-
acetylphelylalanine, N6-((2-azidoethoxy)carbonyl)-L-lysine, selenocysteine – in the primary 
sequence of the antibody that can be readily modified [90-92]. Furthermore, other formats have 
employed short peptide tags or specific attachment to the glycan moiety in the CH2 domain [93, 
94]. Several preclinical studies have reported superiority in efficacy and safety of site-specific 
homogeneous ADCs compared to conventional lysine or cysteine-conjugation chemistry [95, 96]. 
Site-specific conjugates currently account for approximately 15% of ADC formats in development 
[97]. 
Cytotoxic payloads 
A further increasing trend in ADC optimization focuses on the development and employment of 
more potent payloads. In particular, DNA alkylators – predominantly calicheamycins, 
pyrrolobenzodiazepines (PBDs) and duocarmycins – have seen a significant increase in popularity 
in the development of novel ADC platforms [98]. This strategy gained relevance after several 
ADCs failed to demonstrate adequate efficacy in clinical trials early in the decade. In 2013, 80% 
of the clinical pipeline was made up of conjugates bearing antimitotic agents, namely auristatins 
or maytansinoids (mostly DM1, DM4, MMAE and MMAF). Since then, this fraction has dropped 
by more than 15% owing to the introduction of novel formats carrying DNA alkylating agents and 
other novel cytotoxic compounds, e.g. trastuzumab deruxtecan [99], trastuzumab duocarmazine 
[100], vadastuximab talirine [101]. [102]. 
Further optimization of ADC design is sure to bring about major improvements to the field of 
antibody therapeutics and precision medicine. The field has grown dramatically in recent years 
and will likely continue to experience major developments in the near future as novel technologies 
and strategies are implemented in preclinical and clinical development. The ADC field will also 
benefit from advancements in the identification of novel target antigens.  
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Engaging the immune system  
Immune checkpoint blockade 
One of the most important recent developments in antibody therapy in oncology has been the 
introduction of immune checkpoint inhibitors (ICI) in the clinic. ICI therapy consists in the 
utilization of monoclonal antibodies to disrupt key signaling pathways involved in the suppression 
of immune effector cells [103]. Releasing the brakes of the immune system in this way can trigger 
potent and durable antitumor responses. One of the most advantageous features of ICI therapy is 
the capability of eliciting antitumor responses in a wide range of malignancies, since the treatment 
engages the immune machinery as opposed to traditional targeted therapy that is specific to 
antigens expressed in cancer cells. A further key feature of immune checkpoint blockade is the 
observed long-term durability of the anticancer response [104]. 
Two crucial inhibitory pathways have been exploited in the development of these therapeutics, 
namely the cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and the programmed cell death 
(PD-1) receptor or its ligand PD-L1. The first FDA approval was granted in 2011 to ipilimumab 
(anti-CTLA-4) for late-stage melanoma, following the review of a phase III randomized, 
controlled trial that included 676 melanoma patients (stage III or IV) and demonstrated an increase 
in overall survival rate. This was the first drug to achieve a significant improvement in overall 
survival in advanced melanoma and it marked a key development in the field of cancer 
immunotherapy [105]. Following the first approval of ipilimumab the field has experienced a 
remarkable expansion. Anti-PD-1 antibodies pembrolizumab and nivolumab received regulatory 
approval in 2014. More recently, the anti-PD-L1 atezolizumab entered the clinic in 2016 and anti-
PD-L1 mAbs avelumab and durvalumab in 2017 (table 1).  
Table 1. Approved immune checkpoint inhibitors and FDA indications 
Antibody Target FDA indications FDA 
approval 
date  
Ipilimumab 
(Yervoy) 
CTLA-4 Unresectable or metastatic melanoma 2011 
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Adjuvant treatment in cutaneous melanoma 
following surgery 
2015 
Unresectable or metastatic melanoma in 
paediatric patients 12 years of age or older 
2017 
Nivolumab 
(Opdivo) 
PD-1 Unresectable or metastatic melanoma 2014 
Advanced (metastatic) squamous non-small 
cell lung cancer (NSCLC) 
2015 
Advanced (metastatic) renal cell carcinoma 2015 
Classical Hodgkin lymphoma  2016 
Metastatic squamous cell carcinoma of the 
head and neck (HNSCC) 
2016 
Metastatic urothelial carcinoma  2017 
Microsatellite instability-high (MSI-H) or 
mismatch repair deficient (dMMR) 
metastatic colorectal cancer (mCRC) 
2017 
Hepatocellular carcinoma (HCC) 2017 
Pembrolizumab 
(Keytruda) 
PD-1 Advanced or unresectable melanoma 2014 
Advanced (metastatic) NSCLC 2015 
Metastatic HNSCC 2016 
Refractory classic Hodgkin Lymphoma 2017 
Metastatic urothelial carcinoma 2017 
Metastatic solid tumors with microsatellite 
instability-high or mismatch repair 
deficient* 
2017 
Metastatic gastric or gastroesophageal 
junction adenocarcinoma with PD-L1 
expression 
2017 
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Metastatic cervical cancer with PD-L1 
expression 
2018 
Refractory primary mediastinal large B-cell 
lymphoma  
2018 
Hepatocellular carcinoma 2018 
Metastatic Merkel cell carcinoma  2018 
Atezolizumab 
(Tecentriq) 
PD-L1 Urothelial carcinoma 2016 
Metastatic NSCLC 2016 
Avelumab 
(Bavencio) 
PD-L1 Metastatic Merkel cell carcinoma 2017 
Urothelial carcinoma 2017 
Durvalumab 
(Imfinzi) 
PD-L1 Metastatic urothelial carcinoma 2017 
Advanced NSCLC 2018 
Ipilimumab + 
Nivolumab 
CTLA-4 + 
PD-1 
BRAF V600 wild-type unresectable or 
metastatic melanoma 
2015 
BRAF V600 wild-type and BRAF V600 
mutation-positive metastatic melanoma 
2016 
Intermediate- and poor-risk advanced renal 
cell carcinoma 
2018 
Microsatellite instability-high or mismatch 
repair deficient metastatic colorectal cancer  
2018 
*First approval based on the presence of a biomarker instead of the tissue affected 
CTLA-4, cytotoxic T-lymphocyte-associated antigen; PD-1, programmed cell-death 1; 
programmed cell-death ligand 1; NSCLC, squamous non-small cell lung cancer; HNSCC, 
squamous cell carcinoma of the head and neck. 
CTLA-4 therapy 
The CTLA-4 and PD-1 immunosuppressive checkpoints are key regulatory mechanisms in 
immune response modulation and self-tolerance. In cancer, the presentation of neoantigens by 
antigen presenting cells (mainly dendritic cells) in the lymph nodes induces an initial activation of 
naïve T cells that leads to expansion and proliferation of cytotoxic and helper T cells specific to 
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tumor antigens. These activated T cells can subsequently infiltrate the tumor and mount a local 
immune response against cancer cells. The initial activation that takes place in the lymph nodes 
requires two co-stimulatory events: (1) T cell receptor (TCR) activation through interaction with 
an MHC-peptide complex on the APC and (2) co-stimulation through T cell CD28 and APC B7 
ligand (CD80 or CD86) interaction [106]. Upon T cell activation, CTLA-4 (CD152), which is 
localized in intracellular vesicles in naïve T cells, is upregulated and translocates to the cellular 
membrane [107-109]. CTLA-4 is a homologue of CD28 with higher affinity towards CD80 (or 
B7-1) and CD86 (B7-2), therefore its exposure on the cell surface can lead to disruption of CD28-
CD80 stimulation and T cell suppression through CD80-CTLA-4 signaling (Figure 3) [103, 110]. 
CTLA-4 works as a signal damper of T cell activation and compromises the potency of the immune 
antitumor response. Recent data indicate that the therapeutic efficacy of anti-CTLA-4 antibodies 
in oncology could also stem from a selective depletion of intratumoral regulatory T cells (Treg) 
through ADCC or ADCP, mediated by antibody binding to overexpressed CTLA-4 in these Tregs 
[111-113]. Comprehensive reviews of the mechanism of action of anti-CTLA-4 therapy can be 
found in [114], [115]. 
 
Figure 3. CTLA-4 and PD1/PD-L1 blockade using immune checkpoint inhibitors. Dendritic 
cells process and present tumor neoantigens through the MHC to the TCR on T-cells in the 
draining lymph nodes. T-cell activation further requires a co-stimulatory signal by CD80-
CD28 binding. Upon T-cell activation, CTLA-4 can be upregulated in T-cells. CTLA-4 has 
a higher affinity towards CD80 than CD28, therefore the overexpression of CTLA-4 
interferes with the co-stimulatory CD80-CD28 signal preventing T-cell activation. 
Ipilimumab prevents this mechanism by binding to CTLA-4 thus blocking its interaction 
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with CD80. Once activated T-cells migrate to the tumor to mount an immune anti-tumor 
response, tumor cells and macrophages can upregulate PD-L1 and suppress the immune 
response by interacting with the upregulated PD-1 on T-cells. Anti-PD1 and anti-PD-L1 
antibodies inhibit this adaptive immune resistance mechanism. 
PD-1/PD-L1 therapy 
The PD-1/PD-L1 pathway plays a crucial role in adaptive immune responses. PD-1 is expressed 
by activated T cells, B cells, macrophages, natural killer (NK) cells and several APCs [116]. PD-
1 expression on naïve T cells is induced upon TCR stimulation or TGF-β and cytokine (eg, IL-2, 
IL-7, IL-15, IL-21) autocrine/paracrine signaling. When activated tumor-specific T cells infiltrate 
the tumor, TCRs are triggered by recognition of the MHC-cognate antigen complex, resulting in 
the release of interferon-γ (IFN-γ) and other inflammatory cytokines. Secretion of IFN-γ can 
induce the expression of PD-L1, and PD-L2 to a lesser extent (PD-1 ligands), on the cell surface 
of tumor cells and tumor macrophages [117]. PD-1 binding to PD-L1 suppresses the T cell 
response of previously activated T cells at the tumor-invasive margin, leading to adaptive immune 
resistance (Figure 3) [118, 119]. The proposed mechanism of action of PD-1/PD-L1 inhibitors thus 
consists in suppression of the PD-1 regulatory signal exerted on activated tumor-infiltrating T cells 
[120]. Nonetheless, further mechanisms of action have been suggested and are reviewed elsewhere 
[120-122]. 
Targeting PD-1 or PD-L1 has been presumed to be a more tumor-specific approach than CTLA-4 
blockade, given the involvement of the former in restoring T cell function at the effector stage 
which requires previous tumor specific T-cell activation. This is supported by clinical data 
showing improved outcomes and a lower rate of grade 3-4 adverse events with anti-PD-1 therapy 
compared to ipilimumab (anti-CTLA-4) [123]. The open-label, randomized, phase III clinical trial 
KEYNOTE-006 provided a head-to-head comparison of advanced melanoma treatment with 
ipilimumab or two different dose regimens of pembrolizumab (anti-PD-1). Pembrolizumab 
treatment achieved a more than two-fold increase in 24-month progression-free survival rates 
compared to ipilimumab while the 24-month overall survival rate was 55% (pembrolizumab) to 
43% (ipilimumab) [123, 124]. Moreover, pembrolizumab has shown clinical efficacy in advanced 
melanomas refractory to ipilimumab by increasing progression-free survival [125]. A clinical trial 
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comparing nivolumab (anti-PD-1) to ipilimumab in advanced melanoma also reported substantial 
improvements in overall survival and progression free survival rates with PD-1 therapy [126]. 
Moving forward with ICI 
Despite the remarkable clinical outcomes of ICI therapy, immune checkpoint blockade is still a 
relatively new concept and is undergoing extensive efforts for optimization. Key limitations being 
addressed include low objective response rates and primary and acquired resistance to treatment. 
Low objective response rates are presumably associated with primary resistance mechanisms. 
Achieving higher response rates will likely come from a better understanding of tumor biology 
and the elucidation of biomarkers that can identify patients that are more likely to respond to 
specific immunotherapeutics.  
Moreover, since CTLA-4 and PD-1 are non-redundant inhibitory mechanisms, combination 
therapy targeting both pathways can significantly increase objective response rates. This was 
shown in a phase II trial where nivolumab plus ipilimumab therapy displayed a 61% objective 
response rate compared to 11% with ipilimumab mono-therapy [127]. Dual immune checkpoint 
inhibition has shown great promise in increasing therapeutic efficacy and nivolumab plus 
ipilimumab combination has already gained approval for metastatic melanoma, renal cell 
carcinoma and microsatellite instability-high or mismatch repair deficient metastatic colorectal 
cancer (table 1). Notwithstanding, combined therapy also seems to increase the frequency of 
immune-related toxicities [128]. Thorough reviews on strategies and novel concepts for 
combination therapy can be found in [129, 130]. Additionally, alternative inhibitory pathways of 
the antitumor immune response are also being targeted for clinical development; for example, 
blockade of LAG-3, TIM-3, TIGIT, VISTA, and others have started early clinical trials; and are 
reviewed elsewhere [131].  
Bispecific antibodies (BsAbs) 
A conceptually different strategy to engage the immune system in tumor cell depletion consists in 
the use of bispecific antibodies (BsAbs), wherein one arm of the BsAb targets a tumor cell antigen 
while the other arm recruits and activates T cells, or other immune effector cells. Additionally, 
various BsAb formats have been designed for therapeutic approaches that do not involve direct 
immunomodulation; eg, cross-linking or inhibition of two different receptors [132, 133]. A 
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plethora of bispecific antibody formats have started clinical development, and have been reviewed 
by others [134-136]. Nonetheless, only two bispecific formats have obtained approval by 
established regulatory agencies for cancer therapy. The first case – catumaxomab – comprises a 
hybrid rat-mouse full-size mAb with specificity towards tumor-expressed EpCAM and to the CD3 
T cell co-receptor. Catumaxomab was approved by the EMA in 2009 for treatment of malignant 
ascites in EpCAM positive carcinomas [137]. Conversely, the other marketed BsAb – 
blinatumomab – comprises two scFv proteins connected by a peptide linker; a BsAb format called 
Bispecific T cell Engagers (BiTE). Blinatumomab binds to CD19 expressed on malignant B 
lymphocytes, while also engaging the CD3 co-receptor to recruit T cells. Blinatumomab was 
approved by the FDA in 2014 under the accelerated approval program, for use in precursor B-cell 
acute lymphoblastic leukemia [123]. 
Another flourishing strategy in cancer immunotherapy with bispecifics involves the recruitment 
and activation of Natural Killer (NK) cells. Analogous to BiTEs, Bispecific Killer cell Engagers 
(BiKEs) possess two scFv fragments; one directed towards a tumor antigen and another scFv that 
engages FcγRIIIa (CD16) on NK cells. Moreover, trispecific formats (TriKEs) have been created 
by incorporating an additional scFv fragment targeting another tumor antigen [138].; or 
alternatively containing IL-15 to induce NK cell expansion [139]. Several BiKEs and TriKEs are 
undergoing preclinical development [140, 141]. Other strategies to target NK cells for tumor 
eradication have been reviewed in [142]. 
Nanoparticle delivery vehicles to improve tumor delivery 
In cancer therapy, nanoparticle (NP) delivery systems offer the possibility to modify the 
pharmacokinetic profile of small molecule cytotoxins and increase tumor targeting as a means to 
improve therapeutic indices and safety profiles. Nanoparticle delivery systems are typically in the 
10-100 nm range, making them susceptible to accumulation in tumor tissues as a consequence of 
the EPR effect. The EPR refers to the enhanced accumulation of nanostructures in tumor tissue 
following extravasation through the endothelium that irrigates the neoplasm. The vasculature in 
these sites is formed rapidly due to an increased demand of oxygen and nutrients and secretion of 
vascular effectors, leaving large fenestrations or endothelial gaps that allow diffusion of 
nanoparticles (NPs) that are otherwise too large to penetrate through healthy capillaries [143-145]. 
Moreover, accumulation of NPs is further enhanced by a decrease in lymphatic drainage [143, 
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146]. Preferential accumulation due to the EPR effect is termed passive targeting and is an inherent 
property of nano-sized materials. Importantly, the contribution of the EPR effect in preclinical and 
clinical settings has been debated and it is known to depend on myriad factors relating to tumor 
characteristics, including localization, stage, vascular density, fibrotic tumor microenvironment, 
lymphatic drainage and vascular architecture [144, 147, 148]. Still, the EPR remains a fundamental 
principle behind the design and development of nanoparticle delivery strategies for solid tumors. 
Several nanoparticles have also been developed as imaging agents, however this section discusses 
only those formats intended for therapeutic purposes in oncology.  
Since the first reports of the EPR effect in 1986 [143], interest in the development of nanoparticle-
delivery platforms has increased substantially and has led to the approval of several NP 
formulations. At present, liposomal delivery systems comprise the vast majority of nanoparticle-
based therapeutics approved for clinical use in oncology and those undergoing clinical 
development [149]. Doxil (doxorubicin encapsulated in PEGylated liposomes) was the first nano-
carrier to be licensed in the US in 1995 for treatment of AIDS-related Kaposi’s sarcoma. The first 
approval of Doxil served as a benchmark for the validation of NP systems in oncology; and the 
formulation is currently also FDA approved in ovarian cancer and multiple myeloma [150]. 
Importantly, the approval granted for the aforementioned indications was based on superior safety 
profiles compared to established therapy; and it also demonstrated superior efficacy in Kaposi’s 
sarcoma [151-153]. Thereafter, ten other nanotherapeutics have entered the clinic (table 2). Except 
for Abraxane (albumin-bound paclitaxel) and NanoTherm (iron oxide nanoparticles), all other 
approved nanomedicines consist of liposomal chemotherapeutics [149, 154].  
Table 2. Approved nanoparticles in oncology 
Name NP carrier Targetin
g 
Payload Indications Approval 
date (FDA) 
Doxil/Caely
x [149]. 
Pegylated 
liposome 
Passive Doxorubicin • HIV associated 
Kaposi’s 
sarcoma 
• Ovarian cancer 
• Multiple 
myeloma 
1995 (FDA) 
1996 (EMA) 
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Daunoxome 
[171]. 
Non-
pegylated 
liposome 
Passive Daunorubicin • HIV associated 
Kaposi’s 
sarcoma 
 
1996 (FDA) 
Discontinue
d 
DepoCyt 
[172]. 
Non-
pegylated 
liposome 
Passive Cytarabine • Lymphomatous 
meningitis 
1999 (FDA) 
Discontinue
d 
Myocet 
[173]. 
Non-
pegylated 
liposome 
Passive Doxorubicin • Metastatic 
breast cancer 
2000 (EMA) 
Abraxane 
[174]. 
Albumin 
nanoparticl
e 
Passive Paclitaxel • Advanced non-
small-cell lung 
cancer 
• Metastatic 
breast cancer 
• Metastatic 
pancreatic 
adenocarcinom
a 
2005 (FDA) 
2008 (EMA) 
Oncaspar 
[175]. 
PEG protein 
conjugate 
Passive L-
Asparaginase 
• Acute 
Lymphoblastic 
Leukemia 
2006 (FDA) 
MEPACT 
[176]. 
Non-
pegylated 
liposome 
Passive Mifamurtide • Non-metastatic 
resectable 
osteosarcoma 
2009 (EMA) 
Nanotherm 
[177]. 
Iron oxide 
nanoparticl
e 
Passive Thermal 
ablation* 
• Glioblastoma 2010 (EMA) 
Marqibo 
[178]. 
Non-
pegylated 
liposome 
Passive Vincristine • Philadelphia 
chromosome-
negative acute 
lymphoblastic 
leukemia 
2012 (FDA) 
Onivyde 
[179]. 
Pegylated 
liposome 
Passive Irinotecan • Metastatic 
pancreatic 
adenocarcinom
a 
2015 (FDA) 
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Vyxeos 
[180]. 
Non-
pegylated 
liposome 
Passive Daonorubicin
/ 
cytarabine 
• Acute myeloid 
leukemia 
2017 (FDA) 
FDA, Food and Drug Administration; EMA, European Medicines Agency; HIV, human 
immunodeficiency virus. 
Subsequent advancements in nanoparticle synthesis and engineering have allowed for the 
development of multifunctional NP delivery platforms with expanded therapeutic capabilities. For 
instance, a highly attractive characteristic of nanoparticles is the possibility to functionalize their 
surface with multiple bioactive substances that can aid in tumor localization, treatment and 
diagnosis. A representative case is CYT-6091, a construct composed of PEGylated gold 
nanoparticles carrying tumor necrosis factor alpha (TNFα) on its surface that has shown promising 
results in a phase I clinical trial, wherein the maximum tolerated dose of nano-formulated TNFα 
exceeded that of native TNFα by 3-fold due to enhanced localization in tumors [155]. Furthermore, 
NPs can be functionalized with biomolecules that target the tumor stroma to induce changes in the 
extracellular matrix (ECM) and facilitate uptake. This strategy is conceptually appealing, and it is 
thought to hold great promise, yet it requires further understanding of the cross-talk between the 
multiple paracrine interactions that take place during the formation of the ECM [156, 157]. 
Additionally, the physicochemical properties of the NP format can be tailored to enable controlled 
release of a drug cargo upon exposure to tumor-specific or external stimuli. Examples of these NP 
vehicles include pH responsive polymeric micelles, temperature responsive polyN-
isopropylacrylamide nanoparticles, light responsive mesoporous silica nanoparticles and redox 
responsive copolymer-based micelles [91, 158-160].  
 Active-targeting to increase specificity 
Conceptually, the targeting capacity of nanoparticles can be further enhanced through the 
attachment of target-specific biomolecules, such as mAbs, antibody fragments, aptamers, affimers 
and peptides. In this modality, nanoparticles can initially accumulate in tumor tissue due to passive 
targeting and subsequently engage in high affinity interactions with tumoral targets (Figure 4) 
[161-163]. Most commonly, upregulated cell surface receptors (eg, HER2, EGFR, transferrin 
receptor, folate receptor) are targeted, wherein the multivalent presentation of targeting agent on 
the NP surface can cause receptor cross-linking and induce receptor-mediated endocytosis – an 
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advantageous feature for intracellular drug delivery [164].  Monoclonal antibodies play a pivotal 
role in this strategy due to their exquisite specificity; as well as to the existence of well-established 
techniques – primarily phage display – that allow for high-throughput development of mAbs to 
specific antigens. Additionally, the prevailing clinical success of monoclonal antibodies is 
favorable for regulatory approval. 
 
Figure 4. Harnessing the EPR effect to improve tumor delivery using nanoparticle carriers. 
Blood vessels that irrigate the tumor tissue are defective. The lack of pericytes and altered 
structural features make the vessels less stable and leakier. Larger fenestrations between the 
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endothelial cells allow nanoparticles to extravasate into the tumor. The fibrotic ECM lacks 
proper lymphatic drainage, therefore nanoparticles can accumulate in the tissue following 
extravasation (passive targeting). Nanoparticles can be functionalized with monoclonal 
antibodies, or other active targeting agents, to promote specific internalization and drug 
delivery into targeted cells (cancer cells or other cells in the tumor microenvironment) once 
they accumulate in the tumor through passive targeting. 
At present, a plethora of active-targeted nanoparticles have undergone preclinical development, 
however only a few have initiated clinical trials. A notable example is BIND-014, a docetaxel-
containing polymeric nanoparticle targeting the prostate-specific membrane antigen (PSMA) that 
has recently completed phase II clinical trials for various cancers, where it has demonstrated 
clinical efficacy and acceptable safety profiles [165]. Recently, paclitaxel solid lipid nanoparticles 
conjugated to various antibodies as targeting agents have demonstrated remarkable 
pharmacokinetic properties and efficacy in mouse models, and have started clinical development 
[166]. 
In its inception, active targeting was intended to aid tumor localization and retention in conjunction 
with passive targeting. Notwithstanding, experimental data has demonstrated that while 
engagement and internalization within cancer cells are significantly increased, tumor accumulation 
is only marginally improved [20, 163, 167]. An extensive analysis of in vivo data published from 
2005-2015 showed that passive targeting results in 0.6% (median) of the injected dose 
accumulating in tumor tissue, compared to 0.9% with active-targeted nanoparticles [147]. It is 
noteworthy to underscore that these data were obtained with several different nanoparticle formats 
administered in a wide variety of solid tumors. Still, it suggests that accumulation via passive 
targeting is essential for enhanced delivery of payloads through active-targeting. Consequently, 
successful clinical implementation of both passive and active-targeted nanoparticles will require a 
better understanding of the physiological factors that determine the extent of EPR accumulation in 
order to identify patients that can benefit from this approach [168]. Alternatively, therapeutic 
strategies to increase EPR-related accumulation can be implemented, such as administration of 
angiotensin-II receptor blockers to increase vessel perfusion, or sonoporation to promote vascular 
permeability [169, 170]. 
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Conclusion 
Improving tumor penetration and distribution upon systemic delivery are crucial requirements in 
mAb therapy to improve clinical outcomes and prevent the emergence of acquired resistance 
mechanisms. Preventing treatment failure due to intrinsic resistance will require a better 
understanding of cancer biology and the identification of novel biomarkers for a better selection 
of therapeutic agents and treatment regimens. The clinical pipeline of alternative mAb based 
approaches to enhance clinical efficacy has experienced a marked expansion in the last decade. 
The formats discussed in this review – ADC, immune-checkpoint inhibitors and nanoparticle-
delivery systems – are among key strategies with demonstrated clinical benefits in the treatment 
of solid tumors. Of note is the accelerated growth of the ICI class having obtained regulatory 
approval for 6 distinct antibodies since the year 2011 (first approval) and a remarkable broadening 
of clinical indications. Despite their clinical success, these therapeutics are based on relatively new 
technologies that are still undergoing extensive efforts to optimize therapeutic potential. Numerous 
ICI antibodies targeting alternative targets for immune inhibition (eg, LAG-3, TIM-3, TIGIT, 
VISTA, B7-H3) are in phase I/II clinical trials. Safety concerns inherent to the high potency and 
structural versatility of ADCs and nanoparticles have been prominent barriers in their 
implementation, but clinical validation of novel designs could bring about major breakthroughs in 
these fields in the coming years. 
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Abstract 
Nanoparticle carriers offer the possibility of enhanced delivery of therapeutic payloads in tumor 
tissues due to tumor-selective accumulation through the enhanced permeability and retention effect 
(EPR). Gold nanoparticles (AuNP), in particular, possess highly appealing features for 
development as nanomedicines, such as biocompatibility, tunable optical properties and a 
remarkable ease of surface functionalization. Taking advantage of the latter, several strategies have 
been designed to increase treatment specificity of gold nanocarriers by attaching monoclonal 
antibodies on the surface, as a way to promote selective interactions with the targeted cells—an 
approach referred to as active-targeting. Here, we describe the synthesis of spherical gold 
nanoparticles surface-functionalized with an anti-HER2 antibody-drug conjugate (ADC) as an 
active targeting agent that carries a cytotoxic payload. In addition, we enhanced the intracellular 
delivery properties of the carrier by attaching a cell penetrating peptide to the active-targeted 
nanoparticles. We demonstrate that the antibody retains high receptor-affinity after the structural 
modifications performed for drug-conjugation and nanoparticle attachment. Furthermore, we show 
that antibody attachment increases cellular uptake in HER2 amplified cell lines selectively, and 
incorporation of the cell penetrating peptide leads to a further increase in cellular internalization. 
Nanoparticle-bound antibody-drug conjugates retain high antimitotic potency, which could 
contribute to a higher therapeutic index in high EPR tumors. 
Introduction 
Most solid malignancies display a tumor microenvironment with increased interstitial fluid 
pressures (IFP) that significantly impairs tumor penetration of conventional anticancer agents 
following systemic delivery. This effect hinders movement of the therapeutic agent from the 
vascular lumen to the tumor tissue, requiring higher doses to achieve therapeutic efficacy [1, 2]. 
Consequently, the therapeutic index is reduced, and off-target side-effects compromise clinical 
outcomes. Moreover, inefficient localization in the target tissue can lead to tumor regions exposed 
to subtherapeutic doses of the drug, whereby cancer cells can undergo phenotypic alterations that 
render them resistant to the agent administered [3].  
In this context, nanoparticles (NPs) have emerged as drug delivery vehicles that can harness the 
preferential accumulation of nanosized materials in the tumor due to the well-described enhanced 
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permeability and retention (EPR) effect [4]. Several liposome-encapsulated cytotoxic drugs have 
received regulatory approval on the basis of superior therapeutic indices relative to the free drug 
[5]. A further attractive feature of nanoparticles is their functional versatility, as their design can 
be tailored to confer diverse physiological and physicochemical properties to broaden treatment 
modalities. Myriad distinct NP formats are undergoing preclinical development for various 
therapeutic and diagnostic applications, e.g., gene delivery, thermal ablation therapy, magnetic 
resonance imaging (MRI), photoacoustic imaging [6–9].  
Among the diverse range of inorganic NPs, gold nanoparticles (AuNP) have been widely appraised 
as attractive systems for therapeutic applications, e.g., drug delivery, photothermal therapy and 
radiosensitization [9, 10]. AuNPs are easy to synthesize with tunable shapes and sizes, and the 
strong gold-sulfur (Au-S) interaction allows for the modification of the nanoparticle surface with 
sulfhydryl containing linkers, through which functional groups can be incorporated to confer 
biological properties for therapeutic purposes [11]. An analysis of nanoparticle tumor delivery 
efficiency in in vivo models derived from published data from the year 2005 to 2015 showed that 
AuNPs had the highest median delivery efficiency among the analysed inorganic nanoparticle 
types (including iron oxide, silica, quantum dots and others) [12]. Moreover, a PEGylated AuNP 
format coated with TNF-α has already shown a promising safety profile and enhanced 
accumulation in various solid tumors in a phase I dose escalation trial, setting a clinical precedent 
for gold nanoparticles [13, 14].  
Adding to the inherent passive accumulation of NPs in solid tumors, the targeting capacity of a 
nanoparticle carrier can potentially be enhanced by the incorporation of an active targeting agent 
on the NP surface. Active targeting moieties—e.g., antibodies, peptides, aptamers, affimers—can 
engage in high-affinity specific interactions with biomolecules overexpressed in cancer subtypes 
to increase treatment specificity [15]. Within this concept, systemic delivery of the nanocarrier 
results in passive accumulation in the tumor microenvironment, where the subsequent interaction 
of the affixed targeting agent with cancer cells can induce receptor crosslinking, receptor-mediated 
endocytosis and intracellular cargo delivery [16]. 
In this work, we employed an anti-HER2 antibody, Trastuzumab (Tmab), as an active targeting 
agent on spherical gold nanoparticles. Tmab is a therapeutic monoclonal antibody that binds to the 
human epidermal growth factor receptor 2 (HER2) and is approved for the treatment of HER2-
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positive breast cancer and metastatic gastric cancer [17, 18]. Moreover, HER2 overexpression has 
been documented in esophageal [19], ovarian [20]. and endometrial cancer [21]. and has been 
identified as a negative prognostic factor in several of these malignancies [22–24]. Trastuzumab 
exerts its anticancer activity by binding to the extracellular domain of HER2 to prevent 
dimerization with other ErbB receptors, thereby inhibiting its key function in cell proliferation and 
migration. In addition, immune effector components can be engaged through the Fc region of the 
antibody to destroy cancer cells via antibody-dependent cellular cytotoxicity (ADCC), antibody-
dependent cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC) [25, 26]. 
Monoclonal antibodies (mAbs) have become a cornerstone of cancer care since the first therapeutic 
mAb market approval in 1997 (Rituximab) by virtue of their enhanced treatment specificity. As of 
early 2019, more than 20 distinct mAbs are indicated for a wide array of solid malignancies, 
predominantly administered through systemic routes [27]. This notwithstanding, poor tumor 
penetration and distribution are prominent obstacles that compromise the therapeutic index of 
mAbs [28, 29]. To this end, enhancing drug accumulation in the tumor through the employment 
of enhanced delivery systems could provide major improvements in therapeutic safety and 
efficacy. 
Conventional designs of active-targeted nanoparticles for drug delivery typically consist of 
nanoparticles carrying a surface-incorporated targeting agent and a cytotoxic payload either 
encapsulated within the NP core or loaded onto the surface. In this work, we sought to employ a 
novel strategy, wherein a cytotoxic drug is conjugated to the antibody initially, and the resulting 
antibody-drug conjugate (ADC) is employed as a targeting agent-drug carrier on the nanoparticles, 
thereby broadening the functionality of the active-targeting agent. Herein, we describe the 
synthesis and physicochemical characterization of ADC-targeted spherical gold nanoparticles. The 
ADC was produced by chemical attachment of monomethyl auristatin E (MMAE) to Tmab 
through a cathepsin-cleavable valine-citrulline linker; and further reacted with a sulfhydryl-
containing linker for surface conjugation to the gold nanoparticles. We demonstrate that 
Trastuzumab can be chemically modified in this fashion while retaining high affinity towards its 
cognate receptor. Since the valine-citrulline linker must be internalized for payload release, we 
analysed the intracellular uptake of active-targeted AuNPs on various cancer cell lines. 
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Furthermore, we evaluated the effect of surface incorporation of a cell penetrating peptide to the 
active-targeted nanoparticle on intracellular uptake. 
Materials and Methods  
Materials 
Herceptin® (Trastuzumab) was a generous donation from Genentech (San Francisco, CA, USA). 
Thiol PEG NHS (NHS-PEG-SH) (5 kDa) linker (Cat. No. PG2-NSTH-5k) was purchased from 
Nanocs (Boston, MA, USA). The MC-Val-Cit-PAB-MMAE (vcMMAE) linker (Cat. No. 
BP23969) was obtained from Broadpharm (San Diego, CA, USA). The HIV-1 TAT protein (47-
57) (HIV-TAT or CPP) (Cat. No. H0292) was purchased from Sigma-Aldrich (Castle Hill, NSW, 
Australia). The Series S Sensor Chip CM5 (Cat. No. 29-1049-88), the amine coupling kit (Cat. 
No. BR-1000-50) and the anti-HIS capture kit (Cat. No. 28-9950-56) employed in the Biacore SPR 
instrument were purchased from GE Healthcare (Parramatta, NSW, Australia). The recombinant 
HIS-tagged soluble HER2 (Cat. No. SRP6405) was obtained from Sigma-Aldrich (Australia). 
Phosphate buffered saline (PBS) was purchased from Astral Scientific (Gymea, NSW, Australia). 
Amicon 3 kDa (Cat. No. Z740168) and 50 kDa (Cat. No. Z740177) cutoff centrifugal filter units 
were acquired from Sigma-Aldrich (Australia). Millex-GV syringe filters (0.22 µm, PVDF, Cat. 
No. SLGV033RS) were purchased from purchased from Sigma-Aldrich (Castle Hill, NSW, 
Australia). RPMI 1640 and DMEM (high glucose) media were obtained from Life Technologies 
(Mulgrave, VIC, Australia). All other chemicals and reagents were purchased from Sigma Aldrich 
(Australia).  
Synthesis of Spherical Citrate-Capped Gold Nanoparticles 
Spherical gold nanoparticles were synthesized by citrate reduction of gold chloride in aqueous 
solution as described by Turkevich [45], and revised by Frens [46]. All glassware employed in this 
procedure was soaked in aqua regia (3:1 HCl/HNO3 molar ratio) for 3 h prior to the reaction and 
rinsed with double distilled H2O. Briefly, 100 mL of a 254 µM HAuCl4 solution in double distilled 
H2O was heated to boiling under stirring. Once boiling, 2 mL or 1 mL of a 1% w/v (34 µM) sodium 
citrate solution was added to prepare 20 nm and 50 nm, respectively. Following citrate addition, 
the solution was boiled for 15 min, then cooled to room temperature under stirring for 2 h. 
Unreacted citrate was removed by decanting after centrifugation at 10,000 g or 3,500 g for 30 min 
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to pellet the 20 nm and 50 nm nanoparticles. The synthesized gold nanoparticles were resuspended 
in double distilled water. Nanoparticle size, size distribution and morphology were assessed 
through transmission DLS (hydrodynamic size) electron microscopy (size, size distribution and 
morphology) and shifts in the surface plasmon resonance (SPR) absorption band. 
Tmab PEGylation (Tmab-PEG-SH) 
Trastuzumab 21 mg/mL in formulation buffer (L-histidine 4.64 mM, α,α-Trehalose 52.86 mM, 
polysorbate 20 concentration 73.31 µM, HCl 2.58 mM) was buffer exchanged to sodium 
bicarbonate (NaHCO3) 0.1 M pH 8.0 using 50 kDa cutoff centrifugal filters to a final antibody 
concentration of 10 mg/mL (6.87 × 10−5 M). The extinction coefficient ε280 = 2.25 × 10+5 M−1 
cm−1 was used for all antibody concentration determinations. Buffer exchange was carried out 
thoroughly to reduce to a minimum the concentration of L-histidine in the formulation buffer, as 
the primary amine in L-histidine will react readily with the NHS group in the linker. A 5 mg/mL 
(1 mM) NHS-PEG-SH (5 kDa) linker stock solution was prepared in NaHCO3 0.1 M pH 8.0 and 
immediately added to Trastuzumab in 2:1, 5:1, 10:1, 20:1 and 25:1 NHS-linker/Tmab ratios and 
incubated at 4 °C overnight under stirring. The NHS-linker stock solution in NaHCO3 pH 8.0 was 
prepared immediately before adding to the Trastuzumab sample, since the NHS ester can undergo 
rapid hydrolysis at basic pH. Following PEGylation, unreacted NHS-PEG-SH linker was removed 
by centrifugation through 50 kDa cutoff filters and the PEGylated Trastuzumab (Tmab-PEG-SH) 
was buffer exchanged to phosphate buffered saline (PBS) 0.01 M pH 7.4 with 1 mM EDTA to a 
final antibody concentration of 5 mg/mL. EDTA 1 mM was added to inhibit disulfide bond 
formation between the free SH groups in the linker [47, 48]. 
HIV-TAT Cell Penetrating Peptide (CPP) PEGylation (CPP-PEG-SH) 
HIV-TAT (47–57) peptide was dissolved in NaHCO3 0.1 M pH 8.0 to a 1 mg/mL (641 µM) 
concentration. A 10 mg/mL (2 mM) NHS-PEG-SH (5 kDa) solution in NaHCO3 0.1 M pH 8.0 
was added to the HIV-TAT peptide in a 4:1 NHS-linker/CPP molar ratio and incubated overnight 
at 4 °C under stirring. Unreacted CPP was removed by centrifugation through 3 kDa cutoff filters 
and the PEGylated CPP (CPP-PEG-SH) was buffer exchanged to phosphate buffered saline 0.01 
M pH 7.4 with 1 mM EDTA. 
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Tmab-vcMMAE Conjugate Synthesis 
Antibody Partial Reduction 
Trastuzumab in formulation buffer was buffer exchanged to PBS 0.01 M with 10 mM EDTA in a 
final concentration of 5 mg/mL (34 uM). A freshly prepared 10 mM stock solution of dithiothreitol 
(DTT) in PBS 0.01 M EDTA 1 mM was added to the antibody in a 3:1 DTT/Tmab ratio and the 
reaction was incubated at 37 °C for 90 min under stirring. DTT was then removed by buffer 
exchanging the partially reduced Tmab with 50 kDa cutoff centrifugal filters to PBS 0.01 M 
containing 10 mM EDTA to a 10 mg/mL (34 µM) concentration. After partial reduction, the 
integrity of the full-size IgG molecule was confirmed by SE-HPLC. In addition, free sulfhydryl 
(SH) groups per antibody were quantified by reaction with DTNB (5, 5’-dithiobis(2-nitrobenzoic 
acid)) and determination of the absorbance at 412 nm for free SH concentration. The final 
flowthrough of the buffer exchange prior to the DTNB reaction was used as a blank to subtract the 
potential contribution of residual DTT in the solution. The extinction coefficient ε412 = 1.42 × 
10+5 M−1 cm−1 for the TNB2− reaction product was employed for sulfhydryl quantification.  
Conjugate Synthesis 
vcMMAE was dissolved in DMSO at a 1.26 mM concentration and added to a chilled 10 mg/mL 
partially reduced Tmab solution in a 4.6:1 vcMMAE/Tmab ratio. The reaction mixture was 
incubated at 4 °C with stirring for 1 h. A 20-fold molar excess of cysteine—relative to maleimide—
was added to quench the reaction. Unreacted vcMMAE and cysteine were removed by 
centrifugation through 50 kDa cutoff centrifugal filters and buffer exchanged to PBS 0.01 M pH 
7.4 for storage, or NaHCO3 0.1 M pH 8.0 for subsequent PEGylation. The average drug-antibody 
ratio (DAR) was calculated based on absorbance values at 248 nm and 280 nm as has been 
described previously [49]. The following formula was employed: 
𝐷𝐷𝐷𝐷𝐷𝐷 =  𝜀𝜀248𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 −  𝐹𝐹𝜀𝜀280𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇
𝐹𝐹𝜀𝜀280
𝐵𝐵𝐵𝐵𝑀𝑀𝑀𝑀 −  𝜀𝜀248𝐵𝐵𝐵𝐵𝑀𝑀𝑀𝑀  
F=A248/A280 and the extinction coefficients utilized are listed in Table 4. 
Table 1. Extinction coefficients of Trastuzumab and monomethyl auristatin E (MMAE) employed 
for the calculation of drug-to-antibody ratio (DAR) based on UV-Vis spectroscopy 
215 
 
Sample 248 nm 280 nm 
Trastuzumab 7.75 × 10+4 2.25 × 10+5 
MMAE 1.59 × 10+4 1.50 × 10+3 
 
PEGylation of Tmab-vcMMAE (ADC-PEG-SH) was achieved following the same procedure as 
for the unconjugated antibody. 
Intact Mass Analysis 
Trastuzumab and Tmab-vcMMAE were concentrated using 50 kDa cutoff centrifugal filters and 
buffer exchanged to 10% acetonitrile with 0.1% formic acid. The antibody samples were analysed 
through direct injection into a Triple TOF 6600 mass spectrometer (Sciex, Framingham, MA, 
USA). Infusion was performed at 50 µL/min. The mass range for detection was 100–5,000 m/z. 
Deconvolution of the raw data was achieved using SCIEX Peakview 2.2 (Concord, ON, Canada) 
and Bruker BioTools software packages (Billerica, MA, USA). 
Binding Kinetics to Recombinant HER2 through Surface Plasmon Resonance 
The binding kinetics of derivatized Trastuzumab (Tmab-PEG-SH, Tmab-vcMMAE and ADC-
PEG-SH) were tested against a recombinant HER-2 protein using surface plasmon resonance 
(SPR) in a Biacore T200 instrument (GE Healthcare, Parramatta, NSW, Australia). Briefly, an 
anti-HIS antibody was bound to a CM5 sensor chip through amine coupling chemistry. 
Subsequently, a recombinant HIS-tagged HER-2 (4 nM) was bound to the anti-HIS antibody on 
the sensor chip at a 5 µL/min flow rate for 5 min. 2-fold serial dilutions of the Trastuzumab variants 
ranging from 8–0.5 nM in HBS-T running buffer (10 mM HEPES, 150 mM NaCl, 0.05% (v/v) 
Tween 20, pH 7.4) were assayed at 25 °C as single cycle kinetic titrations. The analytes were 
applied to the sensor surface at 20 µL/min for 2 min, followed by 60 min dissociation times. 
Analyses of the sensorgrams were performed by fitting a Langmuir 1:1 binding model to derive 
the association constant (Ka), the dissociation constant (Kd) and the binding affinity (KD—
calculated as Ka/Kd). The analytes were run in duplicate to calculate average values and standard 
deviation. A goodness of fit (χ2) value within 5% of the maximum response level (Rmax) was 
used as acceptance criteria. 
216 
 
Gold Nanoparticle Surface Functionalization 
Trastuzumab-coated (Tmab-PEG-AuNP), OH-PEG coated (OH-PEG-AuNP) and CPP-coated 
(CPP-PEG-AuNP) gold nanoparticles were produced by incubating citrate-capped gold 
nanoparticles (OD = 1) with a 1 × 10+5 molar excess of SH-PEG-Tmab, SH-PEG-OH or SH-PEG-
CPP in NaHCO3 0.01 M pH for 2 h at room temperature while stirring. The unconjugated reagents 
were removed by pelleting the nanoparticles at 3,500 g for 30 min and removing the supernatant. 
The conjugated nanoparticles were centrifuged four times and resuspended in PBS 0.01 M pH 7.4 
for storage at 4 °C. ADC-PEG-AuNP were produced by incubating the nanoparticles with ADC-
PEG-SH following the same procedure. CPP+Tmab-PEG-AuNP were obtained by incubation with 
a 1 × 10+5 molar excess of CPP-PEG-SH for 5 min followed by the addition of a 1 × 10+5 molar 
excess of Tmab-PEG-SH, and further incubation under stirring for 2 h. 
UV-Vis Spectroscopy 
UV-Vis absorption spectra were obtained over a wavelength range of 800–200 nm for gold 
nanoparticles or 400–200 nm for protein samples, using a Shimadzu 2600 UV-Vis 
spectrophotometer (Shimadzu, Japan). AuNP samples in RPMI media were corrected by blank 
subtraction of the RPMI. 
Size-Exclusion High-Performance Liquid Chromatography (SE-HPLC) 
Size-exclusion chromatograms were obtained with a Zorbax GF-250 column connected to an 
Agilent 1200 Liquid Chromatography system (Agilent Technologies, Santa Clara, CA, USA), 
running potassium phosphate buffer 150 mM pH 6.5 as a mobile phase at a 0.5 mL/min flow rate. 
Peak absorption was detected at 280 nm with an in-line UV signal detector (Agilent Technologies, 
Santa Clara, CA, USA). 
DLS and Zeta Potential Measurements 
DLS and zeta potential measurements of the functionalized gold nanoparticles were conducted 
with a Malvern Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK) with a 633 nm 
Helium Neon Laser and an avalanche photo diode (APD) detector. The measurements were 
conducted in triplicate and the values are reported as mean Z-average ± standard deviation. For 
zeta potential measurements, the functionalized nanoparticles suspended in PBS 1X (phosphate 
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buffer 0.01 M, NaCl 0.137 M, KCl 0.0027 M, pH 7.4) were diluted 1:10 in deionized water. Cit-
AuNPs were directly resuspended in PBS 0.1X. The zeta potential was derived from the Henry 
equation using an f(Ka) of 1.5. 
Cellular Uptake Quantification through Inductively Coupled Plasma Mass 
Spectrometry (ICP-MS) 
The SKBR-3 cell line was provided by Dr. Thomas Grewal. The DLD-1 cell line was purchased 
from the American Type Culture Collection (ATCC). The MDA-MB-231 and MCF-7 cell lines 
were obtained from Dr. Fanfan Zhou. SKOV-3 cells were provided by Dr. Pegah Varamini. 
To compare the cellular uptake of gold nanoparticles coated with OH-PEG and Tmab-PEG, 
SKBR-3 cells were seeded at density of 1 × 10+5 cells/well in 24-well plates in RPMI media 
containing 10% FBS. Following incubation at 37 °C for 48 h, the cell media was removed, the 
cells were washed twice with PBS, and fresh RPMI media (10% FBS) containing 50 µg/mL 20 
nm and 50 nm gold nanoparticles (coated with OH-PEG or Tmab-PEG) was added, using 6 wells 
per AuNP sample. The cells were further incubated for 24 h. The AuNP containing media was 
removed and the cell monolayer washed 4 times with PBS. The cells were detached from the plate 
using 0.05% trypsin and collected in 1.5 mL centrifuge tubes. Trypsin was removed by pelleting 
the cells at 300 g for 5 min and the cells were washed twice more with PBS. The cell pellet was 
digested with 200 µL concentrated HNO3 (15.9 M) overnight at room temperature. 800 µL 
concentrated HCl (12.1 M) was then added to dissolve the gold nanoparticles. A 1:4 dilution in 
Milli-Q water was performed for quantification of gold content through ICP-MS. ICP-MS 
measurements were carried out with a Perkin Elmer Nexion 300× ICP-MS instrument (Perkin-
Elmer, Waltham, MA, USA), calibrated with 5, 10 and 20 parts per billion (ppb) gold standard 
solutions.  
To compare cellular uptake in SKBR-3, DLD-1, MDA-MB-231 and MCF-7 cells, the uptake 
assays were carried out following the same procedure as described above albeit with the following 
modifications: (1) 25 µg/mL AuNP concentrations were used, (2) DLD-1, MDA-MB-231 and 
MCF-7 cells were seeded at 3 × 10+4 cells/well, (3) MDA-MB-231 and MCF-7 cell lines were 
cultured in DMEM media containing 10% FBS, (4) each nanoparticle sample was run in triplicate. 
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The concentration of the gold nanoparticles was determined based on their absorbance at 450 nm 
using ε450 = 5.41 × 10+8 M−1 cm−1 and ε450 = 9.92 × 10+9 M−1 cm−1 for 20 nm and 50 nm, 
respectively, according to previous determinations [32]. ICP-MS quantification of gold content in 
the AuNP suspensions was utilized to corroborate that the extinction coefficients used in this 
method provide appropriate estimations of gold concentrations. The nanoparticles in cell culture 
medium were filter sterilized through 0.22 µM filters prior to addition to the cells. 
Cellular Uptake Evaluation by Transmission Electron Microscopy (TEM) 
SKBR-3 cells were seeded at a density of 1 × 10+5 cells/well on collagen-coated Thermanox plastic 
coverslips placed inside each well (24-well plates) and incubated at 37 °C for 48 h in RPMI media 
containing 10% FBS. Fresh RPMI containing 50 ug/mL 50 nm OH-PEG-AuNP or Tmab-PEG-
AuNP was added to the wells and further incubated at 37 °C for 24 h. The wells were washed 
thrice with PBS. The cells were fixed with 2.5% glutaraldehyde in 0.1 M phosphate buffer pH 7.4. 
The cell monolayers were subsequently fixed with osmium tetroxide 1% (w/v) in phosphate buffer 
0.1 M pH 7.4, then embedded into an epon resin. The monolayers were microtomed into 70 nm 
sections and stained with uranyl acetate 2% and Reynold’s lead citrate. TEM images were obtained 
with a JEOL JEM-1400 (Tokyo, Japan) microscope with an accelerating voltage of 120 kV.  
Cell Cytotoxicity Evaluation 
SKBR-3 and SKOV-3 cells were seeded at 5 × 10+3 and 3 × 10+3 cells/well on 96-well plates and 
incubated at 37 °C for 24 h in RPMI media containing 10% FBS. Fresh RPMI media containing 
free MMAE, ADC, ADC-PEG-AuNP, Trastuzumab or OH-PEG-AuNP were added to the wells 
at the corresponding concentrations in triplicates. RPMI media was replenished for negative 
control samples. Images (10x magnification) of four different regions per well were acquired at 2-
h intervals for 72 h after addition of the antimitotic or control sample using an Incucyte® ZOOM 
Live-cell Analysis System (Essen BioScience, Ann Arbor, MI, USA). Cell confluence was 
analysed with the Incucyte® ZOOM integrated analysis software (v2016A) to generate cell growth 
curves over time. Growth rate inhibition metrics were employed to assess the antimitotic effect of 
the samples. Growth rate inhibition metrics have been developed recently to provide more robust 
and biologically relevant drug response parameters [50]. GR values were calculated as: 
𝐺𝐺𝐷𝐷(𝑑𝑑) = 2𝑙𝑙𝑙𝑙𝑙𝑙2�𝑥𝑥(𝑑𝑑)𝑓𝑓𝑥𝑥(𝑑𝑑)0�/𝑙𝑙𝑙𝑙𝑙𝑙2�𝑥𝑥(𝑐𝑐)𝑓𝑓𝑥𝑥(𝑐𝑐)0� − 1 
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Where 𝑥𝑥(𝑑𝑑)0 and 𝑥𝑥(𝑑𝑑)𝑓𝑓 are the confluence values of cells treated with a cytotoxic agent at time t 
= 0 h and t = 72 h, respectively. 𝑥𝑥(𝑐𝑐)0 and 𝑥𝑥(𝑐𝑐)𝑓𝑓 are confluence values of control wells at t = 0 h 
and t = 72 h. 
GR values were plotted against treatment concentration and the data was fitted to a four-parameter 
dose-response curve. GR50 was obtained by interpolating the treatment concentration at which 
GR = 0.5. 
Statistical Analysis 
Gold uptake quantification was analysed with a two-tailed, unpaired Student t-test. Values are 
denoted as mean ± standard deviation, and p < 0.05 was established as statistical significance. 
Results 
Nanoparticle Design 
Figure 1 displays an outline of the nanoparticle design and conjugation strategy. Attachment of 
the bioactive moieties—anti-HER2 mAb and HIV-TAT cell penetrating peptide (CPP)—to the 
gold surface was achieved through the covalent thiol-gold interaction using a bifunctional 5 kDa 
poly ethylene glycol (PEG) linker with a thiol (SH) and an N-hydroxysuccinimide (NHS) ester 
end groups (NHS-PEG-SH). The NHS group reacts with ε-amines in lysine residues (and with α-
amines present at the N-terminals to a lesser extent) under slightly alkaline conditions to produce 
stable amide bonds with the protein or peptide [30]. The 5 kDa PEG linker was employed to 
increase exposure of the functional groups and prevent non-specific interactions between the 
bioactive groups and the gold surface. Furthermore, PEGylation of gold nanoparticles has proven 
to be highly beneficial in increasing circulation half-life by preventing adhesion of serum proteins 
that facilitate uptake by the reticuloendothelial system (RES)—an effect that drastically decreases 
the amount of nanoparticles that can eventually reach the tumor site [31].  
Trastuzumab (anti-HER2 mAb) was employed as an active targeting agent to confer specificity 
towards HER2 overexpressing cancer cell lines. To enhance the anticancer potency of the 
antibody, MMAE was attached to Trastuzumab (Tmab) through a valine-citrulline dipeptide 
cleavable linker (vcMMAE) to produce Tmab-vcMMAE (Figure 1). The valine-citrulline moiety 
is cleaved by the lysosomal protease cathepsin B; thus, MMAE release occurs primarily following 
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endocytosis and subsequent localization into endosomes or lysosomes. The HIV-TAT cell 
penetrating peptide was further added onto the surface via the same NHS-PEG-SH linker to 
increase cellular uptake for intracellular release of the drug cargo (Figure 2B, C). 
 
Figure 1. Molecular structures of the bioactive agents utilized for gold nanoparticle (AuNP) 
surface functionalization. (A) Valine-citrulline momomethyl auristatin E (vcMMAE) linker 
for antibody-drug conjugate (ADC) construction. (B) Human immunodeficiency virus twin-
arginine translocation (HIV-1 TAT 47–57) protein. 
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Figure 2. Schematic outline of the design and synthesis of ADC-coated gold nanoparticles 
with enhanced cell penetrating properties. (A) ADC synthesis. (B) Trastuzumab and CPP 
PEGylation for AuNP attachment. (C) Conjugation of bioactive agents onto the surface of 
AuNPs. 
Antibody-Drug Conjugate (Tmab-vcMMAE) Synthesis 
MMAE was conjugated to free sulfhydryl groups in Trastuzumab via reaction with the maleimide 
group in the vcMMAE linker (Figure 2A). To enable protein attachment, Trastuzumab was 
partially reduced by incubation with dithiothreitol (DTT) at 37 °C in a 3:1 DTT:Tmab molar ratio. 
Partial reduction produces cleavage of the inter-heavy chain disulfide bonds while preserving non-
covalent inter-heavy chain (HC) and heavy-light chain (LC) interactions to conserve full IgG 
structure.  
A colorimetric reaction with 5, 5′-Dithiobis(2-nitrobenzoic acid) (DTNB) was performed to 
confirm the presence of free SH groups following partial reduction. DTNB reacts with SH in a 1:1 
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molar ratio to produce 2-nitro-5-thiobenzoic acid (TNB2−). Absorption at 412 nm (λ max of 
TNB2−) can be utilized to calculate the amount of free SH groups per antibody monomer (Figure 
S1A).  
After confirmation and quantification of the presence of free SH groups, the intact structure (no 
chain dissociation) was confirmed through size exclusion–high performance liquid 
chromatography (SE-HPLC), whereby the elution time of the reduced antibody shifted by 0.0128 
min but did not display peaks at longer elution times indicative of chain dissociation (Figure S1B).  
The drug-linker (vcMMAE) was then attached to free SH groups in the partially reduced Tmab as 
described in the methods section. Successful attachment of vcMMAE was confirmed through 
intact protein mass spectrometry analysis (Figure 3). The deconvoluted mass spectrum of the ADC 
displayed up to 3 vcMMAE attachments per antibody heavy chain in the G0F or G1F glycoforms 
(Figure 3A). Light chain analysis (Figure 3B) showcased a single attachment per LC monomer, 
consistent with a single free SH in LC obtained from partial reduction of the interchain disulfide 
bonds. 
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Figure 3. Protein intact mass analysis of Tmab-vcMMAE. (A) Deconvoluted spectrum of 
Tmab-vcMMAE heavy chain. (B) Deconvoluted spectrum of Tmab-vcMMAE light chain. 
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Figure 4. UV-Vis spectra of unmodified Trastuzumab, Tmab-vcMMAE (ADC) and 
MMAE. The contribution of MMAE to the absorption spectrum of the antibody-drug 
conjugate enables an estimation of the DAR based on the distinct A280/A248 ratios obtained 
with the unmodified antibody and the ADC. 
An average drug-to-antibody ratio (DAR) of 2.91 was obtained from analysis of the UV-Vis 
spectrum of the ADC as described in the methods section (Figure 4). 
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Figure 5. SE-HPLC chromatograms of PEGylated Trastuzumab variants obtained by 
employing varying ratios of PEG:Tmab ratios. Inset shows the zoomed region displaying 
small shifts in elution time. 
Antibody and CPP PEGylation 
Structural Characterization 
Trastuzumab and HIV-TAT were PEGylated via lysine conjugation chemistry (Figure 1). 
Antibody PEGylation was confirmed through SE-HPLC (Figure 5). The SE-HPLC 
chromatograms of the PEGylated Trastuzumab show an increasing shift towards earlier elution 
times as the PEG-linker/tmab ratio increases (Figure 5). Resolving the exact number of PEG 
polymers attached per antibody molecule through SE-HPLC separation and other standard protein 
characterization techniques is challenging, given that the expected molecular weight (MW) 
increment per individual attachment corresponds to less than 4% of the MW of unmodified 
Trastuzumab, namely 5 kDa increments to the ~148 kDa expected MW of the antibody. Moreover, 
PEG molecules display heterogeneity in the number of ethylene glycol units—albeit with only 
small differences in MW—adding to the ensuing heterogeneity. Nonetheless, detailed 
characterization and homogeneity are not crucial for subsequent use as targeting agents, as long as 
the bulk of the protein monomers have been modified and functionality is conserved. A single 
226 
 
Trastuzumab monomer possesses 88 lysine residues and 4 amino-terminal groups available for 
reaction with the NHS group. Hence, reaction with a large number of linkers can potentially impair 
receptor binding. Consequently, conservation of the functionality of the PEGylated derivative was 
assessed prior to subsequent surface functionalization of the nanoparticles. 
Binding Kinetics of Functionalized Trastuzumab  
The chemically modified Trastuzumab variants (Tmab-PEG-SH, ADC and ADC-PEG-SH) were 
tested for their capacity to retain the binding affinity and binding kinetics to a recombinant HER2 
protein after functionalization through surface plasmon resonance (SPR) single cycle kinetic 
analysis Figure S5).  
The binding kinetics to the HER2 receptor were not significantly altered under the assay 
conditions. The affinity constant (KD) of the PEGylated antibodies, ranging from 5.46–6.91 pM, 
showed only minor differences compared to the mean KD of unmodified Trastuzumab—6.07 pM 
(Table 1). Kinetic constants for the antibody drug conjugate were also highly similar to the 
unmodified Trastuzumab. The PEGylated ADC, on the other hand, recorded a slight increase in 
binding rate constant (Ka) accompanied by a 32-fold increase in the dissociation rate constant 
(Kd), for a net 14-fold decrease KD.  
The varying molar ratios of PEG-linker utilized for derivatization were deemed appropriate for 
subsequent attachment to the surface of gold nanoparticles, as the modified antibody did not 
display significant alterations in binding affinity to the cognate receptor. Henceforth, the highest 
molar excess (25:1 PEG-mAb ratio) for reaction was employed in order to maximize Trastuzumab 
attachment to AuNPs. PEGylation of Tmab-vcMMAE caused a significant decrease in KD; 
however, the affinity constant remains in the picomolar range, thus it is still expected to exert 
active targeting capacity. 
Table 2. Kinetics and affinity analysis of functionalized Trastuzumab variants. 
Trastuzumab Variant Ka (× 10+6) M−1·s−1 Kd (× 10+5) s−1 KD (pM) 
Tmab 3.24 ± 0.15 1.98 ± 0.50 6.07 ± 1.27 
Tmab-PEG-SH 2X 3.53 ± 0.15 2.47 ± 0.24 6.83 ± 0.68 
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Tmab-PEG-SH 5X 2.86 ± 0.03 1.97 ± 0.20 6.91 ± 0.78 
Tmab-PEG-SH 10X 2.87 ± 0.11 1.98 ± 0.14 6.89 ± 0.21 
Tmab-PEG-SH 25X 2.05 ± 0.03 1.12 ± 0.11 5.46 ± 0.44 
ADC 2.25 ± 0.01 1.58 ± 0.09 7.05 ± 0.41 
ADC-PEG-SH 7.45 ± 0.07 61.80 ± 0.05 85.01 ± 10.92 
 
Gold Nanoparticle Surface Functionalization 
The surface of 50 nm citrate-capped gold nanoparticles (Cit-AuNP) was functionalized with OH-
PEG-SH (OH-PEG-AuNP), Tmab-PEG-SH (Tmab-PEG-AuNP), CPP-PEG-SH (CPP-PEG-
AuNP), or a combination of CPP-PEG-SH and Tmab-PEG-SH (CPP+Tmab-PEG-AuNP) through 
a sequential addition of the bioactive agents. 
Transmission electron micrograph (TEM) analysis of the synthesized Cit-AuNPs displayed a mean 
diameter of 48.29 ± 5.58 nm showing a narrow size distribution and uniform spherical morphology 
(Table 2). The mean hydrodynamic diameter obtained by DLS was 60.62 ± 0.19 nm (Z-average) 
with a polydispersity index (PDI) of 0.29. The SPR absorption band of the AuNPs had an 
absorption maximum (λ max) at 530.5 nm, consistent with the expected λ max for ~50 nm gold 
nanoparticles according to previously reported determinations of SPR bands of spherical AuNPs 
[32]. Upon surface functionalization, the λ max shifted towards longer wavelengths (red-shift)—
a well-described spectral shift caused by an increase in the local refractive index on the NP surface. 
In increasing order, the λ max shifts were +1.9 nm for OH-PEG-AuNPs, +2.7 nm for CPP-PEG-
AuNP, +3.3 nm for CPP+Tmab-PEG-AuNPs and +3.7 for Tmab-PEG-AuNPs. 
The change in SPR absorption maximum was accompanied by an increase in hydrodynamic 
diameter (Table 2), where Tmab-PEG functionalization showed the highest increment (87.35 ± 
0.41 nm). The PDIs of all surface-functionalized samples decreased relative to Cit-AuNP, 
indicative of enhanced colloidal stability and a consequent reduction of nanoparticle aggregation. 
Surface functionalization caused marked alterations in the zeta potential (ζ) of the colloidal 
dispersions (Table 2). Citrate-capped AuNPs displayed a mean ζ of -34.60 ± 0.91 mV, consistent 
with a negatively charged surface due to the negatively charged OH- groups of the citrate moiety. 
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Conjugation with the PEGylated-CPP yielded a mean ζ of +6.17 ± 071 mV, causing a charge 
reversal attributable to the abundant positively charged arginine residues in HIV-TAT. The 
combination of cell penetrating peptide and Tmab on the AuNP surface (CPP+Tmab-PEG-AuNP) 
also had a slightly positively charged zeta potential (+1.5 ± 0.46 mV). 
Table 3. Size (Z-average), zeta potential (ζ) and absorption maximum (λ max) of surface-
functionalized gold nanoparticles. 
NP Z-ave (nm) PDI  ζ (mV) λ max (nm) TEM (nm) 
Cit-AuNP 60.62 ± 0.19 0.29 −34.60 ± 0.91 530.5 48.29 ± 5.58 
OH-PEG-AuNP 86.61 ± 0.12 0.17 −14.37 ± 0.12 532.4  
Tmab-PEG-AuNP 87.35 ± 0.41 0.17 −1.10 ± 0.46 534.2  
CPP+Tmab-PEG-AuNP 83.42 ± 2.14 0.20 1.5 ± 0.46 533.8  
CPP-PEG-AuNP 81.22 ± 0.39 0.17 6.17 ± 0.71 533.2  
ADC-PEG-AuNP 85.45 ± 1.34 0.19 −2.3 ± 0.37 534.1  
NP: nanoparticle format, PDI: polydispersity index, TEM: transmission electron 
microscope. 
Cellular Uptake in Various Breast Cancer Cell Lines 
Active Targeting in HER2-Positive SBKR-3 Cells 
To evaluate the active targeting capacity of Trastuzumab-conjugated gold nanoparticles (Tmab-
PEG-AuNPs), SKBR-3 cells (HER-2 positive) were incubated with 20 nm and 50 nm AuNPs 
coated with Tmab-PEG-SH or OH-PEG-SH. All reported values for gold uptake were obtained 
from ICP-MS quantification, as described in the methods section. Mean gold nanoparticle uptake 
per cell was significantly higher for 20 nm Tmab-PEG-AuNP (t (10) = 6.61, p > 0.001) and 50 nm 
Tmab-PEG-AuNPs (t (10) = 6.96, p > 0.001) compared to the OH-PEG functionalized AuNPs 
counterparts (Figure 6A). Qualitative assessment of cellular internalization through TEM 
microscopy showed localization into vesicular structures for both nanoparticles formats (Figure 
6B, C).  
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Trastuzumab coated AuNPs did not display enhanced uptake in two other breast cancer cell lines 
(MCF-7 and MDA-MB-231) that are not reported to upregulate HER-2 expression (Figure 7) [33]. 
Uptake into DLD-1 cells (colorectal cancer HER-2 negative cell lines) showed a small increase in 
mean uptake per cell with no statistical significance. ADC conjugated gold nanoparticles were not 
employed for cellular uptake assays as the high potency of the drug can cause significant cell death 
at the concentrations used; thus, evaluation of cellular uptake is not comparable to the other 
formats. 
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Figure 6. Evaluation of the active targeting capacity of Trastuzumab-functionalized gold 
nanoparticles. (A) ICP-MS quantification of OH-PEG-AuNP and Tmab-PEG-AuNP uptake 
into SKBR-3 cells after 24 h incubation. Uptake data are reported as means ± SD. *** p < 
0.001 (Student’s t-test). (B) TEM micrographs of OH-PEG-AuNPs internalized into SKBR-
3 cells. Scale bar 200 nm (C) TEM micrographs of Tmab-PEG-AuNPs internalized into 
SKBR-3 cells. Scale bar: 500 nm. 
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Figure 7. Active targeting of Trastuzumab functionalized gold nanoparticles in various 
cancer cell lines. Uptake data are reported as means ± SD. * p < 0.05 (Student’s t-test). 
Differences between OH-PEG and Tmab-PEG functionalised gold nanoparticle uptake in 
DLD-1 and MCF-7 cell lines were not significant. 
CPP-Driven Enhanced Internalization 
To assess the effect on cell internalization using the HIV-TAT cell penetrating peptide as a coating 
functional group on the surface of the nanoparticles, 4 different cancer cell lines (SKBR-3, DLD-
1, MDA-MB-231 and MCF-7) were treated with 25 µg/mL 50 nm gold nanoparticles 
functionalized with OH-PEG-SH, Tmab-PEG-SH, CPP-PEG-SH, or a combination of Tmab-PEG-
SH and CPP-PEG-SH (CPP+Tmab-PEG-AuNP).  
A significant increase in uptake, relative to OH-PEG-AuNP, obtained by attachment of the anti-
HER2 antibody (Tmab-PEG-AuNP) was recorded for the SKBR-3 cell line (t (4) = 2.22, p > 0.05) 
only (Figure 7). In the same SKBR-3 cell line, AuNP functionalized with the cell penetrating 
peptide (CPP-PEG-AuNPs) showed approximately 1000-fold increase compared to the Tmab-
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PEG-AuNP (Figure 8). Similarly, CPP-PEG-AuNPs displayed a high increase in cell uptake 
relative to OH-PEG-Tmab in all cell lines tested (Figure 8). CPP+Tmab-PEG-AuNP also recorded 
markedly higher uptake across all cell lines compared to OH-PEG-AuNP. CPP-PEG-AuNP 
displayed significantly higher internalization than the combination of CPP+Tmab-PEG-AuNP in 
SKBR-3 and MCF-7 cells, and no statistical difference was observed between these two formats 
in the DLD-1 and MDA-MB-231 cell lines. 
 
Figure 8. Cellular uptake of cell penetrating peptide (CPP) functionalized gold nanoparticles 
into various cancer cell lines. Uptake data are reported as means ± SD. * p < 0.05, ** p < 
0.01, *** p < 0.001 (Student’s t-test). 
In Vitro Cytotoxicity of ADC-PEG-AuNP in HER2 Overexpressing Cancer Cell Lines 
To assess the capacity for intracellular release of the drug payload, the in vitro cytotoxic activity 
of the antibody-drug conjugate bound to the nanoparticles (ADC-PEG-AuNP) was evaluated in 
two HER2 amplified cell lines: (1) SKBR-3 and (2) SKOV-3 (ovarian adenocarcinoma). Growth 
rate inhibition (GR) metrics derived from cell growth curves were determined to compare the 
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GR50 value of free MMAE, Tmab-vcMMAE, ADC-PEG-AuNP and Trastuzumab (Figure 9 and 
Figure S6). Growth rate calculations are specified in the methods section. GR50 corresponds to 
the concentration at which GR(c) = 0.5. ADC and ADC-PEG-AuNP concentrations reported in 
Figure 9 correspond to MMAE concentrations based on DAR and antibody per AuNP estimations.  
The in vitro cytotoxic activity of free MMAE was higher in both cell lines relative to ADC and 
ADC-PEG-AuNP (Table 3). MMAE GR50 values were subnanomolar for both cell lines. SKOV-
3 displayed slightly higher sensitivity to MMAE (GR50 = 0.14 nM) compared to SKBR-3 cells 
(GR50 = 0.33 nM). ADC and ADC-PEG-AuNP displayed similar GR50 values for both cell lines. 
Trastuzumab showed a dramatically decreased potency relative to MMAE containing formats, 
particularly in SKOV-3. Hence, the GR50 value was not determined for this cell line due to the 
high concentration of antibody required to obtain an appropriate dose-response curve. The effect 
on growth rate inhibition was also determined for OH-PEG-AuNP as a control. The stabilized gold 
nanoparticles only caused small reductions in growth rate at high nanoparticle concentrations 
(Figure 9). 
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Figure 9. Growth rate (GR) inhibition of (A) free MMAE, (B) ADC, (C) ADC-PEG-AuNP, 
(D) Trastuzumab and (E) OH-PEG-AuNP in SKBR-3 and SKOV-3 cell lines. Data are 
reported as means ± SD. 95% confidence bands are displayed as dotted lines. Concentration 
of ADC and ADC-PEG-PEG are reported as molar concentrations of MMAE according to 
the estimated DAR and number of ADC per AuNP, respectively. 
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Table 4. GR50 values with confidence intervals (CI) obtained from dose-response curves in Figure 
9. 
Sample SKBR-3 SKOV-3 
Agent GR50 (nM) GR50 95% CI R2 SKOV-3 GR50 95% CI R2 
Free MMAE 0.33 (0.28–0.37) 0.9986 0.14 (0.11–0.17) 0.9851 
ADC 34.91 (29.04–41.02) 0.9847 4.81 (3.56–6.32) 0.9636 
ADC-PEG-AuNP 19.45 (16.52–22.80) 0.9913 10.14 (8.55–11.83) 0.9878 
Tmab 2118.36 (1849.27–2426.61) 0.9931 N.D. N.D. N.D. 
N.D.: not defined, CI: confidence intervals, GR50: concentration required to achieve a 
growth rate inhibition of 0.5. 
Discussion 
The lack of clinical precedent for inorganic nanoparticles has hindered their implementation in 
cancer therapy. However, the results of the Phase I clinical trial (NCT00356980) of CYT-6091 
(PEGylated colloidal gold-rhTNF) published in 2009 were highly promising with regards to safety 
profile and the capacity to accumulate effectively in a wide range of solid tumors [34]. Considering 
the remarkable therapeutic potential of gold nanoparticles and the validation of the EPR effect for 
colloidal gold in human patients, we were prompted to assess three strategies; or a combination 
thereof, to further enhance the potential of AuNPs for clinical implementation: (1) surface 
attachment of PEGylated Trastuzumab for targeted treatment of HER2-positive tumors (active 
targeting), (2) employment of an antibody-drug conjugate as targeting agent to increase the 
anticancer potency of the system, and (2) surface coating with the cationic HIV-TAT cell 
penetrating peptide to enhance intracellular delivery.  
Trastuzumab and HIV-TAT PEGylation 
Attachment of poly ethylene glycol has become a conventional strategy to increase circulation 
times and distribution of nanosized structures. PEGylation prevents opsonization and uptake by 
the RES system—a biological mechanism that severely impedes tumor localization by premature 
clearance [35, 36]. Herein, our results support that Trastuzumab PEGylation for subsequent gold 
surface attachment can be readily achieved without significant modifications in HER-2 affinity or 
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binding kinetics as was reflected by SPR binding measurements to a recombinant HER2 protein. 
The same NHS-linker was used for HIV-TAT PEGylation, taking advantage of the two lysine 
residues in its amino acid composition (Figure 1). 
ADC Construction 
MMAE is a cytotoxic payload with exceptionally high potency that has frequently been employed 
in the construction of antibody drug conjugates. Under our experimental conditions, we obtained 
an average drug-to-antibody ratio of 2.91, as per UV-Vis spectroscopy analysis, consistent with 
DARs reported for similar ADC synthesis methods [37, 38]. For further structural characterization 
and confirmation of vcMMAE attachment, the ADC was analysed through intact protein mass 
spectrometry analysis. The ADC was buffer exchanged to MeCN 10% v/v to induce inter-heavy 
and heavy-light chain dissociation, in order to analyse the number of drugs attached to each 
polypeptide chain. Chain dissociation in MeCN 10% v/v was confirmed by SE-HPLC 
chromatograms showing the appearance of two peaks at longer elution times (Figure S2). The 
deconvoluted mass spectra confirmed that vcMMAE can attach to all possible free sulfhydryl 
groups formed upon partial reduction, i.e., a maximum of three attachments on the heavy chain 
and one attachment on the light chain. 
Herein, our results report on the feasibility of combining two common bioconjugation techniques 
(lysine and cysteine attachment) to PEGylate Tmab-vcMMAE for nanoparticle attachment. 
Furthermore, our data show that HER-2 binding affinity decreases by an order or magnitude with 
ADC PEGylation; yet, the binding affinity remains within the picomolar range. Several studies 
have combined targeting agents and cytotoxic drugs on nanoparticles; however, the added 
complexity of the systems also complicates appropriate characterization for implementation, 
especially in regard to dosage determination as the amount of each individual component requires 
quantification. To this end, the use of antibody-drug conjugates as targeting agents carrying the 
payload could simplify this—provided that the DAR is determined, quantification of protein 
content would be sufficient to estimate drug dosage per nanoparticle.  
Gold Nanoparticle Surface Functionalization 
Adding to improved biodistribution and tumor targeting, PEGylation also increases the colloidal 
stability of gold nanoparticles—a key requirement for long-term storage. Attachment of the 
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bioactive groups was achieved through the thiol moiety of the PEG linker, which, at high pH, can 
form covalent gold-sulfur (Au-S) bonds, providing stable conjugation to the surface [11]. Indeed, 
surface functionalization had a pronounced enhancement in nanoparticle stability upon addition of 
1% NaCl and cell culture media (Figure S3). Attachment was confirmed by an increase in 
hydrodynamic size (DLS) and SPR absorption maxima, and most importantly by alterations in the 
zeta potential that allow to discriminate the presence of the bioactive groups. For instance, the 
positively charged HIV-TAT caused a charge reversal in zeta potential (+6.17 ± 0.71 mV) for a 
+40.77 mV shift compared to the citrate-capped gold nanoparticles (−34.60 mV). In contrast, 
coating with the neutral OH-PEG caused a smaller +20.23 mV shift. Zeta potential values closer 
to the isoelectric point are generally detrimental to colloidal stability; however, the hydrophilic 
PEG polymer on the surface impedes nanoparticle aggregation by steric hindrance to prevent 
surface interactions between AuNPs. The large exclusion volume of the hydration cloud of the 
PEG linkers is known to prevent interactions between nanoparticle surfaces that lead to 
aggregation [35]. 
Quantification of the average number of antibodies that coat individual nanoparticles is 
challenging, insofar as common colorimetric methods for protein quantitation are difficult to 
perform due to the much stronger absorption coefficients of gold nanoparticles throughout the 
wavelength ranges used for protein concentration measurements. Instead, we quantified the 
amount of antibody by accounting for the ensuing decrease in antibody concentration following 
attachment, after removal of the functionalized nanoparticles through centrifugation. According to 
these measurements, an average of 156 antibodies covered the surface of 50 nm AuNPs and 40 
antibodies on 20 nm AuNPs (Figure S4).  
Active Targeting and Cellular Uptake 
The multivalent presentation of Trastuzumab on gold nanoparticles has been shown previously to 
promote HER2 receptor crosslinking, leading to enhanced cellular internalization in HER2 
overexpressing cell lines [39]. In our experimental setup, Trastuzumab-coated gold nanoparticles 
were compared to the AuNPs coated with the SH-linker without antibody derivatization, to 
maximize the similarity in physicochemical properties, excluding the presence of protein. Indeed, 
the mean hydrodynamic diameter of both formats differed by less than 1 nm according to DLS 
measurements (Table 2). Electrophoretic mobility determinations, on the other hand, recorded 
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negative zeta potential values for OH-PEG-AuNPs and close to neutral values for Tmab-PEG-
AuNP. The drift towards more neutral values—relative to citrate-capped nanoparticles—is 
consistent with antibody attachment, as Trastuzumab (isoelectric point (pI) 8.7) possesses a net 
positive charge when dissolved in PBS. A small net positive charge is also expected when 
suspended in cell culture media (pH 7.4). The effect of nanoparticle surface charge on cellular 
uptake is well-documented, whereby positively charged nanoparticles have consistently displayed 
higher uptake rates in nonphagocytic cells [40]. The increase in internalization with positively 
charged surfaces has generally been ascribed to favorable electrostatic nanoparticle/cell 
interactions due to the net negative charge of the plasma membrane [40]. In view of the foregoing, 
it is difficult to rule out a contribution of the more neutral zeta potential of Tmab-PEG-AuNP in 
enhancing cellular uptake. This notwithstanding, the observation that internalization enhancement 
was only recorded in a HER2 overexpressing cell line (SKBR-3)—and not in the HER2 basal 
counterparts (DLD-1, MDA-MB-231 and MCF-7)—supports cellular uptake increase through 
Trastuzumab-mediated HER2 receptor crosslinking. Interestingly, TEM micrographs of SKBR-3 
cells did not show clear distinction between both formats in subcellular localization—i.e., both 
AuNP designs were primarily localized within vesicular structures, presumably coated 
preendosomal and carrier vesicles (early endosomes and lysosomes). Alternatively, it is possible 
that some of these structures are autophagosomes, as gold nanoparticles have been shown to induce 
autophagosome accumulation [41]. This observation warrants further elucidation of the effect of 
surface functionalization on uptake mechanism and localization. 
Cellular Uptake Enhancement with HIV-TAT 
Due to the relatively low loading capacity of spherical gold nanoparticles, it is essential to ensure 
maximum cellular internalization when developed as drug delivery vehicles. Having improved 
selective uptake into HER2 overexpressing cell lines through active targeting, we sought to 
evaluate the effect of combining a cell penetrating peptide with the antibody targeting agent. HIV-
TAT internalization mechanism remains a topic of debate; however, evidence of uptake 
saturability and energy dependency suggest an endosomal pathway [42]. Endosomal and 
subsequent lysosomal localization is required for effective drug release of cathepsin B-cleavable 
linkers, such as those containing the valine-citrulline dipeptide. Enhancing uptake is thus 
paramount in HER2-targeted conjugates for intracellular release, considering that most ErbB 
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receptors have shown impaired ligand-induced receptor trafficking [43]. To this end, 
functionalization with the cell penetrating peptide caused a dramatic increase in cellular uptake 
across all cell lines tested. This enhancement was considerably more significant than that obtained 
by antibody functionalization only. Conversely, our results did not show improvement in uptake 
upon combination of both bioactive agents compared to CPP-PEG-AuNP. In fact, uptake was 
significantly higher with CPP functionalization in SKBR-3 and MCF-7 cells. We presume that this 
observation stems from the more positive zeta potential of CPP-PEG-AuNPs, in which case 
engagement through cell membrane/nanoparticle electrostatic interactions is a stronger 
determinant of uptake rate than antibody-mediated receptor cross-linking. 
These findings warrant further investigation into the effect of the highlighted physicochemical and 
physiological attributes in a more physiological setting. While higher uptake may be desirable in 
delivery applications, internalization must be specific to the targeted tumor cells. Previous studies 
have reported that uptake, rather than diffusion, could be the primary mechanism for nanoparticle 
tumor delivery. Consequently, surface charge has been proposed as a major determinant in tumor 
distribution upon systemic administration [44]. If indeed transcellular transport has a crucial 
impact in tumor penetration, then enhancing cellular internalization through strategies such as the 
attachment of a cell penetrating peptide might provide improved tumor tissue distribution, thus 
enhancing efficacy and therapeutic index. 
In Vitro Cytotoxicity of ADC-PEG-AuNP in HER2 Overexpressing Cancer Cell Lines 
Growth rate inhibition sensitivity in SKOV-3 and SKBR-3 cell lines was markedly higher for free 
MMAE than for the antibody-drug conjugate and for ADC-carrying gold nanoparticles (Figure 8). 
It is plausible that the requirement of linker cleavage and self-immolation of the p-aminobenzyl 
carbamate group in the antibody-drug conjugate hinders conjugated vcMMAE activity compared 
to the free drug. Additionally, although HER2 binding and cross-linking can induce receptor-
mediated endocytosis, free MMAE likely penetrates more readily into the intracellular 
compartment. Nonetheless, the structural characteristics that presumably hinder conjugated 
vcMMAE cytotoxicity in isolated carcinoma cells are expected to provide selectivity advantages 
in more physiological settings.  
Comparison of the cytotoxic activity of free ADC and nanoparticle-conjugated ADC displayed 
similar GR50 for both SKBR-3 and SKOV-3 cells (Table 3). GR50 values for ADC-PEG-AuNP 
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were lower for SKBR-3 cells and higher for SKOV-3 cells relative to free ADC; however, due to 
the degree of uncertainty in the estimation of antibodies per nanoparticle it is difficult to establish 
a significant improvement in MMAE intracellular release and antimitotic activity for either one of 
the formats. Still, concentrations of ADC-PEG-AuNP required to achieve a 50% growth rate 
inhibition were extremely low in both HER2 amplified cell lines. As expected, the antimitotic 
activity of MMAE-containing formats is dramatically higher than that of the unmodified 
Trastuzumab and PEG-stabilized gold nanoparticles. OH-PEG-AuNPs only caused small 
reductions in growth rate at high gold concentrations (100 µg/mL) in SKOV-3, which is higher 
than the equivalent gold concentrations required to achieve a 50% growth rate inhibition in ADC-
PEG-AuNPs (> 20 µg/mL). These results confirm that MMAE antibody-drug conjugate retain a 
highly potent cytotoxic activity when bound to the surface of gold nanoparticles. These findings 
warrant further investigation in animal models, as increased accumulation in high EPR tumors 
could confer potency and safety advantages over the free ADC. 
Conclusions 
The results presented herein report on the feasibility of utilizing multiple bioactive agents to 
construct gold nanoparticles with broader therapeutic capabilities. The construction of a thiol-
functionalized PEGylated antibody drug-conjugate (PEGylated Trastuzumab-vcMMAE) proved 
to yield ADCs with conserved high affinity towards the HER2 receptor; thereby enabling coupling 
to gold nanoparticles to function as targeting agents carrying a cytotoxic payload. ADCs attached 
to the surface of gold nanoparticles demonstrated to retain similar in vitro cytotoxic potency 
against HER2 overexpressing cancer cell lines relative to the free ADC. Notwithstanding, 
enhanced accumulation in high EPR tumors could results in wider therapeutic indices. 
Cellular uptake of AuNPs in a HER2 amplified cell line was significantly improved upon covalent 
attachment of the Trastuzumab targeting agent through the PEGylated-SH linker. Internalization 
into different cancer cell lines was further enhanced by employing the HIV-1 TAT protein (47–
57) as a cell penetrating peptide. Yet, the combination of the antibody targeting agent and the 
penetrating peptide did not provide improvements in uptake—relative to the penetrating peptide 
only—in the conditions tested. Our results support previous observations with different 
nanoparticle formats with regards to the prominent role of surface charge on determining uptake 
rate into cells, insofar as the charge reversal obtained by incorporating the cell penetrating peptide 
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had a more pronounced impact than the addition of the antibody targeting agent. Efficient cleavage 
of the valine-citrulline moiety for drug release requires cellular internalization for exposure to 
cathepsin B in lysosomes or endosomes; therefore, incorporation of the CPP might provide 
improved intracellular delivery of the MMAE payload in this format. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure 
S1: Analysis of the presence of sulfhydryl groups and conservation of intact structure of 
Trastuzumab after partial reduction with DTT, Figure S2: SE-HPLC chromatograms of partially 
reduced Trastuzumab in 1 mM EDTA, Tmab-vcMMAE in H2O and Tmab-vcMMAE in 
acetonitrile 10% with formic acid 1%, Figure S3: AuNP stability upon surface functionalization 
with Tmab-PEG-SH. Addition of 1% NaCl to citrate capped AuNPs caused aggregation as 
evidenced by a broad absorption band in the 700–800 nm range, Figure S4: Representative 
tryptophan fluorescence emission spectra for the estimation of Trastuzumab:AuNP ratio for 20 nm 
AuNPs, Figure S5: Representative sensorgrams of (A) Trastuzumab, (B) Tmab-PEG-SH 25X and 
(C) Tmab-vcMMAE binding to recombinant HER2 receptor, Figure S6: Representative SKBR-3 
cell growth curves employed to analyse growth rate inhibition activity of MMAE-containing 
agents at equivalent MMAE concentrations. 
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Landmark discoveries in the field of molecular biology in the 1990’s ushered in a new era in the 
biomedical field with the introduction of a plethora of recombinant products into the 
pharmaceutical market. Biotherapeutics have since experienced tremendous growth, best 
exemplified by the current dominance of antibody therapeutics in the pharmaceutical market. The 
field continues to capitalize on these discoveries, as novel bio-engineering approaches are sought 
to improve established therapies based on further advancements in molecular biology and other 
disciplines. While the latter provide manifold opportunities, these also entail prominent challenges 
towards clinical development and regulatory approval. The experimental work contained in this 
thesis reports on various novel approaches that make use of recent progress in the field aimed 
towards the improvement of biological therapies, showcasing the application of state-of-the-art 
mass spectrometry techniques to address key aspects in various stages of preclinical development.  
The first aim of this thesis consisted in exploiting recently developed methodologies in mass 
spectrometry to study a structural feature of influenza hemagglutinin that has recently gained 
notoriety in the study of viral evolution, namely the alterations in the number and position of N-
glycosylation sequons on the viral glycoprotein. Remarkably, the implementation of rationally-
designed vaccines for influenza and other infectious diseases has remained elusive, despite myriad 
advancements in recombinant technologies and an imminent need to improve currently available 
options. This, in many cases, stems from insufficient understanding of immune response 
mechanisms, antigenic determinants, and viral adaptation mechanisms. Thus, we sought to apply 
a targeted workflow on whole viruses of a specific H1N1 strain to obtain the glycan profile of 
influenza hemagglutnin as a proof-of-concept. Notably, the MS experimental setup employs 
complementary activation modes that enable the determination of glycan structures on specific 
sites of the protein. Hence, not only does it provide identification of glycosylation sites, but by 
deriving structural features of the glycans it allows to assess the impact of localisation on glycan 
maturation. Through this method, we acquired extensive site-specific structural data on H1 
hemagglutinin without the need for protein purification or complex sample preparation. This work 
CONCLUDING REMARKS AND 
FUTURE DIRECTIONS 
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prompts implementation of such analytical workflows to obtain glycosylation profiles of further 
relevant influenza glycoproteins. This information will contribute to the study of influenza 
antigenicity and serve as an important complement to biological activity and comprehensive 
sequence-data based studies for this aim. Notably, understanding the role of N-glycans in 
antigenicity provides opportunities for glycoprotein engineering towards the development of 
optimized vaccines platforms. For instance, protein glycoengineering strategies, such as the one 
covered in chapters 4 and 5, could be employed to modulate the antigenicity of recombinant 
vaccine formats.  
The succeeding sections of this thesis address further facets in the rational design of biomolecules 
for therapeutic purposes. The second aim of this thesis – addressed in chapters 3, 4, and 5 – sought 
to put forward and evaluate an innovative approach to alter the physicochemical properties of the 
conserved structural regions of IgG1 molecules, with the intent of developing a generalised 
strategy to enhance the clinical potential of antibody therapeutics by increasing their physical 
stability. Chapter 3 serves as an introductory chapter to the subsequent research manuscripts 
(chapters 4 and 5), presenting an overview of the complications that physical degradation poses 
on the development and manufacture of antibody therapeutics. The chapter provides a brief 
description of various computational tools that have been developed to enable in silico 
identification of aggregation-prone regions. The structural modifications implemented in chapters 
4 and 5 were derived from one such tool, namely the Spatial Aggregation Propensity (SAP) 
prediction.  
Chapters 4 and 5 report on the targeted insertion of glycosylation sites on monoclonal antibodies 
to deter aggregation propensity and enhance solubility by shielding aggregation-prone regions 
identified by SAP. Rationally designed mutations were introduced on the primary structure of 
blockbuster therapeutic antibodies – adalimumab in chapter 4 and trastuzumab in chapter 5 – to 
explore the possibility of enhancing the clinical properties of established therapeutics mAbs. 
Naturally, this technique can equally be applied to mAb leads in preclinical development. We 
demonstrated in chapter 4 that the hyperglycosylation strategy can confer important improvements 
in the thermodynamic stability of the Fab region, reflected by increases in the corresponding 
melting temperature. Importantly, this was achieved without compromising the high binding 
affinity to the molecular target of adalimumab (TNF-α) or to Fc-receptors involved in effector 
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functions, indicating that the biological activity of an IgG molecule is unlikely to be impaired by 
glycosylation of the targeted sites. Contrary to previous reports employing this technique in other 
antibodies, it was not possible to establish enhancements in aggregation resistance in accelerated 
stability studies when incorporated in adalimumab. To understand these seemingly contradictory 
observations, further insight is needed into the mechanisms that drive antibody aggregation and 
into the structural modifications that emerge upon glycosite addition. Moreover, additional long-
term experiments evaluating the physicochemical stability of the protein at lower temperatures are 
needed to ascertain the colloidal stability of the protein under conditions that better reflect the 
storage of antibody therapeutics in a clinical context.   
Hyperglycosylation of trastuzumab in chapter 5 revealed an important consequence of the 
technique: the overall structural heterogeneity of the protein increases markedly due to extensive 
glycan maturation in the Fab glycosylation sites. In comparison, glycan heterogeneity in the 
conserved Fc-region is relatively limited as a result of the atypical orientation of these glycans 
towards the core of the protein. Although controlling Fc glycosylation is presumably more 
important, due to the well-studied interactions that glycoforms in this position establish with Fc-
receptors, the large increase in heterogeneity obtained through hyperglycosylation is likely to have 
important implications for regulatory approval if this strategy is to be pursued in therapeutic 
antibodies. These findings prompt further study of the impact of individual glycoforms on self-
association mechanisms and enhancements in thermodynamic stability of the domain.  
Altogether, the experimental data reported herein for the glycosite insertion strategy highlight the 
potential of this method to enhance the physical stability of therapeutic antibodies, yet it also 
underscores aspects of the technique that require further refinement for implementation. We 
presume that combining this approach with other glycoengineering technologies that minimise 
glycan heterogeneity could have great potential. It is important to note that inserting engineered 
glycosylation sites can be employed to enhance the biophysical properties of further therapeutic 
proteins. Moreover, the method enables protein functionalisation in a targeted fashion, since the 
glycan can be used as a chemical handle with a predetermined localisation that grants site-
specificity and homogeneity relative to stochastic protein labelling chemistry. For instance, this 
could be advantageous for the construction of site-specific protein-drug conjugates.  
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The third aim of this thesis involved the exploration of alternative applications of protein 
engineering in the design of novel therapeutic agents. Chapter 7 showcases the feasibility of 
chemically modifying an IgG molecule (trastuzumab) to expand the versatility of the protein. The 
two most common protein labelling techniques (i.e., lysine and native cysteine chemistry) were 
employed concomitantly on trastuzumab to produce an antibody-drug conjugate capable of 
binding covalently to the surface of gold nanoparticles. We showed that the antibody retains its 
antigen binding capacity upon chemical functionalisation, and that it is capable of enhancing 
targeting to tumor cells in vitro. The antibody-targeted nanocarriers synthesized in this chapter are 
expected to improve selective tumour delivery by harnessing the preferential accumulation of 
nanosized materials combined with the active-targeting capacity of the antibodies exposed on its 
surface. The utilisation of an antibody-drug conjugate as a targeting agent provides several 
advantages, including better control of drug loading and the use of commercially available “smart” 
linkers that enable localised release of the payload to diminish off-target toxicity. Future work will 
involve the assessment of safety and efficacy in mouse xenograft models with overexpression of 
HER2. Furthermore, the nanoparticle system presented in chapter 7 provides remarkable 
versatility. A promising possibility consists in tagging the nanoparticle surface with two (or more) 
antibodies with distinct specificities. This “multispecific” format could conceptually allow 
circumvention of resistance mechanisms that evoke downregulation of one of the molecular 
targets.  
Various mass spectrometry methodologies were employed to tackle the different aims of this 
thesis, highlighting the numerous applications that novel MS tools offer in protein engineering. 
Data-dependent acquisition employing HCD and CID activation modes was utilised to derive site-
specific structural information of influenza hemagglutinin glycosylation. For the second aim, a 
combination of workflows and activation modes, including CID, HCD, and ETD, were performed 
to confirm unambiguously the amino acid mutations and the attachment of glycans on the inserted 
asparagine residues, and were subsequently focused on the structural analysis of the glycan 
molecules. In the last aim, intact protein mass analysis was used to confirm the chemical 
attachment of the drug-linker moiety to trastuzumab in the construction of the antibody-drug 
conjugate. The latter also provided information concerning the number of drug molecules attached 
per antibody chain. Mass spectrometry has stood out as a key analytical technique in the current 
era of biopharmaceuticals; and constant technological advancements will continue to extend the 
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capabilities of these techniques to address crucial considerations in the development of novel 
biotherapeutics. 
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Supplementary information from Chapter 2: Site-specific Glycosylation Profile 
of Influenza A (H1N1) Hemagglutinin through Tandem Mass Spectrometry 
Supplementary table 1. Influenza protein coverage across all bands obtained by SDS-PAGE 
fractionation (Fig. 2) and subsequent mass spectrometry analysis. 
Description Coverage 
(%) 
# 
Peptide
s 
# 
PSMs 
# Unique 
Peptides 
# 
AAs 
MW 
[kDa]. 
FDR 
A2 
hemagglutinin  71.50 62 2, 018 62 565 63.2 0% 
nucleocapsid 
protein   
79.72 59 1, 050 59 498 56.2 0% 
polymerase PB2 65.88 64 251 63 759 86 0% 
matrix protein 1 78.57 29 1, 238 29 252 27.9 0% 
neuraminidase 38.59 19 217 19 469 51.5 0% 
polymerase PB1 44.85 50 231 49 758 86.6 0% 
polymerase PA 58.66 57 196 57 716 82.5 0% 
nonstructural 
protein 1   
64.35 15 69 15 230 25.8 0% 
PB1-F2 protein  24.44 4 20 4 90 10.8 23.10
% 
nuclear export 
protein 
24.79 3 9 3 121 14.4 21.40
% 
matrix protein 2  38.14 2 9 2 97 11.1 50% 
Supplementary table 2. Influenza protein coverage for band 4 (Fig. 2) obtained by SDS-PAGE 
fractionation and subsequent mass spectrometry analysis. 
Description Coverage 
(%) 
# 
Peptides 
# 
PSMs 
# Unique 
Peptides 
# 
AAs 
MW 
[kDa]. 
FDR 
A2 
hemagglutinin  56.81 48 855 48 565 63.2 0% 
nucleocapsid 
protein 
71.08 49 121 49 498 56.2 0% 
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matrix protein 1  78.17 27 104 27 252 27.9 0% 
neuraminidase, 
partial  
26.44 16 76 16 469 51.5 0% 
polymerase PB1 32.59 27 42 27 758 86.6 0% 
polymerase PA  37.29 23 31 23 716 82.5 0% 
polymerase PB2  32.81 24 28 24 759 86 0% 
PB1-F2 protein 8.89 1 4 1 90 10.8 20% 
nonstructural 
protein 1  
24.78 3 3 3 230 25.8 0% 
matrix protein 2 38.14 2 3 2 97 11.1 18.80
% 
 
Supplementary table 3. Influenza protein coverage for band 5 (Fig. 2) obtained by SDS-PAGE 
fractionation and subsequent mass spectrometry analysis. 
Description Coverage 
(%) 
# 
Peptides 
# 
PSMs 
# Unique 
Peptides 
# 
AAs 
MW 
[kDa]. 
FDR 
A2 
nucleocapsid 
protein  
80.12 56 556 56 498 56.2 0% 
hemagglutinin  48.85 37 162 37 565 63.2 0% 
matrix protein 
1 
66.67 22 123 22 252 27.9 0% 
neuraminidase 20.64 12 45 12 470 51.6 0% 
polymerase 
PB2  
31.62 21 23 21 759 86 0% 
polymerase 
PB1  
16.36 14 39 14 758 86.6 0% 
polymerase PA  19.55 11 12 11 716 82.5 0% 
polymerase 
PB1  
3.83 3 5 3 757 86.4 18.80
% 
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matrix protein 
2  
10.31 1 1 1 97 11.1 23.50
% 
PB1-F2 protein  8.89 1 1 1 90 10.8 22.20
% 
 
Supplementary table 4. Influenza protein coverage for band 6 (Fig. 2) obtained by SDS-PAGE 
fractionation and subsequent mass spectrometry analysis. 
Description Coverag
e (%) 
# 
Peptid
es 
# 
PSM
s 
# Unique 
Peptides 
# Protein 
Groups 
# 
AA
s 
MW 
[kDa]. 
FDR 
A2 
hemagglutinin  37.35 34 429 34 1 565 63.2 0% 
nucleocapsid 
protein  
51.81 34 59 34 1 498 56.2 0% 
matrix protein 
1  
59.52 19 80 19 1 252 27.9 0% 
nonstructural 
protein 1 
36.52 8 10 8 1 230 25.8 0% 
polymerase 
PA 
11.73 10 11 10 1 716 82.5 0% 
neuraminidase 17.87 8 15 8 1 470 51.6 0% 
polymerase 
PB2 
7.11 5 5 5 1 759 85.9 0% 
nuclear export 
protein 
5.79 1 1 1 1 121 14.3 16.70
% 
matrix protein 
2 
10.31 1 1 1 1 97 11.1 15.40
% 
polymerase 1.98 2 3 2 1 757 86.4 14.30
% 
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Supplementary information from Chapter 4: Enhancing the stability of 
adalimumab by engineering additional glycosylation motifs 
 
Figure S1. HCD spectrum of the chymotryptic peptide 
LSTASSLDYWGQGTNVTVSSASTK for the L116N mutant. 
 
Figure S2. ETD spectrum of the chymotryptic peptide 
LSTASSLDYWGQGTNVTVSSASTK for the L116N mutant. 
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Figure S3. HCD spectrum of the de-glycosylated chymotryptic peptide 
GQGTNVTVSSASTKGPAVFPLAPSSK for the L116N mutant. 
 
Figure S4. HCD spectrum of the chymotryptic peptide 
LSTASSLDYWGQGTLVNVSSASTK for the T118N mutant. 
 
Figure S5. ETD spectrum of the chymotryptic peptide 
LSTASSLDYWGQGTLVNVSSASTK for the T118N mutant. 
 
Figure S6. CID spectrum of the de-glycosylated chymotryptic peptide 
LSTASSLDYWGQGTLVNVSSASTK for the T118N mutant. 
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Figure S7. ETD spectrum of the de-glycosylated chymotryptic peptide 
LSTASSLDYWGQGTLVNVSSASTK for the T118N mutant. 
 
Figure S8. HCD spectrum of the chymotryptic peptide GQGTLVTVSSNSTK for the 
A122N mutant. 
 
 
Figure S9. ETD spectrum of the chymotryptic peptide GQGTLVTVSSNSTK for the 
A122N mutant. 
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Figure S10. CID spectrum of the de-glycosylated chymotryptic peptide 
LSTASSLDYWGQGTLVTVSSNSTK for the A122N mutant. 
 
Figure S11. ETD spectrum of the de-glycosylated chymotryptic peptide 
LSTASSLDYWGQGTLVTVSSNSTK for the A122N mutant. 
 
Figure S12. HCD spectrum of the chymotryptic peptide 
KVDNALQSGNSNESSVTEQDSKDSTY for the Q160N mutant 
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Figure S13. ETD spectrum of the chymotryptic peptide 
KVDNALQSGNSNESSVTEQDSKDSTY for the Q160N mutant 
 
Figure S14. CID spectrum of the chymotryptic peptide NSGALTSGVHTFPAVK for the 
L178K mutant. 
 
Figure S15. ETD spectrum of the chymotryptic peptide NSGALTSGVHTFPAVK for the 
L178K mutant. 
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Figure S16. SHCD spectrum of the chymotryptic peptide PAVNQSSGLY for the L178N 
mutant. 
 
Figure S17. ETD spectrum of the chymotryptic peptide PAVNQSSGLY for the L178N 
mutant. 
 
Figure S18. HCD spectrum of the chymotryptic peptide 
NSGALTSGVHTFPAVLQSSGNY for the L183N mutant. 
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Figure S19. ETD spectrum of the chymotryptic peptide NSGALTSGVHTFPAVLQSSGNY 
for the L183N mutant. 
 
Figure S20. ETD spectrum of the chymotryptic peptide SLSSVVTVPSSSLGNQTY for the 
T198N mutant. 
 
Figure S21. ETD spectrum of the de-glycosylated chymotryptic peptide 
SLSSVVTVPSSSLGNQTY for the T198N mutant. 
 
264 
 
Supplementary information from Chapter 5: Glycan profile analysis of 
engineered trastuzumab with rationally added glycosylation sequons for 
enhanced stability 
Full MS spectra of the Tmab variants 
 
Figure S1. Full MS spectra of released glycans from Tmab WT. 
 
Figure S2. Full MS spectra of released glycans from Herceptin. 
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Figure S3. Full MS spectra of released glycans from L115N. 
 
Figure S4. Full MS spectra of released glycans from A121N. 
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Figure S5. Full MS spectra of released glycans from Q160N. 
 
Figure S6. Full MS spectra of released glycans from L177N. 
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Figure S7. Full MS spectra of released glycans from Q178N. 
 
Figure S8. Full MS spectra of released glycans from L182N. 
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Figure S9. Full MS spectra of released glycans from T198N. 
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MS2 spectra 
 
Figure S10. MS2 spectra of glycan 1 (table 4). 
 
Figure S11. MS2 spectra of glycan 2 (table 4). 
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Figure S12. MS2 spectra of glycan 3 (table 4). 
 
Figure S13. MS2 spectra of glycan 4 (table 4). 
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Figure S14. MS2 spectra of glycan 5 (table 4). 
 
Figure S15. MS2 spectra of glycan 6 (table 4). 
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Figure S16. MS2 spectra of glycan 7 (table 4). 
 
Figure S17. MS2 spectra of glycan 8 (table 4). 
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Figure S18. MS2 spectra of glycan 9 (table 4). 
 
Figure S19. MS2 spectra of glycan 10 (table 4). 
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Figure S20. MS2 spectra of glycan 11 (table 4). 
 
Figure S21. MS2 spectra of glycan 12 (table 4). 
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Figure S22. MS2 spectra of glycan 13 (table 4). 
 
Figure S23. MS2 spectra of glycan 14 (table 4). 
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Figure S24. MS2 spectra of glycan 15 (table 4). 
 
Figure S25. MS2 spectra of glycan 16 (table 4). 
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Figure S26. MS2 spectra of glycan 17 (table 4). 
 
Figure S27. MS2 spectra of glycan 18 (table 4). 
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Figure S28. MS2 spectra of glycan 19 (table 4). 
 
Figure S29. MS2 spectra of glycan 20 (table 4). 
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Figure S30. MS2 spectra of glycan 21 (table 4). 
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Glycopeptide spectra 
 
Figure S31. CID spectrum of the chymotryptic peptide 
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY from the L115N mutant containing 
amino acid positions 177, 178 and 182. 
 
Figure S32. CID spectrum of the chymotryptic peptide 
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY from the A121N mutant amino acid 
positions 177, 178 and 182. 
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Figure S33. CID spectrum of the chymotryptic peptide SGALTSGVHTFPAVLQSSGLY 
from Tmab WT amino acid positions 177, 178 and 182. 
 
Figure S34. CID spectrum of the chymotryptic peptide 
VDNALQSGNSNESVTEQDSKDSTYSLSSTLTLSK from the Q160N mutant confirming 
the mutation at position 160. 
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SPR sensorgrams 
 
Figure S35. Analysed SPR sensorgrams of single cycle kinetic assays of Tmab variants to 
surface captured HER2. (A) Herceptin, (B) Tmab WT, (C) L115N, (D) A121N, (E) L177N, 
(F) Q178N, (G) L182N, (H) T198N, and (I) Q160N. 
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Figure S36. Analysed SPR sensorgrams of single cycle kinetic assays of Tmab variants to 
surface captured FcγR1A. (A) Herceptin, (B) Tmab WT, (C) L115N, (D) A121N, (E) 
L177N, (F) Q178N, (G) L182N, (H) T198N, and (I) Q160N. 
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Figure S37. Analysed SPR sensorgrams of single cycle kinetic assays of Tmab variants to 
surface captured FcγR2A. (A) Herceptin, (B) Tmab WT, (C) L115N, (D) A121N, (E) 
L177N, (F) Q178N, (G) L182N, (H) T198N, and (I) Q160N. 
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Figure S38. Analysed SPR sensorgrams of single cycle kinetic assays of Tmab variants to 
surface captured FcγR3A. (A) Herceptin, (B) Tmab WT, (C) L115N, (D) A121N, (E) 
L177N, (F) Q178N, (G) L182N, (H) T198N, and (I) Q160N. 
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Supplementary information from Chapter 7: Synthesis and Enhanced Cellular 
Uptake In Vitro of Anti-HER2 Multifunctional Gold Nanoparticles 
 
Figure S1. Analysis of the presence of sulfhydryl groups and conservation of intact structure 
of Trastuzumab after partial reduction with DTT. (A) UV-Vis spectra of Ellman’s reagent 
(DTNB) and of partially reduced antibody after reaction with DTNB. (B) SE-HPLC 
chromatogram of intact Trastuzumab and reduced Trastuzumab. 
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Figure S2. SE-HPLC chromatograms of partially reduced Trastuzumab in 1 mM EDTA, 
Tmab-vcMMAE in H2O and Tmab-vcMMAE in acetonitrile 10% with formic acid 1%. 
 
Figure S3. AuNP stability upon surface functionalization with Tmab-PEG-SH. Addition of 
1% NaCl to citrate capped AuNPs caused aggregation as evidenced by a broad absorption 
band in the 700-800 nm range. Tmab-PEG-SH attachment prevented aggregation upon 
addition of NaCl. 
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Figure S4. Representative tryptophan fluorescence emission spectra for the estimation of 
Trastuzumab:AuNP ratio for 20 nm AuNPs. The estimation is based on the loss of 
fluorescence intensity following AuNP surface attachment and centrifugation of the 
functionalized gold nanoparticles. The decrease in intensity is assumed to come from 
removal of the Trastuzumab monomers attached on AuNPs through nanoparticle 
sedimentation. C denotes controls and S the reacted samples. The ratio (R) is calculated as: 
𝐷𝐷 = �1 − 𝜆𝜆𝑆𝑆
𝜆𝜆0
�  × 𝐹𝐹 
Where: 
Is = fluorescence intensity of the supernatant after AuNP removal by centrifugation post reaction 
I0 = fluorescence intensity of the control (identical original concentration of antibody as that in the 
reaction) 
F = Tmab:AuNP molar ratio in the reaction 
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Figure S5. Representative sensorgrams of (A) Trastuzumab, (B) Tmab-PEG-SH 25X and 
(C) Tmab-vcMMAE binding to recombinant HER2 receptor. The sensorgram is shown in 
red and the derived 1:1 binding model fit in black. 
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Figure S6. Representative SKBR-3 cell growth curves employed to analyse growth rate 
inhibition activity of MMAE-containing agents at equivalent MMAE concentrations. (A) 
Cell confluence change over time monitored every 2 hours. Data are reported as means ± 
SD. (B) Representative images of SKBR-3 cells obtained with the Incucyte® ZOOM Live-
cell Analysis System showing decrease in confluence and morphological changes for 
MMAE treated cells. 
 
 
